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1. Alphaherpesviruses 
 
1.1 History and taxonomy 
Herpesviruses are considered to be evolving along with their hosts over a period of 
about 400 million years, and the subfamily alphaherpesvirinae has diverged only 
since 180-210 million years ago (McGeoch et al., 1995; McGeoch et al., 2000). 
Disease caused by animal and human alphaherpesviruses has already been reported 
for a long time (Rybachuk, 2009). In 1933, there was a report on epidemic virus 
abortion in mares in Kentucky (Dimock and Edwards, 1933), while equine 
herpesvirus 1 (EHV-1) was firstly isolated in 1966 from cases of abortion and 
paralysis (Saxegaard, 1966). The first report of disease believed to be due to bovine 
herpesvirus-1 (BHV-1) came from Germany in the 19th century where a condition 
referred to as coital vesicular exanthema (CVE) was described. This venereal disease 
was subsequently shown in 1928 to have a viral etiology when it was demonstrated 
that it could be transmitted by a filterable agent (Muylkens et al., 2007). Infectious 
bovine rhinotracheitis (IBR) was first discovered in the early 1950s in feeder cattle in 
the Western states of the United States of America. Before 1977, genital infections 
were mainly prevalent in Europe whereas respiratory infections were predominant 
throughout the USA and Canada. Since 1977, severe “North American like” IBR 
emerged on the European continent (House, 1972; McKercher et al., 1963; Smith et 
al., 1995).  
 
The genus herpesvirus was established in 1971 in the first report of the International 
Committee for Taxonomy of Viruses (ICTV). In 1976, in the second ICTV report this 
genus was elevated to family level-the Herpetoviridae and changed to Herpesviridae 
in the third report in 1979. In the latest report in 2015, the family Herpesviridae was 
divided into 3 subfamilies (Alphaherpesvirinae, Betaherpesvirinae and 
Gammaherpesvirinae) and 1 unassigned genus, termed iguanid herpesvirus 2. The 
classification is based on host range, tissue tropism, cytopathology, replication 
kinetics, gene content and capacity to establish latency. The alphaherpesviruses have 
a broad host range and a relatively short replication cycle with a rapid destruction of 
infected cells. They spread rapidly in cell culture and establish latency primarily in 
sensory ganglionic neurons. The Betaherpesviruses are characterized by a narrow host 
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range, a slow replication cycle and a frequent enlargement of infected cells. These 
viruses can establish latency in different tissues including secretory glands, kidneys, 
and lymphoreticular cells. The host range of Gammaherpesvirinae is restricted and 
viruses remain latent in lymphoid tissues (Roizman, 1996).  
 
In the subfamily Alphaherpesvirinae, there are six genera, including genus Iltovirus, 
Mardivirus, Scutavirus, Simplexvirus, Varicellovirus and an unassigned genus. The 
genus Varicellovirus consists of viruses from 17 species. Each animal species is the 
host of various herpesviruses belonging to different subfamilies or genera. In equid 
populations, nine herpesviruses have been identified so far, of which EHV-1, EHV-3, 
EHV-4, EHV-6 (Asinine herpesvirus 1), EHV-8 (Asinine herpesvirus 3) and EHV-9 
(Gazelle herpesvirus 1) belong to the genus Varicellovirus of the subfamily 
Alphaherpesvirinae, while EHV-2, EHV-5 and EHV-7 (Asinine herpesvirus 2) are 
members of the subfamily Gammaherpesvirinae (Davison, 2010; Patel and Heldens, 
2005) (Table1). EHV-1 shares its classification with other animal herpesviruses of 
agricultural importance including BHV-1, BHV-5 and suid herpesvirus 1 
(Pseudorabies virus, PRV) (Davison et al., 2005). BHV-1 and BHV-5 belong to the 
genus Varicellovirus, and BHV-2 is a member of the genus Simplexvirus. All three 
mentioned BHV belong to the subfamily Alphaherpesvirinae, while BHV-3, BHV-4 
and BHV-6 are members of Gammaherpesviruses (Table1).    
 
1.2 Virus characteristics  
1.2.1 Virion structure  
The herpesvirus genomic DNA with a size of approximately 150 kbp is packaged into 
an icosahedral nucleocapsid (Bryans and Allen, 1986). The mature viral particles are 
on average 200-250 nm in size and consist of 4 structural elements: the genome, the 
capsid, the tegument and the envelope (Bohannon et al., 2013). The general 
architecture of a herpesvirus particle is given in Figure 1.  
 
1.2.2 Genome organization  
Like other herpesviruses, both EHV-1 and BHV-1 have a linear double-stranded (ds) 
DNA genome encapsidated in a thick-walled, spherical to pleomorphic, ~120 nm 
diameter, icosahedral capsid (Baker et al., 1990; Turin et al., 1999). The genome 
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consists of a long unique region (UL), which, in the case of EHV-1, is flanked by two 
small inverted repeat sequences, known as terminal repeats (TRL) and internal repeats 
(IRL) (Telford et al., 1992). The UL region is covalently linked to a short unique 
region (US), which is also flanked, both for EHV-1 and BHV-1, by two large inverted 
repeat sequences terminally and internally, known as terminal repeats (TRS) and 
internal repeats (IRS), respectively (Telford et al., 1992) (Figure 1).    
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Figure 1. Structure and genome organization of EHV-1 and BHV-1 virions. (a) Transmission electron microscopic 
image of a herpesvirus particle (adapted from CDC/ Dr. Erskine Palmer; B.G. Partin). (b) Schematic representation. (c) 
Genomic organization of EHV-1. (d) Genomic organization of BHV-1. TR, terminal repeat; IR, internal repeat; U, unique; 
L, long; S, short. 
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Table 1   Known herpesviruses isolated from naturally infected equids and bovine 
Host  Virus   Other Name Subfamily Disease 
Domestic horse Equine herpesvirus 1 (EHV-1)  Equine abortion virus  α Respiratory disease & neurological disease & abortion 
 Equine herpesvirus 2 (EHV-2)  Equine cytomegalovirus γ Associated with respiratory disease & conjunctivitis & malaise 
 Equine herpesvirus 3 (EHV-3)  Equine coital exanthema virus α Genital disease 
 Equine herpesvirus 4 (EHV-4)  Equine rhinopneumonitis virus α Respiratory disease 
 Equine herpesvirus 5 (EHV-5)  Equine cytomegalovirus γ Associated with respiratory disease & equine multinodular pulmonary 
fibrosis 
Donkey Equine herpesvirus 6 (EHV-6)  Asinine herpesvirus 1  α Lesions on external genitalia & udder 
 
Equine herpesvirus 7 (EHV-7)  Asinine herpesvirus 2 γ ? 
 Equine herpesvirus 8 (EHV-8)  Asinine herpesvirus 3 α Rhinitis 
 Asinine herpesvirus 4 (AHV-4) Asinine herpesvirus 4 γ Pneumonia 
 Asinine herpesvirus 5 (AHV-5) Asinine herpesvirus 5 γ Pneumonia 
 Asinine herpesvirus 6 (AHV-6) Asinine herpesvirus 6 γ Pneumonia 
Gazella  Equine herpesvirus 9 (EHV-9)  Gazella herpesvirus α Respiratory disease & encephalitis 
Zebra Zebra herpesvirus (ZHV)  Zebra herpesvirus γ ? 
Wild ass Wild ass herpesvirus (WAHV) Wild ass herpesvirus γ ? 
          
Cattle Bovine herpesvirus 1 (BHV-1) Infectious bovine rhinotracheitis α Infectious bovine rhinotracheitis & infectious pustular vulvovaginitis & 
infectious pustular balanoposthitis 
 Bovine herpesvirus 2 (BHV-2) Bovine mammillitis virus α Bovine mammillitis & lumpy skin disease 
 Bovine herpesvirus 4 (BHV-4) Bovine herpesvirus 4 γ Subclinical disease & reproductive disease 
Wildebeest Bovine herpesvirus 3 (BHV-3) Alcelaphine herpesvirus 1 (AIHV-1) γ Malignant catarrhal fever  
Cattle/Sheep Bovine herpesvirus 5 (BHV-5) Bovine encephalitis virus α Meningoencephalitis & respiratory disease 
Goat/Cattle Bovine herpesvirus 6 (BHV-6) Bovine lymphotropic virus γ Asymptomatic latent infections 
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1.2.3 Structural proteins 
EHV-1 has the capacity to encode 77 different types of proteins from 76 unique genes 
because of the alternative splicing of open reading frame 64 (ORF64) (Telford et al., 
1992), while BHV-1 contains 73 ORFs in the genome and encodes 71 proteins 
(Robinson et al., 2008). All these proteins are divided into three types, including 
capsid, tegument and envelope proteins. 
 
Capsid 
The viral capsid is composed of an outer layer and an intermediate shell, with 
potential channels between the core and the outside of the capsid. The genome and 
capsid together form the nucleocapsid. The capsid is comprised of 162 capsomers and 
protects the inner viral genome.  
 
Tegument 
The tegument surrounding the nucleocapsid is a proteinaceous matrix, which lines the 
space between the nucleocapsid and the envelope (Davison, 2010; Roizman et al., 
2001; Roizman and Pellett, 2001). The tegument is encoded by at least 15 genes and 
contains many virus-encoded proteins, which serve both as structural components of 
virus particles and as modulators of cellular and viral functions in infected cells 
(Eaton et al., 2014; Feng et al., 1996). Since the role of Us3 in host invasion is studied 
in this thesis, a more detailed description about the Us3 protein is given below. 
 
Us3  
The Us3 gene, which is highly conserved among alphaherpesviruses, codes for a 
serine/threonine kinase. EHV-1 Us3 is a 42 kDa protein, whereas the Us3 of BHV-1 
is a 58 kDa protein and the Us3 is a multifunctional protein that plays diverse roles in 
virus replication and pathogenesis. It acts by phosphorylating a number of viral and 
cellular substrates, including UL47, UL34, VP11/12, glycoprotein B, dUTPase and 
cellular KIF3A for HSV-1 (Eaton et al., 2014; Kato et al., 2009; Kato et al., 2011; 
Kato et al., 2014; Purves et al., 1991; Xiong et al., 2015), VP8 and VP22 for BHV-1 
(Labiuk and Babiuk, 2009; Labiuk et al., 2010). In addition, the Us3 proteins of HSV-
1 and PRV also can directly phosphorylate the nuclear matrix protein matrin 3 (Erazo 
et al., 2011) and histone deacetylases (HDAC) (Walters et al., 2010). The 
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hyperphosphorylation of HDAC by HSV-1 enhanced viral gene expression, whereas 
this is not the case for PRV (Walters et al., 2010). Both HSV-1 and PRV Us3 can 
mediate their anti-apoptotic activities at least partly by phosphorylating the pro-
apoptotic protein Bad (Cartier et al., 2003; Deruelle et al., 2007), while BHV-1 Us3 is 
not involved in the inhibition of apoptosis (Brzozowska et al., 2010). The Us3 
proteins of HSV, PRV, BHV-1 and EHV-1 are all involved in modulation of the actin 
cytoskeleton, including cell rounding due to stress fibre breakdown and formation of 
cellular protrusions (Proft et al., 2016; Van Minnebruggen et al., 2003). For PRV, 
group A p21-activated kinase (PAKs) and Us3 kinase lead to activation of cofilin, and 
cofilin contributes to Us3-mediated actin rearrangements (Jacob et al., 2013). 
 
Envelope 
Herpesvirus envelope proteins are typically, but not solely, transmembrane 
glycoproteins that are co-translationally incorporated in the endoplasmic reticulum 
(ER), and travel via the Golgi network to the plasma membrane (Favoreel, 
2006).  The genome of EHV-1 encodes 12 different glycoproteins whereas BHV-1 
encodes at least 10 different ones (Paillot et al., 2008; Schwyzer and Ackermann, 
1996). These envelope glycoproteins, which are explained in detail, are involved in 
virus attachment, penetration, egress, cell-to-cell spread, pathogenicity and virulence 
(Osterrieder and Van de Walle, 2010; Turtinen and Allen, 1982). Given that the role 
of Us9 in BHV-1 invasion of the respiratory mucosa is studied in this thesis, a more 
detail description about the Us9 protein is given below. 
 
Us9 
The Us9 protein is a non-glycosylated type II tail-anchored membrane protein that is 
highly conserved among members of the alphaherpesvirus subfamily (Brideau et al., 
2000; Lyman et al., 2009). The Us9 proteins of both BHV-1 (Al-Mubarak et al., 
2007) and PRV (Kramer et al., 2012; Kratchmarov et al., 2013), together with gE or 
gE/gI, are crucial for efficient anterograde-directed transport of viral particles in 
neurons. For HSV, gE, gI and Us9 can form a trimolecular complex in HSV infected 
Vero cells and the interaction between gE and Us9 is specific but transient (Awasthi 
and Friedman, 2016). BHV-1 Us9 is an early (β)/late (γ1) protein (Chowdhury et al., 
2006). Us9 protein has one predicted protein kinase C phosphorylation site and four 
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potential casein kinase II phosphorylation sites. It is phosphorylated, which is visible 
on western blotting as a protein band with a higher apparent molecular mass at 30-32 
kDa compared to 14.7 kDa of the non-phosphorylated Us9 protein (Chowdhury et al., 
2006). BHV-1 Us9-deleted mutants do not shed virus in the nose or eyes following 
dexamethasone-induced reactivation (Butchi et al., 2007). It has been shown that Us9 
of EHV-1 or BHV-1 is able to compensate for the loss of PRV Us9 in anterograde 
neuron-to-cell spread (Lyman et al., 2009). 
 
Glycoprotein B  
Envelope glycoprotein B (gB) is highly conserved among herpesviruses. The gB 
protein is one of the most antigenic proteins and the target of many neutralizing 
antibodies for both EHV-1 and BHV-1 (Ahmed et al., 1993). It is presumed that gB 
has a function in attachment and membrane fusion for alphaherpesviruses (Eisenberg 
et al., 2012). Initially, it binds to heparin sulfate (HS) moieties on the cell membrane 
and later causes fusion of the viral envelope with the host cell (Eisenberg et al., 2012; 
Trybala et al., 2000). The gB protein is essential for viral penetration and plays an 
important role in direct cell-to-cell spread of virions (Keil et al., 2010; Neubauer et 
al., 1997; Wellington et al., 1996a).  
 
Glycoprotein C  
Like gB, the glycoprotein C (gC) of EHV-1 and BHV-1 also mediates binding to HS 
molecules on cells and initiates cell entry (Azab et al., 2010; Liman et al., 2000; 
Osterrieder, 1999; Sugahara et al., 1997). Hydrophilic regions of EHV-1 gC may be 
responsible for binding to HS (Sugahara et al., 1997). EHV-1 gC is also known to 
bind complement factor C3b, which allows the virus to mediate inhibition of 
complement-mediated neutralization of cell-free virus and complement-mediated lysis 
of infected cells (Azab et al., 2010). In addition, BHV-1 gC null virus is only slightly 
reduced in virulence and is not impaired in cell-to-cell spread (Kaashoek et al., 1998), 
while EHV-1 gC is a critical factor for virion release (Osterrieder, 1999). EHV-1 gC 
has haemagglutination (HA) activity towards equine red blood cells (RBCs) 
irrespective of HS (Andoh et al., 2015).  
 
Glycoprotein D  
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The envelope glycoprotein D (gD) is conserved among most alphaherpesviruses and 
is required for virus entry via cell-cell fusion and/or endocytosis (Azab and 
Osterrieder, 2012; Connolly et al., 2011; Csellner et al., 2000; Van de Walle et al., 
2008). In general, gD is a key determinant of cell tropism by binding to cellular 
receptors (Eisenberg et al., 2012). The gD receptors include members of the tumor 
necrosis factor (TNF) receptor family (HveA), the poliovirus receptor family (HveB 
and HveC, members of the immunoglobulin (Ig) superfamily), integrins, and a 
modified form of HS called 3-O-sulfated HS. All of these receptors have been 
identified to mediate entry of HSV-1 and/or HSV-2 (Geraghty et al., 1998; 
Krummenacher et al., 2004; Montgomery et al., 1996; Shukla et al., 1999). Stable 
binding of gD to one of the above mentioned receptors triggers membrane fusion. 
HveB fails to mediate BHV-1 entry. HveC, also known as nectin-1, is the main 
receptor of gD on epithelial and neuronal cells and can mediate entry of BHV-1 
(Geraghty et al., 1998). However, cells expressing HS-modified 3-O-sulfotransferases 
or the HVEM receptor are not susceptible to BHV-1 (Spear et al., 2000). For EHV-1, 
it was shown that major histocompatibility complex class I (MHC-I) molecules play a 
role as a gD receptor for EHV-1 entry into equine cells (Kurtz et al., 2010).  
 
Glycoprotein E - Glycoprotein I  
Glycoprotein E (gE) is a non-essential and multifunctional virulence protein among 
alphaherpesviruses. It plays an important role in immunomodulation by acting, 
together with glycoprotein I (gI), as an Fc-receptor (Fcγ) but is also crucial for 
efficient antibody-induced viral glycoprotein capping for HSV-1 and PRV 
(Nagashunmugam et al., 1998; Van de Walle et al., 2003). It has been reported that 
intramuscular vaccination with an attenuated EHV-1 gE deletion mutant provides a 
partial protection against EHV-1 induced respiratory disease in foals (Tsujimura et al., 
2009). The BHV-1 genes encoding gE and gI are not essential for propagation of the 
virus in cell culture, but gE is required for anterograde transport of the virus from 
trigeminal ganglia (TG) to nerve endings in the respiratory and ocular epithelia (Liu et 
al., 2008). The gE and gI deletion mutants have a strongly reduced virulence in cattle 
and current marker vaccines for BHV-1 are based on this deletion (Kaashoek et al., 
1994). Knockout of gI results in an export and modification defect of gE. However, 
this defect is kinetic in nature and not absolute as gE can be detected on the surface of 
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BHV-1 gI null infected cells (Whitbeck et al., 1996).  
 
Glycoprotein G  
Glycoprotein G (gG) is a non-essential protein and functions as a host chemokine 
binding protein, a mimicry which allows modulation of the host immune response by 
several alphaherpesviruses, including BHV-1, BHV-5, EHV-1, felid herpesvirus 1 
(FeHV-1) and PRV (Bryant et al., 2003; González-Motos et al., 2016). The gG 
protein of EHV-1 and BHV-1 can bind a broad range of chemokines with high 
affinity and block chemokine activity by preventing their interactions with specific 
receptors, such as glycosaminoglycans (Bryant et al., 2003; González-Motos et al., 
2016). For EHV-1, one of the notable functions of gG is interfering with leukocyte 
migration in tissue, which can contribute to virulence and organ dissemination 
(Osterrieder and Van de Walle, 2010). BHV-1 gG is involved in stabilizing the cell 
structure, postponing apoptotic process, and contributes to efficient cell-to-cell spread 
(Nakamichi et al., 2002).  
 
Glycoprotein H - Glycoprotein L  
Glycoprotein H (gH) is one of the most highly conserved herpesvirus glycoproteins 
and forms a heterodimer with glycoprotein L (gL, complex gH/gL). The gH-gL 
complex has an unusual boot-shaped architecture. The structure reveals extensive 
interactions between gL and the N-terminal domain H1 of gH. The gH/gL complex, 
an unusually tight complex of a novel architecture, acts as a fusion regulator for HSV-
1, PRV, EHV-1 and BHV-1 (Azab et al., 2013; Eisenberg et al., 2012). Unexpectedly, 
the complex does not resemble any known viral fusogen. Instead, it was proposed that 
gH/gL activates gB for fusion, possibly through direct binding (Chowdary et al., 
2010). In the absence of gL, expression of gH polypeptide in transfected cells is not 
folded and processed correctly. In viruses lacking gH, gL is either secreted or retained 
in cells in its immature form. On the other hand, gL is necessary for correct folding 
and trafficking of gH. EHV-1 gH and cellular α4β1 integrins are important 
determinants in the choice of virus cellular entry pathways (Azab et al., 2013). 
Recently, it has been shown that gH is essential for virus entry as well as cell-to-cell 
spread of BHV-1 and different domains within gH might be involved in penetration 
and direct spreading (Schr and Keil, 1999).  
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Glycoprotein K  
The glycoprotein K (gK) of BHV-1 is important for cell-to-cell spread, viral egress, 
syncytia formation, neurovirulence and immunomodulation (Haque et al., 2016; 
Khadr et al., 1996). Moreover, the amino terminus of gK interacts with gB and gH to 
regulate cell fusion (Chowdhury et al., 2013). In addition, the gK proteins of EHV-1 
and BHV-1 interact with UL20 and promote egress of mature viral particles and virus 
production (Guggemoos et al., 2006; Haque et al., 2016). 
 
Glycoprotein M - Glycoprotein N  
Glycoprotein M (gM) is a hydrophobic class III membrane protein with multiple 
transmembrane domains and forms a complex with glycoprotein N (gN) among 
alphaherpesviruses (Crump et al., 2004; Jöns et al., 1998; Osterrieder et al., 1996). 
The gM protein is nonessential for EHV-1 and BHV-1, though is associated with 
virus entry and cell-to-cell spread. The gN protein is involved in efficient virus 
replication and immunomodulation and is necessary and sufficient for functional 
processing of gM (Lipińska et al., 2006; Rudolph et al., 2002). Herpesviruses can 
evade elimination by cytotoxic T lymphocytes through specific interference with the 
transporter associated with antigen processing (TAP) and subsequent antigen-
presenting function of MHC-I. For BHV-1, gN has been shown to act as a TAP 
inhibiting molecule (Verweij et al., 2011). The heterodimer gM/gN complex is 
thought to modulate membrane fusion during HSV infection (Kim et al., 2013).  
 
Glycoprotein 2  
The glycoprotein 2 (gp2) is a unique glycoprotein, which has been only recognized in 
the equid alphaherpesviruses. The gp2 (also known as gp300) protein is encoded by 
ORF71, located within the US region of the genome, with abundant O-glycosylation 
sites in the N-terminal part (Hansen et al., 1995; Smith et al., 2005; Wellington et al., 
1996c). The gp2 protein is a major EHV-1 virulence factor and plays an important 
role in virus attachment and egress as well as cell-to-cell spread (Sun et al., 1996). 
Mutation of ORF71 attenuated the virus but did not inhibit virus replication in the 
murine lung (Frampton et al., 2002; Smith et al., 2005). Some studies indicate that 
gp2 has immunomodulatory properties, as expression of full-length gp2 was sufficient 
to restore full respiratory virulence to the attenuated KyA strain in a murine model of 
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EHV-1 infection (Smith et al., 2005; von Einem et al., 2004). 
 
1.3 Replication cycle  
A general overview of the alphaherpesvirus productive replication cycle, valid for 
EHV-1 and BHV-1, is depicted in Figure 2. 
 
Viral entry and transport to the nucleus  
In general, the first step in initiating alphaherpesvirus infection is the attachment of 
free virions to the surface of a target cell, followed by virus penetration involving 
membrane fusion. The EHV-1 permissive cells include equine cell cultures, e.g. 
epithelial cells, endothelial cells and dermal cells and a number of continuous cell 
lines, such as Chinese hamster ovary (CHO) cells, rabbit kidney (RK-13) cells, human 
cervical cancer (HeLa) cells, Madin-Darby bovine kidney (MDBK) cells, and human 
embryonic kidney (HEK) cell 293 (Azab, et al., 2012). The initial attachment of 
EHV-1 is mediated by interactions of positively charged residues on EHV-1 gB and 
gC with HS proteoglycans present on the cell surface, which are negatively charged 
(Spear and Longnecker, 2003). The gB-HS and gC-HS interactions have also been 
observed for BHV-1 (Byrne et al., 1995; Li et al., 1995; Liang et al., 1993; Okazaki et 
al., 1991), which are relatively unspecific, reversible and serve to concentrate the 
virus at the targeted cell surface. In the step subsequent to viral attachment, at least 
three envelope glycoproteins (gB, gD and gH) have been shown to be essential for 
penetration by BHV-1 (Fehler et al., 1992; Lawrence et al., 1986; Meyer et al., 1991). 
gD forms a stable binding with the possible cellular entry receptors and this binding 
triggers membrane fusion governed by the fusion apparatus gB and gH/L (Eisenberg 
et al., 2012). It has been shown that EHV-1 gD is essential for both virus attachment 
and entry in CHO cells (Csellner et al., 2000; Wellington et al., 1996b; Whittaker et 
al., 1992). It is postulated that there is an entry receptor for EHV-1 gD different from 
HveA, HveB and HveC, which are the receptors for HSV-1 and HSV-2 (Frampton et 
al., 2005). The MHC-I molecules were shown to play a role as a gD receptor for 
EHV-1 entry into equine cells (Kurtz et al., 2010). The protein gH or gH/L 
heterodimer also plays a major role in virus entry, which seems to be conserved 
among alphaherpesviruses (Azab et al., 2012). 
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Figure 2.  Replication cycle of the alphaherpesvirus, with illustrative electron micrographs of the 
respective stages (Mettenleiter et al., 2009).  (1) Initial attachment and (2) penetration allow the release 
of nucleocapsid and tegument into the host cytoplasm. Then, (3, 4) nucleocapsids are transported to the 
nucleus via interaction with microtubules and (5) dock at the nuclear pore (NP) by interacting with 
nucleoporin. In the nucleus, (6) DNA replication and transcription occur. The genome (7, 8) is cleaved 
and packaged into newly formed capsids, (9) which leave the nucleus by budding into the inner nuclear 
membrane (INM). In the perinuclear space, (10) these primary enveloped particles fuse with the outer 
nuclear membrane (ONM), which results in (11) cytoplasmic release of unenveloped particles. These 
particles (12) bud into vesicles of the trans-Golgi network (TGN) to acquire their secondary envelope. 
The mature virions (13) are transported to the cell surface within sorting vesicles and (14) released via 
exocytosis in the extracellular space. RER, Rough endoplasmic reticulum; M, mitochondrion. 
 
A non-endocytotic pathway via direct fusion with the cell membrane is considered as 
the major entry mode for herpesviruses. However, increasing evidence showed that at 
least in some cell types, virus entry might also happen through low-pH-dependent 
endocytosis (Frampton et al., 2007; Rahn et al., 2011). Once the nucleocapsid is 
released in the cytoplasm, capsids misuse the cellular motor protein dynein for direct 
microtubule-based transport towards the nuclear pore complexes. At the nuclear 
pores, docking complexes are formed and the viral DNA is released within the 
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nucleus (Sodeik et al., 1997; Zaichick et al., 2011). 
 
Gene expression and replication  
For all alphaherpesvirus, it is believed that the circular viral DNA genome serves as a 
template for a first round of theta replication, starting from specific origins of 
replication. Two such sequences have been identified in each of the repeats flanking 
the Us regions. The theta replication then switches to a rolling circle mechanism, 
yielding concatemers. The concatemers are cleaved into unit-length genomes and 
packaged into capsids (Muylkens et al., 2007). Host RNA polymerase II is 
responsible for viral DNA transcription. A cascade of transcription drives several 
phases of the viral replication cycle. Viral genes can be subdivided into three 
categories and transcribed sequentially: immediate early (IE), early (E) and late (L) 
genes (Nicoll et al., 2012). First, the IE gene is transcribed, which results in the 
production of a regulatory proteins. These proteins are pivotal for activating 
transcription of E and L genes. EHV-1 IE proteins include EHV-1 infected cell 
protein 0 (EICP0), EICP22, IR4, EICP27, IR2 protein (splice variants of IE gene) and 
EHV-1 α-gene transinducing factor (ETIF or VP16) (Albrecht et al., 2004; Bowles et 
al., 2000; Holden et al., 1995; Kim et al., 2006; Kim and O'Callaghan, 2001; Lewis et 
al., 1997). BHV-1 contains four IE genes encoding ICP0, ICP4, ICP22 and circ 
protein, which localize predominantly to the nucleus and stimulate expression of E 
and L genes. ICP0 is involved in blocking host cell silencing by the nuclear domain 
ten (ND10) protein of promyelocytic leukemia (PML) nuclear bodies (Tavalai and 
Stamminger, 2009). The E gene products mainly play a role in nucleotide metabolism 
and DNA synthesis. The expression of L genes is triggered by DNA synthesis, and 
typically encode structural proteins, such as glycoproteins, required for virus 
assembly and egress (Lehman and Boehmer, 1999).  
 
Virion assembly and egress 
The capsid assembly takes place in the nucleus of the host cell (Rixon et al., 1996). A 
procapsid is first assembled with the formation of the capsid shell and an internal 
scaffolding structure. Then, the procapsid is converted into a mature nucleocapsid 
structure. The internal scaffolding protein is released and replaced by the viral DNA 
genome whereas the capsid shell undergoes a major conformational change (Liu and 
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Zhou, 2007; Mettenleiter et al., 2009). The capsid assembly starts only after the 
replication of viral DNA and synthesis of new capsid proteins, and is initiated by the 
oligomerization of the major capsid protein VP5.  
 
Fully assembled nucleocapsids are too large to pass through the nuclear pores, hence 
they utilize an envelopment/development mechanism for transport to the cytoplasm 
(Mettenleiter et al., 2006). Firstly, nucleocapsids bud through the inner nuclear 
membrane thereby gaining some tegument proteins and a primary nuclear membrane 
envelope. Capsids become released into the cytoplasm by primary envelope fusion 
with the outer leaflet of nuclear membrane. Certain tegument proteins (inner 
tegument) are associated with the capsids, while others (outer tegument) are 
associated with the cellular membrane (Mettenleiter et al., 2006). Final envelopment 
occurs by budding into vesicles at the TGN, and mature virions are released after 
fusion of the vesicles with the plasma membrane (Mettenleiter, 2002). 
 
1.4 Pathogenesis  
1.4.1 Pathogenesis of equine herpesvirus 1 (EHV-1) 
EHV-1 is one of the most pathogenic and contagious herpesviruses of horses. 
Transmission of the virus occurs via direct contact with infectious saliva, nasal 
discharge or fomites. It can be also transmitted by inhalation of infectious aerosols. 
An overview of the complete pathogenesis of EHV-1 is given in Figure 3.  
 
Primary replication in the upper respiratory tract (URT) - respiratory disease   
The primary replication site is the URT after inhalation of EHV-1 or direct contact 
with infectious secretions/fomites (Kydd et al., 1994; Patel and Heldens, 2005). The 
infected URT includes nasal septum, turbinates, nasopharynx, soft palate and trachea 
(Gryspeerdt et al., 2010). During replication in the URT, viral shedding generally 
starts at 1 day post infection (dpi) and lasts for 7 to 14 days, with destruction and 
erosion of the epithelium in several tissues (Edington et al., 1986; Gryspeerdt et al., 
2010; Heldens et al., 2001). Infection of the lower respiratory tract can be observed 
from 2 to 13 dpi, with a peak on 9 dpi when occasional nonocclusive thrombi may 
occur in the pulmonary interstitium (Kydd et al., 1994).  
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In equine respiratory mucosa (nasal and nasopharyngeal mucosa) explants, single 
infected epithelial cells were visible at 12 hour post infection (hpi) and EHV-1 
induced plaques were observed starting from 24 hpi in the epithelium of nasal and 
nasopharyngeal explants. Afterwards, EHV-1 hitchhikes single infected leukocytes, 
mainly CD172a+ monocytic cells and T lymphocytes to cross the basement membrane 
(BM) en route to the blood vessels of the lamina propria and the draining lymph 
nodes (Edington et al., 1986; Kydd et al., 1994; Vandekerckhove et al., 2011). Most 
Alphaherpesviruses, e.g. PRV, BHV-1 and HSV-1, breach the BM barrier in a plaque-
wise manner (Glorieux et al., 2009; Steukers et al., 2012), whereas EHV-1 hijacks 
immune cells, mainly monocytic cells to cross the BM. 
 
The airway form of EHV-1 infection is characterized by rhinopharyngitis and 
tracheobronchitis, which is usually mild or subclinical in adult horses (Del Piero et 
al., 2000). However, young horses can develop more severe clinical signs consisting 
of fever, serous to mucopurulent nasal discharge, swelling of the submandibular and 
retropharyngeal lymph nodes and sometimes anorexia, depression and conjunctivitis 
with ocular discharge (Bryans and Allen, 1986; Del Piero and Wilkins, 2001; Del 
Piero et al., 2000; Patel et al., 1982). Similar to EHV-1, EHV-4 can replicate in the 
epithelium of the URT and the majority of respiratory infections have a subclinical 
course. However, animals that are severely affected show vasculitis, haemorrhages 
and edema in the lungs and may die suddenly during a period of respiratory distress 
(Ostlund, 1993; Patel et al., 1982). 
 
Viral replication in the draining lymph nodes and cell - associated viremia 
After penetrating the BM via infected immune cells, EHV-1 can reach the 
bloodstream and the draining lymph nodes. This results in a cell-associated viremia 
lasting for up to 8 to 18 dpi (Edington et al., 1986; Gibson et al., 1992; Gryspeerdt et 
al., 2010). EHV-1 infection is amplified in the draining lymph nodes with the 
circulation of a large amount of infected leukocytes, which are discharged via the 
efferent lymph, into the blood circulation. Infectious viruses as well as viral antigens 
have been detected in submandibular, retropharyngeal and bronchial lymph nodes 
within 1-2 dpi (Kydd et al., 1994). As a result, EHV-1 initiates a cell-associated 
viremia in peripheral blood mononuclear cells (PBMCs) that allows it to disseminate 
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within the host, which arises from 1 dpi and persists for at least 18 days (Gryspeerdt 
et al., 2010). The cell-associated viremia enables EHV-1 to reach the internal organs 
such as the pregnant uterus and/or central nervous system (CNS).  
 
It has been well documented that PBMCs are susceptible to EHV-1 infection both in 
vitro and in vivo (Goodman et al., 2007; Van de Walle et al., 2009; van der Meulen et 
al., 2000; Wilsterman et al., 2011). However, the load of EHV-1 in different PBMC 
subpopulations is still a point of discussion. One in vivo study showed that the T-
lymphocyte population was used as the primary PBMC subpopulation during the 
viremia induced by EHV-1 infection (Scott et al., 1983). Another in vivo study using 
neurovirulent and non-neurovirulent EHV-1 strains identified CD172a+ monocytic 
cells and to a lesser extent T- and B-lymphocytes as the main virus carrier cells of 
both EHV-1 strains in the blood (Gryspeerdt et al., 2010). This discrepancy could be 
due to the variety of EHV-1 strains used, the immunological status of the horse and/or 
the different technologies to isolate the PBMC subpopulations. During viremia, viral 
envelope proteins are not shown on the surface of the majority of PBMC and both 
neurovirulent and non-neurovirulent EHV-1 infections were mainly non-productive in 
susceptible CD172a+ monocytic cells (Gryspeerdt et al., 2012; Laval et al., 2015a; van 
der Meulen et al., 2003). This indicates that the virus misuses these PBMCs to 
disseminate through the body without being efficiently detected by the immune 
system. In addition, it has been shown that epigenetic modification involving HDACs 
regulate the silencing of non-neurovirulent EHV-1 gene expression in CD172a+ 
monocytic cells whereas this does not appear to influence the replication of 
neurovirulent EHV-1 in these cells (Laval et al., 2015a). In contrast to EHV-1, cell-
associated viremia is extremely rare during EHV-4 infection. Thus, EHV-4 is very 
rarely associated with abortion and neurological diseases (Osterrieder and Van de 
Walle, 2010; Patel and Heldens, 2005; Verheyen et al., 1998).  
 
Secondary replication in the pregnant uterus - abortion and neonatal disease  
During cell-associated viremia, infected leukocytes can transfer EHV-1 to the blood 
vessel endothelial cells of the pregnant uterus (Smith et al., 2001). Secondary 
replication in the endothelial cells of the pregnant uterus can cause vasculitis, 
multifocal thrombosis and disseminated ischemic necrosis (Smith et al., 1996; 
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Wilson, 1997). Based on the severity of the vascular damage, there are two conditions 
of the abortion described. A widespread endometrial blood vessel infection may cause 
detachment of the fetal membranes, thus resulting in the abortion of a virus-negative 
fetus. Less extensive uterine vascular pathology may allow focal transfer of virus 
across the uteroplacental barrier and replication in the fetus, leading to abortion of a 
virus-positive fetus (Patel and Heldens, 2005).  
 
Transfer of EHV-1 from infected leukocytes to placental maternal endothelial cells 
plays a major role in the pathogenesis of abortion. It was shown that activation of 
adhesion molecules present on both leukocytes and endothelial cells surfaces is a 
prerequisite for this virus transfer (Smith et al., 2001). A recent study showed that 
integrin-mediated PI(3)K and ERK/MAPK signaling pathways were involved in 
EHV-1-induced CD172a+ cells adhesion at early time of infection and EHV-1 
replication was enhanced in adherent CD172a+ cells, which correlates with the 
production of TNF-α (Laval et al., 2015b). However, the exact nature of the adhesion 
molecules present on the surface of both equine leukocytes and endothelial cells still 
need to be further identified.  
 
The period between EHV-1 infection and EHV-1 induced abortion differs from 9 
days to 4 months but most infected mares abort within 21 days. During the last 4 
months of pregnancy, there is a much higher chance (up to 95%) of abortion (Bryans 
and Allen, 1986). During abortion, the fetus usually dies from hypoxemia due to the 
separation of the placenta from the endometrium and fetuses that are still alive usually 
succumb quickly by asphyxia due to virus-induced pulmonary lesions. The fetus may 
be born alive when infection occurs during late gestation. However, most of these 
foals die within a few days with jaundice and respiratory distress, which is known as 
neonatal foal disease (Murray et al., 1998; Perkins et al., 1999). Following abortion, 
virus is cleared rapidly from the genital tract, and future breeding capacity is not 
impaired unless some uterine damage has occurred due to dystocia (Smith et al., 
1997). Although mares are not immune to subsequent infection, EHV-1 induced 
abortions in successive pregnancies are rare (Doll et al., 1955; Ostlund, 1993).  
 
Secondary replication in the CNS - neurological disorders 
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When EHV-1 reaches the CNS through a cell-associated viremia in PBMCs, viral 
replication in this organ system can lead to vasculitis and perivasculitis, ultimately 
resulting in equine herpes myeloencephalopathy (EHM) (Edington et al., 1986; 
Jackson et al., 1977). EHM is the result of an inflammatory cascade that is associated 
with EHV-1 infection of the endothelial cells in the CNS (Jackson and Kendrick, 
1971; Wilson, 1997).  
 
EHM can occur without preceding signs, but sometimes fever or upper respiratory 
disease during the 2 weeks before the onset of neurological signs is observed (Reed 
and Toribio, 2004; Van Maanen, 2002). The incubation period of EHV-1 induced 
neurological disorders can vary between 6 to 8 days (Edington et al., 1986; Jackson 
and Kendrick, 1971; Jackson et al., 1977). Clinical signs consist of mild ataxia, 
swaying, stumbling and falling to complete paralysis (Stierstorfer et al., 2002). Other 
clinical signs include distal limb edema, head tilting, edema of testes, tail paralysis, 
bladder infection and fecal and/or urinary incontinence (Van Maanen, 2002). In some 
cases, cerebral disorders such as blindness and torticollis are observed (Friday et al., 
2000; van der Meulen et al., 2003). Macroscopic lesions involve small focal 
haemorrhages distributed throughout meninges, brain parenchyma and spinal cord. 
Histological lesions comprise vasculitis and thrombosis, resulting in a secondary 
hypoxic degeneration of adjacent neural tissue (Bryans and Allen, 1986; Wilson, 
1997). 
 
Secondary replication in eyes - ocular disorders 
EHV-1 infection in the vasculature of the eyes can induce chorioretinopathy, with 
multifocal chorioretinal lesions in infected horses (Slater et al., 1992). This type of 
lesion is typically caused by endothelial damage with subsequent ischemic injury to 
the chorioretina that may result from direct infection of the vascular endothelium 
following viremia. Most EHV-1 induced ocular infections are subclinical, though 
diffuse lesions sometimes may lead to extensive retinal destruction and blindness 
(Hussey et al., 2013).  
 
Latency and reactivation  
After the primary infection in respiratory epithelial cells, EHV-1 enters a latent state 
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in leukocytes and in sensory nerve cell bodies within the trigeminal ganglia. Latency 
is an important epidemiological strategy that ensures virus survival and spread within 
the equine populations (Whitwell and Blunden, 1992). The molecular mechanism of 
how EHV-1 enters into a latent relationship with its host is still not clear. During 
latency, the transcription of EHV-1 genome is restricted and only a viral RNA 
transcribed from the IE gene, which is also named latency-associated transcript 
(LAT), is present (Paillot et al., 2008). EHV-1 can be reactivated from latency upon 
corticosteroid treatment and natural stimuli such as stress, weaning and castration 
(Burrows and Goodridge, 1984; Slater et al., 1994). Following reactivation, EHV-1 
can be transferred back to the URT and starts a lytic infection. This can result in virus 
shedding with the potential to infect other horses. A cell-associated viremia may also 
be initiated following infection of the respiratory epithelium upon reactivation and 
may allow EHV-1 to reach the pregnant uterus or the CNS to cause abortions or 
neurological disorders. The majority (>60%) of horses is latently infected by EHV-1 
(Lunn et al., 2009). Latently infected cells are masked from immune surveillance, and 
are difficult to eliminate by conventional antiviral therapies and vaccine strategies. 
 
The development of abortion versus EHM  
The ability of EHV-1 strains to induce abortion or neurological damage appears to be 
correlated with differences in the ability to establish infection at vascular endothelial 
sites, in particular within the endometrium and CNS (Edington et al., 1986; Patel et 
al., 1982). It was reported that horses inoculated with EHV-1 neurovirulent strains 
developed both a greater magnitude and duration of PBMC-associated viremia 
compared to animals inoculated with non-neurovirulent strains (Allen and 
Breathnach, 2006). However, severe symptoms do not necessarily follow the cell-
associated viremia. The incidence of EHV-1 induced abortions is higher (approx. 
50%) than that of EHM (10%) (Goehring et al., 2006). Recent investigations 
demonstrated that a single amino acid polymorphism is strongly associated with 
neurological versus non-neurological disease outbreaks (Nugent et al., 2006). It was 
found that a single nucleotide mutation that induced substitution of asparagine (N) by 
aspartic acid (D) at position 752 in ORF30 (DNA polymerase) is a major contributory 
factor in determining abortion or EHM. More than 95% of non-neuropathogenic 
outbreaks are caused by virus strains with N752, and more than 86% of 
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neuropathogenic outbreaks are caused by strains encoding D752. However, a 23-year 
retrospective study of the prevalence of neurologic EHV-1 demonstrated that 24% of 
the EHM outbreaks are caused by N752 EHV-1 strains and 2% of the EHV-1-induced 
abortions are caused by D752 genotype strains (Perkins et al., 2009). Thus, the 
specific genomic mutation of DNA polymerase (D752 verse N752) is correlated with 
disease, but is not a universal finding in all cases. Several factors including virus 
strains, age of the host, previous EHV-1 infection history, immune function and 
possibly hormonal status have been proposed to contribute to the development of 
different symptoms.   
 
1.4.2 Pathogenesis of bovine herpesvirus 1 (BHV-1) 
Diseases caused by BHV-1 include infectious bovine rhinotracheitis (IBR), 
conjunctivitis, infectious pustular vulvovaginitis (IPV), infectious pustular 
balanoposthitis (IPB) and abortion in adult cattle (Huck and Millar, 1974; Kendrick et 
al., 1958; McKercher et al., 1963; Ormsbee and Weiss, 1963) as well as encephalitis, 
enteritis, and generalized diseases in calves (French, 1962a; French, 1962b; 
Vankruiningen and Bartholomew, 1964). BHV-1 is also a significant initiator of and 
contributor to “shipping fever” pneumonia (Yates, 1982). It has been reported that 
virus can be transmitted by nose-to-nose contact, aerosol, breeding contact with 
infected prepuce or vaginal epithelium, artificial insemination with infected semen, 
and even transmission by ticks (Dinter and Morein, 1990) (Figure 3). 
 
Respiratory and genital infection - respiratory and genital diseases 
BHV-1 initiates replication in epithelial cells of respiratory and genital tract. In vivo, 
primary infection with the virus will result in extensive nasal shedding of progeny 
virus, which will excrete from 1 dpi and last for 10 to 16 days (Jones and Chowdhury, 
2007). BHV-1 replication in the respiratory tract can induce severe dyspnea and open 
mouth breathing. Clinical symptoms of respiratory infection include mucopurulent 
discharge from the nose and eyes, high fever, anorexia, and hypersalivation. 
Secondary bacterial infection is a common complication and might aggravate the 
clinical feature. Indeed, the severity of disease is influenced by multiple factors such 
as virus strains, age and host resistance factors (Muylkens et al., 2007). In bovine 
respiratory mucosa explants, a plaque-wise spread of BHV-1 across the BM was 
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observed at 24 hpi. Moreover, BHV-1 exhibited an increased capacity to invade 
proximal tracheal tissues compared to tissues of the deeper part of the nasal septum 
and ventral conchae (Steukers et al., 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Pathogenesis of EHV-1 (a) and BHV-1 (b) infection. (1) The respiratory tract is the primary 
replication site for EHV-1 while either the respiratory or genital tract is considered as the primary 
replication site for BHV-1. (2) After local replication, the virus gains access to the blood vessels and 
spreads via viremia to internal organs. (3) In horses, EHV-1 may reach the CNS or uterus, resulting in 
neurological disorders or abortion and neonatal disease. In addition, EHV-1 may reach eyes and induce 
ocular disorders. In pregnant cows, BHV-1 may reach the uterus and cause extensive replication within 
the fetus, resulting in abortion. (4) EHV-1 or BHV-1 invades nerve endings at the primary replication 
sites and establishes life-long latency in the trigeminal ganglion.  
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Initial genital manifestations of BHV-1 are pustules in the caudal vagina and/or vulva 
for cows and pustules on the penis for bulls, termed IPV and IPB, respectively. 
Additionally, hyperemia and edema can also be observed. In general, genital 
infections are less severe and less common than respiratory infections, as the use of 
artificial insemination and negative bulls repressed this clinical image (Muylkens et 
al., 2007). In bovine genital mucosa explants, BHV-1 exhibited a less profound 
invasion capacity but with larger plaque latitude in genital tissue compared to that in 
respiratory tissue at 24 hpi (Steukers et al., 2011). 
 
Cell-associated viremia and latency 
BHV-1 establishes a lifelong latency in sensory neurons of the peripheral nervous 
system following replication in mucosal epithelium. However, there is limited 
information regarding the mechanisms by which the virus gains access to blood 
vessels and spreads to internal organs.  
 
After local dissemination, the virus can reach internal organs via leukocytes and 
invade nerve endings and hide in the infected host. The main sites of latency are 
sensory neurons of trigeminal ganglia (TG) and reactivation occurs within TG 
(Winkler et al., 2000). In latently infected neurons, only the BHV-1 region containing 
the latency-related transcript (LRT) is expressed leading to the inhibition of the lytic 
virus cycle and the induction of an anti-apoptotic state of the infected cells. 
Periodically, latent BHV-1 may be reactivated, leading to a widespread transport of 
the virus, virus replication in the respiratory mucosa, virus shedding and transmission 
to naïve contact animals (Turin et al., 1999). Reactivation may be triggered by stress 
associated with parturition (Thiry et al., 1985), transport (Thiry et al., 1987), animal 
movement and mixing (Jones and Chowdhury, 2010), inclement weather (van Drunen 
Littel-van den Hurk, 2006), concomitant infection, poor husbandry or diet (Turin et 
al., 1999), overcrowding (van Drunen Littel-van den Hurk, 2006) or following 
treatment with corticosteroids (Winkler et al., 2000).  
 
2. Equine arteritis virus  
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2.1 History and taxonomy 
Equine arteritis virus (EAV) was first isolated in 1953 from an aborted fetus on a 
standardbred farm in Bucyrus, Ohio. In 1957, the agent isolated from the Ohio 
outbreak was named EAV because of the distinctive vascular lesions arteritis (Doll et 
al., 1968). The clinical description of equine virus arteritis (EVA) was first reported in 
the European veterinary literature over a century ago. An especially large outbreak of 
EVA occurred on several thoroughbred breeding farms in Kentucky in 1984, which 
led to the establishment of importation regulations by a number of countries 
(Timoney et al., 1987). EVA is an economically important viral disease of equids and 
its prevalence is increasing, possibly due to intensified transportation of horses and 
their semen.  
 
EAV is the prototype virus of the family Arteriviridae (genus Arterivirus), order 
Nidovirales, which also includes porcine reproductive and respiratory syndrome virus 
(PRRSV), simian hemorrhagic fever virus (SHFV), lactate dehydrogenase elevating 
virus of mice (LDV) and wobbly possum disease virus  (WPDV) (Balasuriya, 2014). 
Based on phylogenetic analysis of the RNA-dependent RNA-polymerase, the order of 
the Nidovirales was divided in three families: Arteriviridae (1 genus), Roniviridae (1 
genus) and Coronaviridae (2 subfamilies: Coronavirinae and Torovirinae) (Fauquet 
et al., 2005; Knowles et al., 2012; Siddell and Snijder, 2008). Nidovirales are 
characterized by an extraordinary genetic complexity, which allows them to expand 
their host range and to adapt rapidly to changing environmental conditions (Ziebuhr et 
al., 2000).  
 
2.2 Virus characteristics  
2.2.1 General structure of the virion 
The mature EAV particle is a spherical virus with a diameter of 40-60 nm. EAV 
genomic RNA with a size of approximately 12.7 kbp is packaged into an icosahedral 
nucleocapsid core of 25-35 nm in diameter (Horzinek et al., 1971). This nucleocapsid 
consists of nucleocapsid proteins, which are enclosed in an envelope with tiny surface 
projections (Horzinek et al., 1971). EAV virions include seven structural proteins, 
with one phosphorylated nucleocapsid (N) protein and six envelope proteins (GP 2b, 
E, GP3, GP4, GP5 and M) (De Vries et al., 1992) (Figure 4). 
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Figure 4. Equine arteritis virus particle: (a) electron micrograph of EAV ((Friedland, 1998).). (b) 
schematic representation of an EAV particle (adapted from (Balasuriya et al., 2013)). 
 
2.2.2 Genomic organization  
The EAV genome is a single-stranded positive-sense RNA that consists of 9 ORFs. In 
addition, the genome contains a 5’ non-coding region that carries a cap at its 5’ end 
and a 3’ non-coding region attached to a poly-A tail. The two 5’ proximal ORFs (1a 
and 1b) occupy approximately three-fourths of the genome and encode 2 replicase 
polyproteins. These precursor proteins are extensively processed after translation into 
13 nonstructural proteins. Seven overlapping ORFs (2a, 2b, 3, 4, 5a, 5b, and 6) 
encode 7 structural proteins, including six envelope proteins E, GP2b, GP3, GP4, 
GP5, and M and a nucleocapsid N protein. Three of the minor envelope glycoproteins 
(GP2, GP3, and GP4) form a heterotrimer in the EAV particle, and the membrane 
protein M (non-glycosylated) and GP5 (glycosylated) proteins form a disulfide-linked 
heterodimer (De Vries et al., 1992; Firth et al., 2011).  
 
2.2.3 Structural viral proteins  
Nucleocapsid N protein  
The N protein, encoded by ORF7, is a small hydrophilic protein with a high content 
of basic amino acids (De Vries et al., 1992). The EAV N protein appears to be 
organized as dimers of dimers (tetramers), which may reflect the arrangement of the 
protein in the viral nucleocapsid. The dimeric N protein structure is similar to the 
structure of the N protein of PRRSV (Spilman et al., 2009).  
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Envelope proteins 
The major envelope protein M and GP5 protein are the most abundant envelope 
proteins, which are presented as disulfide-linked heterodimers in virus particles. The 
minor envelope E protein is the third most abundant protein in the viral membrane 
(Snijder et al., 1999). The minor envelope GP2, GP3, and GP4 proteins exist in 
equimolar amounts in virus particles, which are covalently associated and form a 
heterotrimeric complex on the surface of the virion (De Vries et al., 1992; Wieringa et 
al., 2003a; Wieringa et al., 2002; Wieringa et al., 2003b; Wieringa et al., 2004). The 
major envelope proteins M and GP5 as well as the N protein are essential for EAV 
particle formation, whereas neither E protein nor the minor envelope proteins are 
required for production of viral particles (Molenkamp et al., 2000). In contrast, with 
the exception of the ORF5a protein, all major (N, GP5, and M) and minor (E, GP2, 
GP3, and GP4) structural proteins are required for production of infectious progeny 
virus (Wieringa et al., 2004).  
 
2.3 Replication cycle 
EAV North American strains, with high virulence, replicate primarily in equine 
macrophages and endothelial cells lining small blood vessels, as well as in selected 
epithelia, mesothelium, and smooth muscle cells of the tunica media of smaller 
arteries, venules, and the myometrium; whereas EAV 08P178, a mildly virulent 
European strain does not infect endothelial cells of large blood vessels but does infect 
a considerable number of endothelial cells in terminal capillaries (Balasuriya and 
Snijder, 2008; Del Piero, 2000; Kim et al., 1993; MacLachlan et al., 1996; Plagemann 
and Moennig, 1992; Rossow, 1998; Vairo et al., 2012). Both the North American and 
European strains can replicate in vitro in a variety of primary cell cultures, including 
equine pulmonary artery endothelial cells, horse kidney, rabbit kidney, and hamster 
kidney cells, and in a number of continuous cell lines such as baby hamster kidney 
(BHK-21), RK-13, African green monkey kidney, rhesus monkey kidney, MARC-
145, hamster lung, SV-40 transformed equine ovary and canine hepatitis virus-
transformed hamster tumor cells (Hyllseth, 1969; Konishi et al., 1975; Lu et al., 2012; 
Maess et al., 1970; Radwan and Burger, 1973).  
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Figure 5. Replication cycle of equine arteritis virus (ICTV 9th report, 2011). The process includes virus 
attachment, entry, viral genome replication, mRNA transcription, viral protein synthesis, virus 
assembly, budding, and release. ER, endoplasmic reticulum; PM, plasma membrane; NC, non-coding. 
 
Like other viruses, EAV infection of cells involves virus attachment, entry, viral 
genome replication, mRNA transcription, viral protein synthesis, virus assembly, 
budding, and release (Figure 5). The viral envelope protein(s) involved in EAV 
attachment and entry and the associated receptors have not been fully characterized. It 
is proposed that EAV is taken up via clathrin-dependent endocytosis and then 
delivered to acidic endosomal compartments (Nitschke et al., 2008). Following entry 
and release into the cytosol, the plus-stranded RNA genome is uncoated and 
translated into two replicase polyproteins 1a and 1ab from which at least 13 non-
structural proteins are released by autoproteolytic processing mediated by viral 
proteases (Fang and Snijder, 2010; Ziebuhr et al., 2000). The non-structural proteins 
assemble into a membrane-bound replication/transcription complex (RTC) (Knoops et 
al., 2012; Monastyrska et al., 2013). Genome replication and subgenomic (sg) mRNA 
transcription occur in the RTC and sg mRNAs are then translated into the viral 
structural proteins. The newly synthesized genome is encapsidated into the N protein 
to form the nucleocapsid, which becomes enveloped by budding through the ER-
Golgi intermediate compartment that contains membranes that include the viral 
envelope proteins. Newly formed virions mature in the Golgi complex during their 
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movement through the exocytotic pathway and are ultimately released from infected 
cells. 
 
2.4 Pathogenesis  
EVA is a global infectious disease of horses and is characterized by panvasculitis 
inducing edema, hemorrhage, and abortion in pregnant mare. In 1964 a very large 
EVA outbreak occurred in Switzerland where over 400 horses showed clinical signs ( 
Burki and Gerber, 1966). In 1984, a widespread EVA outbreak occurred in 41 
Thoroughbred breeding farms in Kentucky (Timoney, 1984). In 2006, outbreaks 
occurred in a breeding farm of Quarter Horses in New Mexico in the USA and 
subsequently extended to premises in five other states (Kansas, Montana, Oklahoma, 
Utah, and Alabama) where a quarantine period of 7 months was subsequently 
imposed. In France, an outbreak was registered in the summer of 2007. Both 
incidences were associated with artificial insemination of cool-shipped semen 
(Holyoak et al., 2008).  
 
Transmission of EAV between horses occurs via either the respiratory or venereal 
route (Bryans et al., 1957a; Cole et al., 1986; McCollum et al., 1971). Horizontal 
respiratory transmission occurs after aerosolization of infected respiratory tract 
secretions, urine and other body secretions with direct and close contact (Burki et al., 
1992; Collins et al., 1987; Guthrie et al., 2003; McCollum et al., 1971). Venereal 
transmission of EAV via contaminated semen of stallions that are either acutely or 
chronically infected with the virus is an important route of natural transmission of the 
virus (Timoney et al., 1986a; Timoney et al., 1986b).  
 
2.4.1 Pathogenesis following respiratory uptake of the virus 
Upon EAV infection via the respiratory tract, high titers of EAV can be observed in 
respiratory secretions for 7-14 days during acute infection. For EAV North American 
strains, the virus infects the alveolar macrophages and pneumocytes with viral 
antigens localized within their cytoplasm at 24 hpi (Wilkins et al., 1995). At 48 hpi, 
the virus can be found in the satellite lymph nodes, especially in the bronchial lymph 
nodes. EAV antigens are contained within stromal dendrite-like cells and within the 
macrophages of the lymph node sinuses (Bryans et al., 1957b). Viremia starts from 2 
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to 3 dpi depending on the animal and the virus strain. Recent studies on EAV 
European strain 08P178 showed that the virus has a main tropism for CD172a+ and 
CD3+ mononuclear leukocytes. This strain does not infect endothelial cells of large 
blood vessels but does infect a considerable number of endothelial cells lining 
terminal capillaries. EAV 08P178 infection in these capillaries is probably the cause 
of an increased vascular permeability leading to leakage of fluid (edema-serous 
exudate) but not to severe vasculitis and hemorrhages as seen with highly virulent 
American EAV strains (Vairo et al., 2012).   
 
2.4.2 Pathogenesis following the venereal route of infection 
Until now, there is no report on the pathogenesis of EAV following venereal exposure 
to the virus. However, it is presumed that the virus is taken up from vaginal mucosa 
and is transported to the local lymph glands where it likely replicates and is released 
into the bloodstream and the lymphatic circulation (Vairo, 2013). 
 
3. Monocytic cells and cytokines  
 
3.1 Monocytic cells   
The term monocytic cell is used for blood cells of a lineage comprising monoblasts, 
monocytes, macrophages and dendritic cells (DCs). Blood monocytes originate from 
bone marrow precursors, circulate through the blood for a few days, during which a 
proportion of cells migrate constitutively into tissues, where they differentiate into 
macrophages or DCs. Under steady state condition, blood monocytes migrating into 
the tissues will differentiate into dendritic cells, except for the intestine where they 
can differentiate into DCs and macrophages. During inflammation, blood monocytes 
migrating into the tissues can differentiate into macrophages and inflammatory DCs. 
Recruitment, or homing, of monocytes into tissues is directed by chemokines, which 
are divided into lymphoid and inflammatory chemokines. The lymphoid chemokines 
recruit cells into noninflamed tissue, whereas inflammatory chemokines recruit cells 
into inflamed tissue. Besides, monocytes are also functionally characterized by the 
ability to phagocytose, and to present antigen (Ziegler-Heitbrock, 2015). Monocytic 
cells constitute a group of cell types crucial for the control of pathogens and induction 
of immune responses as well as for the support of tissue functions. These properties 
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make them highly relevant targets for immune therapy, vaccination, and treatment of 
autoimmune and inflammatory diseases (Ginhoux and Jung, 2014; Schlitzer and 
Ginhoux, 2014).  
 
As explained above, monocytic cells initially have been characterized by function and 
morphology but these criteria were misleading especially when disease processes 
altered these features. Therefore, attempts have been made to define unequivocal 
criteria for monocytes. Thus, monoclonal antibodies (mAb) against cell surface 
molecules have been proposed. CD14 has been used as a marker for human 
monocytic cells (Ziegler-Heitbrock and Ulevitch, 1993), while CD115 is often 
employed for mouse monocytic cells (Sunderkötter et al., 2004). However, part of the 
human B cells have been reported to express some CD14 (Schwarz et al., 2014; 
Ziegler-Heitbrock et al., 1994). Therefore, monocytic cells can be identified with 
markers like CD14 and CD115, but this should be supported by additional markers 
and by functional studies. In 2010, an international consortium under the auspices of 
the International Union of Immunological Societies (IUIS) and the World Health 
Organization (WHO) has proposed a nomenclature for monocyte subpopulations 
(Ziegler-Heitbrock et al., 2010). The proposal defined the major population of CD14 
high cells found in human blood as classical monocytes and the minor population of 
cells with low CD14 and high CD16 as non-classical monocytes. A population in 
between these two subsets was termed intermediate monocytes (Ziegler-Heitbrock, 
2015) (Figure 6). Gene expression profiling reveals the defining features of the three 
human monocyte subsets (Wong et al., 2011). Classic monocytes express AP-1 
transcription factor genes, CLEC4D and IL-13Rα1 surface proteins, whereas non-
classic monocytes are distinguished by cytoskeleton rearrangement genes, 
inflammatory cytokine production, and CD294 and Siglec10 surface expression. The 
features for intermediate monocytes include highest levels of MHC II, GFRα2 and 
CLEC10A expression. In mouse, classical and non-classical monocytes are defined 
by their expression of Ly6C (Shi et al., 2011) (Figure 6). 
 
The same nomenclature as proposed for humans can be used in other species (Ziegler-
Heitbrock, 2014). In horses, the study of monocyte subsets is at its infancy. Recently, 
mAbs against horse CD14 and CD16 have been used to define equine monocytes 
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(Kabithe et al., 2010; Noronha et al., 2012; Ziegler-Heitbrock, 2014). During EHV-1 
infection in the URT, equine CD172a+ monocytic cells have been shown to be one of 
the main target cells and were proposed to serve as ‘Trojan horses’ to facilitate the 
dissemination of EHV-1 to target organs, which has also been detected for EAV 
infection (Vairo et al., 2013; Vandekerckhove et al., 2010). CD172a belongs to the 
family of Signal Regulatory Proteins (SIRP), which is expressed primarily by myeloid 
cells such as macrophages, DCs, monocytes and granulocytes (Barclay and Brown, 
2006; Van Beek et al., 2005). CD172a-positive macrophages are produced by 
differentiation of monocytes and their main function is phagocytosis of cellular debris 
and destroy pathogens. They are found between the epithelium and in the lamina 
propria of the respiratory mucosa (Holt, 1993). 
 
 
3.2 Cytokines  
Cytokines are small, water-soluble, signaling proteins and glycoproteins secreted by 
hematopoietic and non-hematopoietic cells (Holloway et al., 2002). There are both 
pro-inflammatory cytokines (promote inflammation) and anti-inflammatory cytokines 
(reduce inflammation and promote healing). Cytokines are involved in virtually every 
facet of immunity and inflammation, including innate and adaptive immunity, antigen 
presentation, bone marrow differentiation, cellular recruitment and activation, and 
adhesion molecule expression. During these processes, they potentiate cellular 
communication via autocrine and paracrine mechanisms (Borish and Steinke, 2003). 
In response to injury/infection, cytokines are secreted by inflammatory cells over 
several hours to days, and in some instances even weeks (Medzhitov, 2008; Ryan and 
Majno, 1977).  
 
Human monocytes                                          Mice monocytes 
CD14++CD16−       CD14++CD16+        CD14+CD16++                                                Ly6Chigh                        Ly6Clow 
 
 
classical         intermediate    non-classical         classical        non-classical 
Figure 6.  Classification of human and mice monocytes. Human monocytes are divided into three types, 
including classical, intermediate, non-classical monocytes whereas mice monocytes are divided into 
classical and non-classical monocytes.  
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3.2.1 Pro-inflammatory cytokines  
Pro-inflammatory cytokines are produced predominantly by activated macrophages 
and are involved in the up-regulation of inflammatory reactions (Zhang and An, 
2007). The cytokines predominantly produced by monocytes include TNF, and 
several interleukin (IL) molecules known as IL-1, IL-6, IL-8, IL-12, IL-15, IL-18, and 
IL-23. IL-8 is also classified as a chemokine known as CXCL8, which is secreted by 
APCs (Borish and Steinke, 2003).  
 
TNF 
TNF was originally identified in 1975 by Lloyd Old as a macrophage-derived factor 
that could “necrotize” tumors in mice (Carswell et al., 1975). TNF represents two 
homologous proteins primarily derived from mononuclear phagocytes (TNF-α) and 
lymphocytes (TNF-β) (Beutler and Cerami, 1989). TNF is a classic pro-inflammatory 
cytokine secreted by a number of cells including mononuclear phagocytes, 
neutrophils, activated lymphocytes, natural killer (NK) cells, endothelial cells, mast 
cells, and tumor cells (Borish and Steinke, 2003; Remick and Friedland, 1997; 
Spriggs et al., 1987). TNF is induced in response to a variety of stimuli, including 
bacterial endotoxins, oxygen radicals, and viruses. TNF is a potent activator of 
neutrophils, mediating adherence, chemotaxis, degranulation, and respiratory burst. 
TNF interacts with endothelial cells to induce adhesion molecules known as 
intracellular adhesion molecule (ICAM)-1, vascular cell adhesion molecule (VCAM)-
1, and E-selectin, thus promoting diapedesis of granulocytes into inflammatory loci. 
TNF induces antitumor immunity through direct cytotoxic effects on cancerous cells. 
It has been reported that TNF production can also induce various other cytokines 
including IL-1β and IL-8 (Cassatella et al., 1993; DeForge et al., 1992).  
 
IL-1 
The Interleukin-1 family (IL-1 family) is a group of 11 cytokines, which plays a 
central role in the regulation of immune and inflammatory responses to infections or 
sterile insults. The members IL-1α and IL-1β have similar biological activities, and 
both of these proteins interact with similar affinities to the IL-1 receptors (IL-1Rs) 
(Dinarello and Wolff, 1993). Human IL-1 is primarily produced by the mononuclear 
phagocytic lineage cells, but is also expressed by EC, keratinocytes, synovial cells, 
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osteoblasts, neutrophils, glial cells, and numerous other cells. IL-1 production may be 
stimulated by a variety of agents, including endotoxin, other cytokines, 
microorganisms, and antigens. IL-1 is able to activate T lymphocytes by enhancing 
the production of IL-2 and expression of IL-2 receptors. The production of IL-1 
during the immune response produces a spectrum of changes associated with being ill. 
In the absence of IL-1, a diminished immune response or a state of tolerance 
develops. IL-1 interacts with the CNS to produce fever, lethargy, sleep, and anorexia. 
And IL-1 also contributes to the hypotension of septic shock. During these processes, 
IL-1 stimulates adherence of leukocytes through the upregulation of ICAM-1, 
VCAM-1, and E-selectin.  
 
IL-6 
IL-6 is most often produced by monocytes/macrophages in response to endotoxin 
stimulation; however, IL-6 is also produced by T and B lymphocytes, fibroblasts, 
endothelial cells, keratinocytes, hepatocytes, and bone marrow cells (Akira et al., 
1990; Kato et al., 1990). IL-6 elicits not only acute phase reactions but also the 
development of specific cellular and humoral immune responses, including end-stage 
B cell differentiation and immunoglobulin secretion (Gabay, 2006). In addition, IL-6 
also mediates T lymphocyte activation, growth, and differentiation as well as 
induction of pyrexia and the production of acute phase proteins. IL-6 is considered the 
most important inducer of hepatocyte synthesis of acute phase proteins and has been 
shown to play a central role in the neuronal reaction to nerve injury (Zhang and An, 
2007). In contrast to these pro-inflammatory effects, IL-6 mediates several anti-
inflammatory effects. Whereas both IL-1 and TNF induce synthesis of each other, as 
well as IL-6, IL-6 terminates this up-regulatory inflammatory cascade and inhibits IL-
1 and TNF synthesis. Furthermore, IL-6 stimulates the synthesis of the IL-1 receptor 
antagonist (Borish and Steinke, 2003). 
 
3.2.2 Immunomodulating cytokines 
The immunomodulating cytokines are a series of immune regulatory molecules that 
possess both anti-inflammatory activities and substantial pro-inflammatory activities. 
Cytokines act in concert with specific cytokine inhibitors and soluble cytokine 
receptors to regulate the immune response. The major immunomodulating cytokines 
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include IL-1ra, IL-4, IL-11, and IL-13. Leukemia inhibitory factor, interferon (IFN)-
alpha, IL-6, and transforming growth factor (TGF)-β are categorized as either anti-
inflammatory or pro-inflammatory cytokines, under various circumstances.  
 
IL-1ra 
IL-1ra is a member of the IL-1 cytokine family, which is secreted by various types of 
cells including immune cells, epithelial cells, and adipocytes (Perrier et al., 2006). IL-
1ra is a naturally occurring inhibitor, which binds to the IL-1 receptor (IL-1R1) with 
nearly irreversible affinity, and does not trigger signal transduction (Antin et al., 
1994; Dinarello, 1994). Thus, it functions as an anti-inflammatory cytokine by 
blocking the binding of IL-1α and IL-1β to the IL-1R1 (Granowitz et al., 1991) and 
modulates a variety of IL-1 related immune and inflammatory responses. IL-1ra is 
used in the treatment of rheumatoid arthritis, and the treatment of equine lameness 
secondary to joint and soft-tissue injury. 
 
IL-4 
IL-4 is a cytokine that plays a pivotal role in shaping immune responses. It induces 
differentiation of naive helper T cells to Th2 cells (Sokol et al., 2008). Upon 
activation, naive peripheral CD4+ T cells begin to synthesize and secrete cytokines. 
These cytokines serve as autocrine growth and differentiation factors and induce 
naive T cells to proliferate and differentiate into effector cells. In addition, IL-4 also 
stimulates the activation of B-cell proliferation, and the differentiation of B cells into 
plasma cells. IL-4 induces B-cell class switching to IgE, and up-regulates MHC II 
production. 
 
IL-11 
IL-11, also known as adipogenesis inhibitory factor (AGIF) (Kawashima et al., 1991) 
or oprelvekin, was originally described as a stimulatory factor for hematopoietic 
precursor cells. It is a multifunctional cytokine and a key regulator of multiple events 
in hematopoiesis, most notably the stimulation of megakaryocyte maturation (Paul et 
al., 1990). IL-11 stimulates the production of acute phase proteins, the growth of 
certain lymphocytes, an increase in the cortical thickness and strength of long bones. 
In addition to having lymphopoietic/hematopoietic and osteotrophic properties, it has 
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functions in many other tissues, including the brain, gut, testis and bone (Sims et al., 
2005).  
 
3.3 Chemokines  
Chemokines are a group of low molecular weight secreted proteins (8 to 12 kDa), 
which are able to induce chemotaxis in a variety of cells including neutrophils, 
monocytes, lymphocytes, eosinophils, fibroblasts, and keratinocytes. These molecules 
regulate activity through interactions with members of the seven-transmembrane, G-
protein-coupled receptor superfamily (Zlotnik and Yoshie, 2000). Many of the 
chemokine receptors can bind more than one ligand, allowing extensive overlap and 
redundancy of chemokine function. 
 
Typically, chemokines are produced at the site of infection or in response to a pro-
inflammatory stimulus. The inflammatory chemokines produced by many cell types 
in multiple locations can recruit and activate leukocytes to mount an immune 
response and initiate wound healing. Other chemokines have now been shown to have 
a homeostatic or housekeeping function, which tend to be expressed in specific tissues 
or organs. These chemokines are involved in adaptive immune responses including 
lymphocyte trafficking, hematopoiesis, antigen sampling in secondary lymphoid 
tissue, and immune surveillance (Moser and Loetscher, 2001).  
 
Chemokines have conserved N-terminal cysteine residues that allow them to be 
assigned to four subfamilies (Figure 7). In the C-C subfamily, the cysteine residues 
are adjacent to each other, including CCL2 (monocyte chemoattractant protein, MCP-
1), CCL5 (regulated on activation, normal T cell expressed and secreted, RANTES), 
CCL3 (monocyte inflammatory protein, MIP-1α), CCL4 (MIP-1β) and so on 
(Fernandez and Lolis, 2002). The C-X-C subfamily is characterized by the separation 
of the first two cysteines by a variable amino acid, such as CXCL8 (IL-8) (Ludwig et 
al., 2000; Strieter et al., 1995). The C subfamily contains a single cysteine residue in 
the conserved position and this subfamily includes the lymphocyte-specific 
chemotactic peptide XCL1 (lymphotactin) (Maghazachi et al., 1997). The CXXXC 
subfamily has also been recognized in which the two N-terminal cysteine residues are 
separated by three variable amino acids, and this subfamily contains one member, 
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CX3CL1 (fractalkine, a membrane-bound chemokine with a mucin-like glycosylated 
stalk) (Bazan et al., 1997). Since CCL2 and CCL5 as well as CXCL8 are studied in 
this thesis, a more detailed description about the three chemokines is given below. 
 
 
 
 
 
 
 
 
 
Figure 7.  Classification of the four families of chemokines and their respective receptors (modified 
from (de Munnik et al., 2015; Rostène et al., 2007)). 
 
CCL2    
CCL2 (MCP-1) is the first discovered human C-C chemokine and one of the key 
chemokines that regulate migration and infiltration of monocytic cells/macrophages. 
Human CCL2 is composed of 76 aa and is 13 kDa in size.		Different molecular mass 
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forms of CCL2 have been purified and show differences in O-glycosylation, which 
has a slight impact on its chemotactic potency (Deshmane et al., 2009).  
 
CCL2 is produced by a variety of cell types, including endothelial cells, fibroblasts, 
epithelial, smooth muscle, mesangial, astrocytic, monocytic, and microglial cells, 
either constitutively or after induction by oxidative stress, cytokines, or growth factors 
(Barna et al., 1994; Brown et al., 1992; Cushing et al., 1990; Standiford et al., 1991). 
These cells, which can induce the expression of CCL2, are important for antiviral 
immune responses in the peripheral circulation and in tissues. During the antiviral 
immune responses, CCL2 regulates the migration and infiltration of monocytes, 
memory T lymphocytes, and NK cells. CCL2 mediates its effects through its receptor 
CCR2, whose expression is relatively restricted to certain types of cells. There are two 
alternatively spliced forms of CCR2, namely, CCR2A and CCR2B (Charo et al., 
1994). CCR2A is the major isoform expressed by mononuclear cells and vascular 
smooth muscle cells (Bartoli et al., 2001), whereas monocytic cells and activated NK 
cells express predominantly the CCR2B isoform. CCR2 plays dual roles in both pro-
inflammatory and anti-inflammatory actions. 
 
Inflammatory chemokines are rapidly induced following infection, and they bind to 
their receptors to initiate cellular migration and activation. Recruiting inflammatory 
cells expeditiously and directing them to sites of infection so they can kill invading 
microbes is a core responsibility of the innate immune system. CCL2 has been 
demonstrated to recruit monocytes into foci of active inflammation (Ajuebor et al., 
1998). CCL2 and its receptor CCR2 also play pivotal roles in monocyte recruitment 
during infection. It has been reported that HIV induced CNS disease is sustained by 
virus replication in monocytic cells, a process amplified by the recruitment of 
mononuclear cells via HIV-induced CCL2 (Cinque and others 1998; Zink and others 
2001). Interestingly, CCL2 properly suppresses HIV infection of target cells by 
blocking viral attachment to CCR2 and CCR5 coreceptors (Frade et al., 1997; Homan 
et al., 2002). 
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CCL5 
CCL5 (RANTES) is an 8 kDa protein classified as a C-C chemokine subfamily 
member. CCL5 is expressed by many cells including T lymphocytes, platelets, 
macrophages, eosinophils, and synovial fibroblasts, as well as endothelial cells, 
epithelial, endometrial cells and certain types of tumor cells (Appay and Rowland-
Jones, 2001). CCL5 is a target gene of NF-κB activity and plays an active role in 
recuiting a variety of leukocytes into inflammatory and infection sites (Appay and 
Rowland-Jones, 2001; Soria and Ben-Baruch, 2008). With the help of particular 
cytokines that are released by T lymphocytes such as IL-2 and IFN-γ, CCL5 also 
induces the activation and proliferation of particular NK cells to generate C-C 
chemokine activated killer cells (Soria and Ben-Baruch, 2008).  
 
CCL5 activity is mediated through its binding to CCR1, CCR3, and mainly CCR5 
(Soria and Ben-Baruch, 2008). CCL5/CCR5 interactions may favor tumor 
development in multiple ways: acting as growth factors, stimulating angiogenesis, 
modulating the extracellular matrix, inducing the recruitment of additional stromal 
and inflammatory cells, and taking part in immune evasion mechanisms (Kershaw et 
al., 2013). 
 
CCL5 production is relevant to inducing proper immune responses against tumors 
(Hanahan and Coussens, 2012), however, CCL5 may also be associated with cancer 
progression and metastasis (Borsig et al., 2014). CCL5 produced by CD8+ T cells and 
other immune cells has been shown to inhibit HIV entry into target cells as CCR5 is 
an essential coreceptor for HIV entry to host cells (Oppermann, 2004).  In this way, 
CCR5 has become an attractive target for anti-HIV therapeutics development. 
Maraviroc, a CCR5 antagonist that has already been licensed by FDA for the use in 
humans, can prevent the development of hepatocellular carcinoma (Ochoa-Callejero 
et al., 2013) in a mouse model and decrease pulmonary metastasis in a preclinical 
mouse model of breast cancer (Velasco-Velázquez et al., 2012; Velasco-Velázquez 
and Pestell, 2013), which suggests that CCR5 antagonists could be used as an 
adjuvant therapy to reduce the risk of metastasis in patients with the basal breast 
cancer subtype. 
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CXCL8 
CXCL8 (IL-8) is a pro-inflammatory CXC chemokine that was discovered for its role 
in promoting chemotaxis and degranulation of neutrophils. IL-8 has also been named 
neutrophil activating protein-1 (NAP-1), since it stimulates release of neutrophil 
granules. IL-8 is thought to exist as non-covalently linked dimer and signals via 
binding with the G protein-coupled receptors C-X-C chemokine receptor 1 (CXCR1, 
IL-8Rα) or CXCR2 (IL-8Rβ). These receptors differ markedly in their chemokine-
binding specificity; CXCR1 only binds IL-8 and CXCL6, whereas CXCR2 can bind 
to multiple chemokines, including IL-8, CXCL1, CXCL2 and so on (Balkwill, 2004). 
Ligand binding to these receptors leads to the activation of multiple primary 
downstream signaling pathways, including the PI3K/Akt, phospholipase C/protein 
kinase C (PLC/PKC), and mitogen-activated protein kinase (MAPK) pathways, as 
well as activation of focal-adhesion kinase (FAK), Rho-family GTPases, and 
JAK/STAT   signaling (Long et al., 2016; Waugh and Wilson, 2008). 
 
Like many other chemoattractants, IL-8 induces rearrangements of the cytoskeleton, 
changes in intracellular Ca2+ levels, activation of integrins, exocytosis of granule 
proteins, and respiratory burst (Paccaud et al., 1990). IL-8 is overexpressed during 
some chronic inflammatory diseases, such as psoriasis, rheumatoid arthritis, as well as 
pulmonary diseases, and high levels of IL-8 are also seen after septic shock or 
systemic administration of endotoxin (Kunkel et al., 1991; Martich et al., 1991; 
Palomino and Marti, 2015). 
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The upper respiratory mucosa is an important primary replication site for 
alphaherpesviruses and arteriviruses in mammals. Alphaherpesviruses have developed 
various ways to reach the deeper tissues of the respiratory tract in order to increase 
their access to lymph and blood vessels for further spread and to neurons for the 
establishment of latency. In this thesis, two alphaherpesviruses bovine herpesvirus 1 
(BHV-1) and equine herpesvirus 1 (EHV-1), as well as an arterivirus equine arteritis 
virus (EAV) were used to explain their invasion mechanism in the respiratory 
mucosa. 
 
BHV-1 easily spreads across the basement membrane (BM) in a plaque-wise manner. 
The mechanism underlying passage of BHV-1 from epithelial cells across the 
underlying BM is not well understood. To be able to penetrate the BM, directional 
transport of BHV-1 virions in epithelial cells towards the BM appears to be important. 
Such directional transport may involve polarized microtubule-based transport of virus 
particles. The Us3 and Us9 proteins have been implicated in directional microtubule-
mediated transport of alphaherpesviruses. Thus, we examined the function of Us3 and 
Us9 proteins on the stromal invasion of BHV-1 in the respiratory mucosa (Chapter 3). 
 
In contrast to BHV-1, EHV-1 hitchhikes across the BM using local immune cells, 
mainly CD172a+ monocytic cells. At present, it is not clear how CD172a+ monocytic 
cells become infected by EHV-1, e.g. whether these cells are present at steady-state 
conditions or are attracted to the site of infection. Answers to these questions will be 
formulated in the present thesis (Chapter 4). 
 
During an infection of EAV in the upper respiratory tract, the CD172a+ monocytic 
cells also function as Trojan horses in a similar fashion as described for EHV-1, 
allowing viral invasion of these tissues. Co-infections of EHV-1 and EAV may occur 
in horses under field conditions. However, the behavior of dual infections with EHV-
1 and EAV in the equine respiratory mucosa was never studied before and was one of 
the main goals of this PhD thesis (Chapter 5).  
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Abstract 
 
Bovine herpesvirus 1 (BHV-1) infection may lead to conjunctivitis, upper respiratory 
tract problems, pneumonia, genital disorders and abortion. BHV-1 is able to spread 
quickly in a plaque-wise manner and to invade by breaching the basement membrane 
(BM) barrier in the respiratory mucosa. BHV-1 Us3, a serine/threonine kinase, 
induces a dramatical cytoskeletal reorganization and BHV-1 Us9, a tail-anchored 
membrane protein, is required for axonal transport of viruses in neurons. In this study, 
we investigated the role of Us3 and Us9 during BHV-1 infection in the respiratory 
mucosa. First, we constructed and characterized BHV-1 Us3 null, Us9 null and 
revertant viruses. Then, we analyzed the viral replication and plaque size (latitude) in 
MDBK cells and respiratory mucosa as well as viral penetration depth underneath the 
BM of respiratory mucosa when inoculated with these recombinant viruses. Knockout 
of Us3 resulted in a one log10 reduction in viral titer and plaque size (latitude) in 
MDBK cells and trachea mucosa while there was no defect on cell-to-cell spread 
observed for BHV-1 Us9 null virus. Both BHV-1 Us3 null and Us9 null viruses 
showed a significant reduction of plaque penetration underneath the BM, however the 
penetration was not completely inhibited. In conclusion, the current findings 
demonstrated that Us3 and Us9 play an important role in the invasion of BHV-1 
through the BM of the respiratory mucosa, which shows the way for research-based 
attenuation of viruses in order to make safe and more performant vaccines.   
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1. Introduction  
 
Bovine herpesvirus 1 (BHV-1) is a member of the Alphaherpesviridae. BHV-1 
infection may cause conjunctivitis, upper respiratory tract problems, pneumonia, 
genital disorders and abortion (Jones and Chowdhury, 2010; Muylkens et al., 2007; 
Tikoo et al., 1995). The BHV-1 virion is composed of a capsid containing a double-
stranded DNA genome, which is surrounded by a tegument layer and an envelope 
containing viral glycoproteins.  
 
Alphaherpesviruses of different species have evolved various ways to reach deeper 
tissues of the upper respiratory tract for further spread and inducing latency. In our lab 
using ex vivo trachea mucosa explants it was found that BHV-1 is able to disseminate 
quickly in a plaque-wise manner and invade in the lamina propria by breaching the 
basement membrane (BM) barrier (Steukers et al., 2011). BHV-1 Us3 can alter 
intracellular localization of the virus and has been found to colocalize with 
microtubules in cell protrusions, which implicates possible direct interactions of Us3 
with kinesin or dynein motors (Brzozowska et al., 2010). There are some evidences 
that Us9 and UL56 together with kinesins might contribute to the directional transport 
of alphaherpes viral glycoproteins in the epithelial cells of the respiratory mucosa 
(Steukers, 2013). 
 
The Us3 gene, which is highly conserved among alphaherpesviruses, codes for a 
serine/threonine kinase. It is a multifunctional protein that was reported to play a role 
in the nuclear egress of capsids, prevention of apoptosis, modulation of host immune 
response and rearrangement of the cytoskeleton (Benetti and Roizman, 2004; Klupp et 
al., 2001; Murata et al., 2002). BHV-1 Us3 is a 58 kDa protein, which possesses a 
protein kinase (PK) activity (Takashima et al., 1999). It has been reported that BHV-1 
Us3 can induce morphological changes of the infected cells based on a dramatically 
cytoskeletal reorganization. It is not involved in the inhibition of apoptosis 
(Brzozowska et al., 2010).  
 
The Us9 protein is an unglycosylated type II tail-anchored membrane protein that is 
highly conserved among members of the alphaherpesvirus subfamily (Brideau et al., 
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2000; Lyman et al., 2009). It is essential for axonal sorting of viral structural proteins 
and localizes predominantly to the trans-Golgi network (TGN) (Lyman et al., 2009). 
BHV-1 Us9 is an early (β)/late (γ1) protein (Chowdhury et al., 2006). Us9 protein has 
one predicted protein kinase C phosphorylation site and four potential casein kinase II 
phosphorylation sites and it is readily phosphorylated yielding a protein with a 
molecular weight of 30-32 kDa (Chowdhury et al., 2006). BHV-1 Us9-deleted 
mutants are not shed from the nose or eyes following dexamethasone-induced 
reactivation (Butchi et al., 2007).  
 
The gC protein is a late γ2 protein, which requires ongoing DNA replication for its 
expression (Arsenakis et al., 1988). The gC protein is obviously involved in cell 
attachment mechanisms (Liman et al., 2000). In addition, gC null virus is only slightly 
reduced in virulence and is not impaired in cell-to-cell spread (Kaashoek et al., 1998). 
 
The directional transport of BHV-1 towards the BM is important for virus 
dissemination and invasion to penetrate the BM. As there is no UL56 in the genome 
of BHV-1, we focused on Us3 and Us9 to examine their role in the invasion of BHV-
1 through the BM. The ex vivo trachea mucosa model and Us3, Us9 as well as gC null 
mutants were used as tools for the identification of the invasion determinants. The gC 
null mutant was included as negative control.   
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Table 1. Primers used for generating Us9, Us3 and gC null and revertant viruses 
 
Genetic 
engineering Gene Primers Nucleotide sequence (
a) 
        
Deletion Us9 Forward 5'-CTCACACAAAGCCTCGTGCGGC-TGCTTCGAAGGCATG-
TAAATAGCAGCGGCCCT- aggatgacgacgataagtaggg-3' 
    Reverse 5'-CCGAGGCCAATGCAAGTCA-GGGCCGCTGCTATTTA- 
CATGCCTTCGAAGCA-caaccaattaaccaattctgattag-3' 
 
  Us3  Forward 5'-GCGATCCCGCGACACGACCCGACGT-TCTTGGGCACCCATG-
TAACTGACCTTTGAC-aggatgacgacgataagtagggat-3' 
  
   Reverse 5'-GCGGCGGTGGGGCGCGCGCGAAA-GTCAAAGGTCAGTTA-
CATGGGTGCCCAAGA-caaccaattaaccaattctgattag-3' 
  
 gC Forward 5'-AGAGACCGCCAGCCCGAGACCTCGC-CGCGCGTCCGCCATG-
TAAAAGGCCCGGGCG-aggatgacgacgataagtaggg-3' 
  
   Reverse 5'-CGTCGGGGCCCCGCGCCTACAGGCG-CGCCCGGGCCTTTTA-
CATGGCGGACGCGCG-caaccaattaaccaattctgattag-3' 
    Revertant -
Kan 
insertion 
Us9 Forward 5'-CTCACACAAAGCCTCGTGCGGC-TGCTTCGAAGGCATG-
CAAAACCGGCACCGCGGC- aggatgacgacgataagtaggg-3' 
  
  Reverse 5'-CCGAGGCCAATGCAAGTCA-GCCGCGGTGCCGGTTTTG- 
CATGCCTTCGAAGCA-caaccaattaaccaattctgattag-3' 
      
Us3  Forward 5'-GCGATCCCGCGACACGACCCGACGT-TCTTGGGCACCCATG-
CAACTCTACGCTGGCCGA-aggatgacgacgataagtaggg-3' 
  
   Reverse 5'-GCGGCGGTGGGGCGCGCGCGAAA-TCGGCCAGCGTAGAGTTG-
CATGGGTGCCCAAGA-caaccaattaaccaattctgattag-3' 
  
 gC Forward 5'-AGAGACCGCCAGCCCGAGACCTCGC-CGCGCGTCCGCCATG-
CAACGCTGTGACTTGGTG-aggatgacgacgataagtaggg-3' 
  
   Reverse 5'-CCGAGGCCAATGCAAGTCA-GCCGCGGTGCCGGTTTTG- 
CATGCCTTCGAAGCA-caaccaattaaccaattctgattag-3' 
    Revertant-
pull out 
Us9 Forward 5'-GTTCAAAGTTTGGTTTAGGGACCCGCTTGAAGACGATGCCGCGCC-3' 
 
  Reverse 5'-CGGCTCCTCGCCGGGCTCCTCGCCATACCCGTCGCCGGGGGGCTC-3' 
 
Us3  
 
Forward 
 
5'- AAGGAAACGCCACACCCGCGCGGGCACGTCTGGGCTTGCCCCTGG-3' 
   
Reverse 
 
5'-CGGCGGCCCCGCAGAGCAGGATTAGGGCGACGGCGGCCAAGGTGC-3' 
 
 
gC 
 
Forward 
 
5'-GTGCCGCTCACACCGCGCGCCACAACCGCGACGTGTGGCAGCGCT-3' 
 
  Reverse 5'-CGCGCCCGCAGCGCTGGCCTCGGCAGCCGCGGGCACGCTGGTGGC-3' 
Note:  Nucleotides in lower case share homology to pEP-kan-S2. Sequences that are underlined 
are complementary to each other in inverse orientation. The introduced stop codons in the primers 
are in bold.   
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2. Materials and methods        
 
2.1 Virus strains and cell line   
 
The BHV-1 Cooper strain (Colorado) was propagated and titrated in Madin-Darby 
bovine kidney (MDBK) cells grown in Dulbecco modified Eagle’s medium (DMEM, 
Gibco) supplemented with 10% fetal bovine serum (Gibco), 1% sodium pyruvate 
(Gibco), 0.1mg/mL streptomycin (Certa, Braine l’Alleud, Belgium), 100U/mL 
penicillin (Continental Pharma, Puurs, Belgium) and 1µg/mL gentamycin (Gibco).  
 
2.2 Antibodies 
 
The rabbit antiserum against Us3 was a kind gift from Sylvia van Drunen Littel-van 
den Hurk. The goat antiserum against Us9 and the murine monoclonal antibody 
specific for gC (10B) were kindly provided by Shafiqul I. Chowdhury. The 
monoclonal antibodies 14B11 (anti-BHV-1 gE) and 2E12 (anti-BHV-1 gE/gI) were 
gifts from Brigitte Caij (Veterinary and Agrochemical Research Centre, Belgium). 
Mouse anti-collagen VII antibodies (Sigma, St. Louis, MO, USA) and FITC®-labeled 
goat anti-IBR polyclonal antiserum (VMRD, Pullman, WA, USA) were used for the 
BM and BHV-1 stainings, respectively.   
 
2.3 Construction of BHV-1 Us3 null, Us9 null, gC null and their revertant viruses by 
en passant mutagenesis  
 
A previously established BHV-1 Cooper BAC clone (Liu et al., 2008), which 
transformed the BAC plasmid containing BHV-1 genome into Escherichia coli (E. 
coli) strain GS1783 (containing a temperature-sensitive Red recombination system 
and a gene encoding the endonuclease I-SceI in its genome), was used for en passant 
mutagenesis. The GS1783 cells harboring pBHV-1 (wild type BAC, WT BAC) were 
maintained in Luria-Bertani (LB) medium with 30µg/ml chloramphenicol. The 
construction of Us3 null, Us9 null, gC null and their revertant viruses was performed 
by two-step Red recombination as described earlier (Tischer et al., 2010). The 
construction of Us3 deleted and revertant  
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mutants will be given as an example. Firstly, PCR primers (Table 1) were used to 
amplify the fragment from the plasmid pEP-Kan-S2 to replace Us3 by the aphAI 
(kanamycin resistance) gene. Secondly, approximately 100ng of DpnI-digested PCR 
product from above was incorporated into 50µl of recombinant and electrocompetent 
pBHV-1 via electroporation. After arabinose induction, several kanamycin-sensitive 
clones were obtained and screened via RFLP, PCR and sequencing. This resulted in 
pBHV-1-Kan-ΔUs3. Subsequently, a similar approach was applied to remove the 
aphAI gene, and then pBHV-1-ΔKan-ΔUs3 was obtained. Finally, to excise the BAC 
cassette, all obtained clones as well as the WT BAC clone were co-transfected with 
pCAGGS-nls-cre into MDBK cells. At least three rounds of plaque purification were 
performed to obtain pure BAC-excised clones. Henceforth, reconstituted BAC-
excised vBHV-1 and vBHV-1-ΔUs3 were named WT-R and Us3 null virus, 
respectively.  
 
To construct the revertant virus, the aphAI gene was firstly inserted into the open 
reading frame coding (ORF) for Us3 of the pBHV-1. A similar PCR was performed 
as described for the construction of mutant alleles using forward and reverse primers 
(Table 1) and plasmid pEP-Kan-S2 by en passant mutagenesis. This resulted in 
pBHV-1-Kan-Us3. Secondly, a pull-out of the Us3 region out of the WT BAC was 
performed. To this end, primers were designed (Table 1) and pBHV-1-Kan-Us3 was 
used as template to generate the fragment with the ORF of Us3 and aphAI gene. 
Finally, the authentic Us3 was reintroduced in pBHV-1-ΔKan-ΔUs3. We used the 
obtained pull-out Us3 fragment, which still possessed a kanamycin marker in-between 
the ORF of Us3, to transform pBHV-1-ΔUs3. After arabinose induction, kanamycin 
sensitive clones were screened by RFLP, PCR and sequencing, co-transfected with 
the plasmid pCAGGS-nls-cre into MDBK cells for BAC excision, three times plaque 
purified and finally named vBHV-1-ΔUs3-Rev (Us3 revertant virus). The BHV-1 Us9 
or gC null and revertant viruses were constructed in the same way. 
 
2.4 Characterization of the BHV-1 Us3 null, Us9 null, gC null and their revertant 
viruses via Western blot (WB)    
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WB was used to identify the deleted and revertant proteins, respectively. In brief, 
BHV-1 Us3 null, Us9 null, gC null and their revertant viruses were propagated (2nd 
passage) and titrated in MDBK cells (Chowdhury, 1995). The monolayer of MDBK 
cells in 6-well plates (Nunc A/S, Roskilde, Denmark) were inoculated with the above 
viruses at a multiplicity of infection (MOI) of 1. Twenty-four hours later, the 
supernatant was gently removed and the cells were collected. Afterwards, the cells 
were mixed with lysis buffer, boiled for 10 minutes and subjected to SDS-PAGE 
(12% gel) using a BioRad Mini Protean 3 system. For WB analysis, proteins were 
transferred from the SDS-PAGE gel to a PVDF membrane (Membrane Hybond-P, GE 
Healthcare). The membrane was blocked overnight in 5% skimmed milk (PBS with 
0.1% Tween-20) at 4°C. Subsequently, the blot was incubated with the primary 
antibodies. The rabbit antiserum against Us3, goat antiserum against Us9 and murine 
monoclonal antibody specific for gC (10B) were used to analyse the Us3 null, Us9 
null, gC null and revertant viruses, repectively. Goat anti-rabbit IgG (HRP), rabbit 
anti-goat IgG (HRP) and goat anti-mouse IgG (HRP) were used as secondary 
antibodies. As a control for loading, total β-actin (Abcam) levels were assessed. 
Afterwards, visualization was done by enhanced chemiluminiscence (ECL; GE 
Healthcare).   
 
2.5 Bovine respiratory mucosa explants  
 
Bovine respiratory mucosa explants were collected from 3 cows, between 2 and 5 
years old at a local slaughterhouse. The blood was collected to determine the BHV-1 
specific neutralizing antibody level. Three animals showing a seroneutralization 
antibody titer of < 2 for BHV-1 specific antibodies via a complement-dependent 
seroneutralization test were selected for the study. The collected tracheas were 
transported on ice in PBS supplemented with 10µg/ml gentamicin, 1mg/ml 
streptomycin, 1000U/ml penicillin, 1mg/ml kanamycin (Sigma, Bornem, Belgium), 
and 5µg/ml fungizone (Bristol-Myers Squibb, New York, USA). Trachea mucosae 
were stripped from the proximal portion of trachea and divided into small pieces of 
50mm2. The explants were placed on fine-meshed gauze with the epithelium upwards 
for culture on an air-liquid interface at 37°C with 5% CO2. The medium used for 
cultivation contains serum-free medium (50% DMEM/50% Ham’s F-12 GlutaMAX)  
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supplemented with 0.1mg/mL streptomycin, 100U/mL penicillin and 1µg/mL 
gentamycin.  
 
2.6 Analysis of the replication and dissemination of BHV-1 Us3 null, Us9 null and gC 
null and revertant viruses in MDBK cells and trachea mucosa   
 
Confluent MDBK cells were seeded in 24-well culture plates with inserts and 
inoculated with 1ml containing 103 TCID50 of BHV-1 WT, deleted mutants and 
revertants for 1h at 37°C with 5% CO2. Cell supernatant was harvested at 2, 24 and 48 
hour post inoculation (hpi) for virus titration. Meanwhile, the cells infected with the 
respective viruses were stained at 48 hpi to observe the plaque size via 
immunofluorescence staining (IF). In brief, the infected cells were fixed with 4% 
paraformaldehyde for 10 minutes at room temperature (RT), then permeabilized with 
0.1% Triton X-100 for 5 minutes at RT. Subsequently, the cells were incubated with 
FITC®-labeled goat anti-IBR polyclonal antiserum (undiluted) directed against viral 
proteins. Before mounting with glycerin-DABCO, a Hoechst staining was performed 
to visualize the nuclei (10µg/ml, Molecular Probes). For each virus, 50 plaques were 
measured microscopically, and the average plaque size was determined using the line 
tool of the software imaging system ImageJ. Values were calculated and compared to 
that of BHV-1 WT, which was set at 100%. Average percentages as well as standard 
deviations were determined from three independent experiments.  
 
Trachea mucosa explants were taken from their gauzes and placed in a 24-well plate 
after 24 h of cultivation. In each well, the explants were submerged and incubated for 
1h with 107 TCID50 of BHV-1 WT, Us3 null, Us9 null, gC null and revertant viruses 
at 37°C with 5% CO2. Before the explants were placed back again on their gauzes, 
they were thoroughly washed. At 2, 24 and 48 hpi, the supernatant was collected for 
viral titration. The explants were frozen at -70°C for the plaque characteristics as well 
as viral penetration analysis. Mock-inoculated explants were included as controls. 
Cryosections were made from the frozen explants and fixed in methanol at -20°C for 
20 minutes. A double staining was performed as previously described (Steukers et al., 
2011). Firstly, an FITC®-labeled goat anti-IBR polyclonal antiserum was used to stain 
BHV-1 viral proteins. Next, for the BM staining, mouse anti-collagen VII antibodies 
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(1:300 in PBS) and goat anti-mouse IgG Texas Red® (1:200 in PBS) were used. A 
Hoechst staining was included for visualizing the nuclei before mounting with 
glycerin-DABCO. In between each step, three thorough washing steps were included.     
 
2.7 Statistical analysis  
 
Three independent experiments were performed and the data were presented as means 
± standard deviations (Givens and Marley). Two-way ANOVA was used to calculate 
statistical significance among multiple groups. Data were classified: P > 0.05, not 
significantly different; P ≤ 0.05 (*), significantly different; P ≤ 0.01 (**), very 
significantly different. 
 
3. Results 
 
3.1 Characterization of BHV-1 Us3 null, Us9 null, gC null and their revertant viruses 
 
The recombinant viruses, BHV-1 Us3 null, Us9 null, gC null and revertant viruses 
were analyzed by WB (Figure 1). Us3 (58 kDa), Us9 (32 kDa) and gC (91 kDa) were 
successfully deleted and rescued.   
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3.2 Knockout of BHV-1 Us3 resulted in a defect in virus replication in MDBK cell 
cultures and trachea mucosa explants 
 
The growth kinetics of the recombinant viruses were analyzed in MDBK cell cultures 
and trachea mucosa explants. At 24 hpi, a 0.8 log10 reduction in viral titers of Us3 
knockout was observed in trachea mucosa explants but not in MDBK cells. At 48 hpi, 
the knockout of Us3 resulted in a 1 log10 reduction in MDBK cells (Figure 2A) and a 
1.5 log10 reduction in trachea mucosa explants (Figure 3A). The restoration of the Us3 
gene fully rescued the viral titers in MDBK cells and trachea mucosa explants. The 
Us9 null, gC null and revertant viruses did not show any kinetic defect in either 
MDBK cells or trachea mucosa explants.  
 
The plaque size of Us3 null virus in MDBK cells was reduced by 30.2±5.3% (P<0.05) 
at 48 hpi (Figure 2B&C) while in trachea mucosa the plaque latitude of Us3 null virus 
was 31.2±6.3% (P<0.05) smaller compared to BHV-1 WT (Figure 3B&D). The 
deletion of Us9 or gC resulted in an 8.0±3.5% (P>0.05) or 6.7±2.3% (P>0.05) 
reduction of the plaque size in MDBK cells and 6.1±2.8% (P>0.05) or 5.7±3.1% 
(P>0.05) reduction of the plaque latitude in trachea mucosa. The restoration of Us3, 
Us9 or gC gene resulted in plaque sizes that were similar to those of BHV-1 WT.  
 
3.3 BHV-1 Us3 null or Us9 null viruses induced a severe impairment in stromal 
invasion in trachea mucosa  
 
Figure 1: Characterization of BHV-1 Us3 null, Us9 null, gC null and their rescue viruses by 
western blot. (A) Lysates of MDBK cells infected with BHV-1 Us3 null, revertant and wild type 
viruses as well as lysates of non-infected MDBK cells were incubated with rabbit antiserum against 
Us3, followed by goat anti-rabbit IgG (HRP). (B) Lysates of MDBK cells infected with BHV-1 Us9 
null, revertant and wild type viruses as well as lysates of non-infected MDBK cells were incubated 
with goat antiserum against Us9, followed by rabbit anti-goat IgG (HRP). (C) Lysates of MDBK cells 
infected with BHV-1 gC null, revertant and wild type viruses as well as lysates of non-infected MDBK 
cells were incubated with murine monoclonal antibody specific for gC (10B), followed by goat anti-
mouse IgG (HRP). (D) Lysates of MDBK cells infected with BHV-1 Us3 null, Us9 null, gC null and 
their revertant, and wild type viruses as well as lysates of non-infected MDBK cells were incubated 
with a murine monoclonal antibody specific for β-actin, followed by goat anti-mouse IgG (HRP). 
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In a previous study from our lab, it was found that the majority of BHV-1 plaques are 
crossing the BM at 48 hpi (Steukers et al., 2011). In order to examine the role of Us3 
and Us9 in the stromal invasion of BHV-1, the plaque penetration depth underneath 
the BM was measured for BHV-1 Us3 null or Us9 null viruses (Figure 3C&D). The 
plaque penetration of Us3 null virus and Us9 null virus were significantly reduced 
compared to BHV-1 WT, with 69.1±10.7% (P<0.01) and 60.2±12.3% (P<0.01), 
respectively. The Us3 and Us9 revertant viruses as well as gC null and revertant 
viruses displayed similar viral penetration characteristics as BHV-1 WT, with no 
significant differences (P>0.05).  
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Figure 2: Viral titers at 2, 24 and 48 hpi (A) and plaque size at 48 hpi (B&C) in MDBK cells inoculated with 
BHV-1 Us3 null, Us9 null, gC null and their revertant viruses, as well as wild type viruses. BHV-1 infected 
cells are stained green. Two-way ANOVA; *: P<0.05.    
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Figure 3: Viral titers at 2, 24 and 48 hpi (A) and 
plaque latitude as well as plaque penetration at 48 
hpi (B&C&D) in trachea mucosa explants 
inoculated with BHV-1 Us3 null, Us9 null, gC null 
and their revertant viruses, as well as wild type 
viruses. BHV-1 infected cells are stained green and 
the basement membrane is stained red. Two-way 
ANOVA; *: P<0.05; **: P<0.01.  	
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4. Discussion  
 
The respiratory mucosa is an important portal for BHV-1 entry. The previous studies 
in our lab showed that BHV-1 could induce prominent epithelial plaques and 
penetrate the BM in a plaque-wise manner in the respiratory mucosa. The epithelial 
plaques displayed a clear stromal invasion at 48 hpi (Steukers et al., 2011).  
 
In the present study, we found that the Us3 protein contributes to cell-to-cell spread in 
both MDBK cells and tracheal mucosa epithelium. Analysis of growth kinetics of Us3 
null virus in trachea mucosa explants showed a kinetic defect at 24 hpi compared to 
WT and revertant strains. However, this defect was only observed in MDBK cells 
starting from 48 hpi. These defaults were similar with those described for BHV-1 gE/I 
null virus, which showed a kinetic defect in trachea mucosa explants at 24 hpi 
whereas this defect was only found at 48 hpi in MDBK cells (Steukers, 2013). For 
Us3 null virus, the kinetic defect was also demonstrated by the small plaque size in 
both MDBK cells and trachea mucosa. This small plaque size may be related with a 
hampered rearrangement of the cytoskeleton as BHV-1 Us3 contributes to the 
formation of cellular projections, which are filled with virus particles (Brzozowska et 
al., 2010). For PRV, a related alphaherpesvirus a similar phenomenon was observed. 
These branched cell projections contain both actin and microtubules and may reach 
several cell diameters of length, which is associated with enhanced virus spread 
(Deruelle and Favoreel, 2011). Whether cellular projections are formed in between 
epithelial cells of the respiratory tract allowing the virus to spread needs further 
research. Most of the studies that showed that Us9 protein is involved in cell-to-cell 
spread are focused on neurons. Deletion of Us9 in PRV is associated with failure of 
viral spread both in vitro and in vivo (Brideau et al., 2000; Lyman et al., 2007). In 
HSV-1, it has been found that Us9 plays a critical role in cell-to-cell spread in 
neurons, but that other viral proteins are involved as well (Haugo et al., 2011). 
Similarly, BHV-1 Us9 deleted viruses demonstrated a defective anterograde neuronal 
spread in neuron culture systems and in vivo (Butchi et al., 2007; Coats, 2010). In the 
present study, it was demonstrated that BHV-1 Us9 displays no defect in cell-to-cell 
spread in MDBK cells and respiratory mucosa. PRV Us9 also had no defect on cell-
to-cell spread in MDBK cells (Brideau et al., 2000). 
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More striking was the finding that both Us3 and Us9 proteins contributed to the viral 
passage across the BM barrier during BHV-1 infection in bovine trachea mucosa 
explants in our study. Knockout of Us3 or Us9 caused a remarkable reduction of 
penetration depth underneath the BM in trachea mucosa at 48 hpi, however the 
penetration was not completely inhibited. For Us3, this defect may be explained by 
the involvement of serine/threonine kinase Us3-affected signal pathways. Recent 
work on PRV showed that Us3 protein kinase mediated invasion in respiratory 
mucosa explants was hampered by interfering with Rho GTPase signaling (Lamote et 
al., 2016). The Us3 protein of HSV-1 has been reported to display an Akt-like activity 
(Chuluunbaatar and Mohr, 2011) and Akt has been reported to contribute to the BM 
passage (Sun et al., 2013). Thus, HSV-1 Us3 protein may be involved in BM crossing 
as well. However, this still needs to be confirmed. Another explanation may be that 
the Us3 deletion in BHV-1 induced a functional change due to the lack of some Us3 
phosphorylated proteins. For BHV-1, it has been reported that Us3 is involved in the 
phosphorylation of tegument proteins VP8 and VP22 (Labiuk and Babiuk, 2009; 
Labiuk et al., 2010). In line with these findings in BHV-1, HSV Us3 has been shown 
to modulate different viral proteins at various time points during the course of 
infection (Jiang et al., 1998; Kato et al., 2005; Matsuzaki et al., 2005). Besides, it has 
been reported that Us3 proteins of HSV and PRV have anti-apoptotic activities that 
protect cells from apoptosis during infection (Geenen et al., 2005; Leopardi et al., 
1997). This anti-apoptosis can facilitate either the establishment and maintenance of a 
persistent viral infection or prolong the survival of lytically-infected cells in order to 
maximize the virus production (Young et al., 1997). Hence, the anti-apoptosis may 
function during the viral penetration of the BM. Whether BHV-1 Us3 possesses the 
anti-apoptotic activity in the respiratory mucosa and whether the anti-apoptosis is 
involved in BHV-1 stromal invasion will be further determined. In the present study, 
it was shown that Us9 is also important for BHV-1 invasion in the respiratory 
mucosa. It has been reported that Us9 proteins of both BHV-1 (Al-Mubarak et al., 
2007) and PRV (Kramer et al., 2012; Kratchmarov et al., 2013), together with gE or 
gE/I, are crucial for efficient anterograde-directed transport of viral particles in 
neurons. In our study, we found that Us9 knockout had no effect on the expression of 
gE (Us8) or gE/gI (Us8/7). However, the expression of Us9 protein in gE null and 
gE/gI null viruses displayed two bands and one with a higher molecular weight of 34 
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kDa. With Calf Intestinal Alkaline Phosphatase (CIP) treatment, WB showed a 
similar band pattern of Us9 protein in BHV-1 WT, gE null, gE/gI null and revertant 
viruses (supplementary data, Figure A). These results indicated that the high apparent 
molecular weight of the Us9 protein in gE null and gE/I null viruses may be due to the 
overphosphorylation of Us9, which has five predicted phosphorylation sites (Prosite). 
In other words, gE and gE/gI complex may mediate a dephosphorylation of the Us9 
protein during BHV-1 infection. It is in line with the explanation that gE or gE/gI is 
required for localization of some viral proteins in the Golgi apparatus where proteins 
are posttranslationally modified (Ch'ng and Enquist, 2005) and the deletion of gE or 
gE/gI may interupt this modification and induce overphosphorylation. In addition, for 
BHV-1 Us9 protein, besides phosphorylation (Chowdhury et al., 2006), other 
posttranslational modifications will also be involved as after CIP treatment the 
molecular weight of Us9 protein (30 kDa) is still higher than expected (14.7 kDa) 
(supplementary data, Figure A). In neurons, the expression and localization of Us9 is 
independent of those of gE, however, there is no report on expression and localization 
of BHV-1 Us9 in respiratory epithelial cells. An increased expression of Us9 protein 
was observed in trachea mucosa explants inoculated with gE and gE/gI null virus 
compared to the WT and gE/gI revertant viruses (supplementary data, Figure B). 
These data indicate that some interactions exist between Us9 and gE or gE/gI during 
BHV-1 infection in the respiratory mucosa. It is in agreement with a recent report that 
gE, gI and Us9 form a trimolecular complex in HSV infected Vero cells and the 
interaction between gE and Us9 is specific but transient (Awasthi and Friedman, 
2016). A previous study from our lab showed that BHV-1 gE/gI are required for 
BHV-1 invasion and are involved in a basal sorting towards basal domains in basal 
cells (Steukers, 2013). Based on these findings, we hypothesize that Us9 works 
together with gE/gI in the viral penetration in the respiratory mucosa. Further work is 
needed to fully reveal other respiratory invasion proteins.  
 
In conclusion, we have shown that BHV-1 Us3 and Us9 proteins play a crucial role in 
viral passage across the BM barrier during infection of bovine trachea mucosa 
explants. BHV-1 Us3 protein also contributes to the lateral cell-to-cell spread in both 
MDBK cell cultures and tracheal mucosa epithelium while BHV-1 Us9 null virus 
showed no defect. The current findings on the role of Us3 and Us9 proteins during 
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BHV-1 infection in trachea mucosa give new insights in the early pathogenesis events 
of BHV-1 and show the way for research-based attenuation of viruses in order to 
make safe and more performant vaccines.   
 
Supplementary data  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure Identification of the effect of the deletion of BHV-1 gE (Us8) and gI 
(Us7) proteins on their flanking protein Us9. (A) WB was performed to detect the expression of 
Us9 protein (upstream of the deleted gE or gE/gI proteins). Phosphorylation status was determined by 
the use of a phosphatase treatment (CIP, 10 units, 37ºC, 1 h) of MDBK cells infected with BHV-1 
WT, gE null, gE/gI null, gE/gI revertant and Us9 null viruses (Deruelle et al., 2007). (B) The 
immunofluorescence staining of the trachea mucosa explants infected with gE null, gE/gI null, gE/gI 
revertant and WT was shown at 48 hpi. BHV-1 infected cells were stained green; Us9 protein was 
stained red; The localization of basement membrane is indicated as a white dashed line.    	
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Abstract 
 
Equine herpesvirus type 1 (EHV-1) causes respiratory disease, abortion and 
neurological disorders in horses. Besides epithelial cells, CD172a+ monocytic cells 
become infected with EHV-1 in the respiratory mucosa and transport the virus from 
the apical side of the epithelium to the lamina propria en route to the lymph and blood 
circulation. Whether CD172a+ monocytic cells are specifically recruited to the 
infection sites in order to pick up virus is unknown. In our study, equine nasal mucosa 
explants were inoculated with EHV-1 neurovirulent strains 03P37 and 95P105 or the 
non-neurovirulent strains 97P70 and 94P247 and the migration of monocytic cells 
was examined by immunofluorescence. Further, the role of chemokines CCL2 and 
CCL5 was determined and the effect of migration inhibitors rosiglitazone (RSG) or 
quinacrine (QC) was analyzed. It was shown that with neurovirulent strains but not 
with the non-neurovirulent strains, CD172a+ monocytic cells specifically migrated 
towards EHV-1 infected regions and that CCL2 and CCL5 were involved. CCL2 
started to be expressed in infected epithelial cells at 24 hpi and CCL5 at 48 hpi, which 
corresponded with the CD172a+ monocytic cells migration. RSG treatment of EHV-1-
inoculated equine nasal mucosa had no effect on the virus replication in the 
epithelium, but decreased the migration of CD172a+ monocytic cells in the lamina 
propria. Overall, these findings bring new insights in the early pathogenesis of EHV-1 
infections, illustrate differences between neurovirulent and non-neurovirulent strains 
and show the way for EHV-1 treatment.  
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1. Introduction 
 
Equine herpesvirus 1 (EHV-1) is an important pathogen of horses. It is a member of 
the subfamily Alphaherpesvirinae with a 150 kilobases double stranded DNA genome 
(Telford et al., 1992). Alphaherpesviruses of different species have developed in 
evolution various ways to reach the deeper tissues of the upper respiratory tract in 
order to find lymph and blood vessels for further spread and neurons for inducing 
latency. Among them, pseudorabies virus (PRV), bovine herpesvirus-1 (BHV-1) and 
herpes simplex virus-1 (HSV-1) easily spread across the basement membrane (BM) in 
a plaquewise manner upon the activation of cellular proteases whereas EHV-1 
employs a more discrete manner to invade (Glorieux et al., 2011a; Glorieux et al., 
2011b; Steukers et al., 2012). It hitchhikes across the BM using local immune cells, 
mainly CD172a+ monocytic cells as Trojan horse (Vandekerckhove et al., 2010). 
EHV-1 enters CD172a+ monocytic cells via an endocytic mechanism that requires 
cholesterol, tyrosine kinase activity, actin, dynamin activity and endosomal 
acidification, pointing towards a phagocytic mechanism (Laval et al., 2015b). EHV-1 
infection of nasal mucosa epithelial cells leads to an increase of the thickness of the 
collagen VII and a degradation of integrin alpha 6 of the BM underneath the EHV-1 
plaques (Baghi and Nauwynck, 2016). Afterwards, a cell-associated viremia allows 
EHV-1 to reach internal organs such as the pregnant uterus and/or central nervous 
system (CNS). Replication in these organs may result in abortion, neonatal foal death 
and myeloencephalopathy (Lunn et al., 2009; Pusterla et al., 2009). Based on the 
difference of a single nucleotide polymorphism (A2254/G2254) in the EHV-1 DNA 
polymerase gene (ORF30), EHV-1 can be divided into neurovirulent strains and non-
neurovirulent strains (Nugent et al., 2006). It has been reported that the neurovirulent 
strains infect a higher number of CD172a+ cells than the abortigenic strains in the 
upper respiratory mucosa (Vandekerckhove et al., 2010).  
 
Our lab has found that CD172a+ monocytic cells can become infected with EHV-1 in 
the respiratory mucosa and transport the virus from the apical side of the epithelium to 
the lamina propria en route to the lymph and blood circulation (Baghi and Nauwynck, 
2014). In general, cytokines and chemokines are orchestrating the migration of 
monocytic cells during viral infections in the airways (Rudraraju et al., 2013; Vareille 
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et al., 2011). It has been reported that infection of alveolar epithelial cells with 
influenza A virus can strongly induce the release of monocyte chemoattractants CCL2 
and CCL5 followed by a strong recruitment of monocyte transepithelial migration 
(Herold et al., 2006). Whether EHV-1 infection is activating the attraction of 
CD172a+ monocytic cells to the infection sites and whether CCL2 and CCL5 are 
driving forces during this process are largely unknown. In a previous study, it has 
been shown that EHV-1 infected PBMC can up-regulate inflammatory chemokines 
CCL5, CXCL9 and CXCL10, and down-regulate chemotactic CCL2 and CCL3 with 
clear strain differences (Wimer et al., 2011). During an infection with another 
alphaherpesvirus, HSV-1, in mice, it has been reported that CCL3 attracts NK cells 
(Wuest and Carr, 2008), CCL2 recruits monocytes (Rebenko-Moll et al., 2006), and 
CCL5 recruits monocytes, NK cells, and PMNs (Carr and Tomanek, 2006) while 
CXCL9 recruits T-cells to the sites of infection (Wuest et al., 2006; Wuest and Carr, 
2008). In our study, we mainly focused on the well-known monokines CCL2 and 
CCL5. IL-8/CXCL8 that can specifically induce neutrophil recruitment during an 
EHV-1 infection (Van de Walle et al., 2007) was also included. 
 
EHV-1 infection has a significant economic impact on the equine breeding industry 
worldwide every year (Bażanów et al., 2014). Current vaccines do not provide full 
protection against severe symptoms induced by EHV-1 and there is no efficacious 
antiviral treatment available for EHV-1 infection. As CD172a+ monocytic cells 
function as Trojan horses during EHV-1 invasion in the respiratory mucosa, inhibition 
of the recruitment of these cells may prevent migration of infected monocytic cells 
into the deep tissues. This might be an effective way to impede the generation and 
invasion of infected CD172a+ monocytic cells and reduce the viremia. Phenotypical 
and functional analysis of the nasal mucosal CD172a+ monocytic cells indicated that 
they mainly consist of immature dendritic cells (DC) (Baghi et al., 2014).  
 
Thus, DC migration inhibitors might be an option to inhibit the EHV-1 deep invasion. 
It has been demonstrated that rosiglitazone (RSG), which has been used to treat type 2 
diabetes, can specifically impair the departure of Langerhans cells (LCs) from the 
epidermis and moreover can block accumulation of DC in the draining lymph nodes 
(DLNs). In the respiratory mucosa, RSG can also inhibit the migration of DCs from 
the airway mucosa to the thoracic lymph nodes (LNs) (Angeli et al., 2003). Another 
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DC migration inhibitor, quinacrine (QC), originally used as an antiprotozoal and anti-
rheumatic agent, has also been reported to inhibit the epidermal DC migration by 
blocking NF-κB-dependent production of TNF-α, IL-1β and CCL21 in the skin 
(Gorbachev et al., 2007).   
 
In the current study, equine nasal mucosa explants were used as a model to study 
whether CD172a+ monocytic cells are specifically recruited to the EHV-1 infection 
sites in order to capture virus and whether the monokines CCL2 and CCL5 are 
involved during this process. In addition, treatment with RSG or QC at different 
concentrations was performed 12 hours prior to or at the same time of the viral 
inoculation to test whether the treatment can impede EHV-1 deeper infection.  
 
2. Materials and Methods 
 
2.1 Cells and virus  
 
RK-13 cells were used. They were cultured in Dulbecco’s Modified Eagle Medium 
(DMEM) (Invitrogen, Paisley, UK) supplemented with 10% fetal calf serum 
(Invitrogen), 100U/ml penicillin, 0.1mg/ml streptomycin and 1µg/ml gentamicin.  
 
Four Belgian EHV-1 strains were used in this study. The neurovirulent strains 95P105 
and 03P37 were originally isolated in 1995 and 2003 from the blood of a paralytic 
horse (Garré et al., 2009; Van der Meulen et al., 2003) and the abortigenic strains 
97P70 and 94P247 strains were isolated in 1997 and 1994 from the lungs of an 
aborted fetus (van der Meulen et al., 2000). All the EHV-1 strains were at the sixth 
passage, four passages in equine embryonic lung cells and two subsequent passages in 
RK-13 cells, with a titer of 106.5 tissue culture infectious dose with 50% endpoint per 
milliliter (TCID50/ml). For virus inactivation, a thin layer of viral suspension was 
exposed to short-wave UV light at 1.2×105 µJ/cm2 for 10 minutes. Absence of viral 
infectivity was checked by virus titration on RK-13 cells.  
 
2.2 Equine nasal mucosa explants and inoculation with EHV-1  
 
The nasal mucosa explants were collected from 3 healthy horses, between 4 and 6 
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years old at a local slaughterhouse. Firstly, the nasal mucosa explants were stripped 
from the nasal surface and divided into pieces of 50 mm2. After 24 hours of culture on 
fine-meshed gauze, explants were washed twice with warm medium and transferred 
on top of solid agarose. The margins were filled with agarose. Afterwards, the 
explants were inoculated with 500µl medium containing 106.5 TCID50 EHV-1 of the 
neurovirulent strains 03P37 and 95P105 or the non-neurovirulent (abortigenic) strains 
97P70 and 94P247 for 1h at 37°C with 5% CO2, respectively. After inoculation, the 
explants were rinsed and further incubated with fresh medium (Vairo et al., 2013). 
Mock inoculations, incubated with DMEM medium, were performed in parallel.  
 
2.3 Localization and quantification of CD172a+ monocytic cells in equine nasal 
mucosa explants  
 
At 0, 24, 48 and 72 hours post incubation (hpi) the explants were collected and snap 
frozen in methocelTM. At each time point, 20 serial 16µm cryosections were made for 
immunofluorescence stainings. In brief, biotinylated equine polyclonal anti-EHV-1 
IgG (diluted 1:10 in PBS) (Van der Meulen et al., 2003), followed by streptavidin-
Texas Red® (Invitrogen, 1:200 in PBS) were added to check for EHV-1 infected cells. 
Next, mouse monoclonal antibody (mAb) DH59B (VMRD Inc., Pullman) was used as 
cell marker to detect CD172a+ monocytic cells, followed by FITC-labeled goat anti 
mouse IgG. The nuclei were counterstained with Hoechst 33342 (10µg/ml, Molecular 
Probes). After staining, the cryosections were rinsed three times in PBS and mounted 
with glycerin/1,4-diazabicyclo [2.2.2] octane. All IF stainings were analyzed by 
confocal microscopy (Leica Microsystems GmbH, Wetzlar, Germany). An 
appropriate isotype-matched, irrelevant control (IgG1) mouse monoclonal anti-PRV 
gD antibody 13D12 was included for testing the specificity of the stainings 
(Nauwynck and Pensaert, 1995). Two regions of interest (ROI) were chosen for the 
quantification of CD172a+ monocytic cells and EHV-1+ cells. One was the region 
where the epithelial cells were infected with EHV-1 (ROIWI) and the other was the 
region without EHV-1 infection in the epithelial cells (ROIWOI) (Figure 1). Three 
independent replicates were performed and 20 images were taken for each experiment 
at each time point.   
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2.4 The expression of chemokines CCL2 and CCL5 in EHV-1 infected nasal mucosa 
explants  
 
To check whether chemokines CCL2 and CCL5 may be involved in the recruitment of 
CD172a+ cells towards the infected epithelial cells, their expression was examined. 
The equine nasal mucosa explants were collected, cultured and inoculated with EHV-
1 as described above. Mock inoculations were carried out in parallel. A scratch-wound 
assay using a yellow pipette tip to make a straight scratch and simulate a wound was 
performed to detect the expression of CCL2 or CCL5 in the wounded nasal mucosa 
explants. Inoculation with UV-inactivated EHV-1 was performed to test whether the 
production of CCL2 or CCL5 could be induced only by the binding/entry step of 
EHV-1 to the epithelial cells. Finally, the explants were collected at 0, 24, 48 and 72 
hpi, embedded in methocelTM, and frozen at -70°C.   
 
Of each explant, 50 serial 16µm cryosections were made for IF stainings and the 
aforementioned protocol was followed to detect EHV-1 infected cells. For the 
detection of CCL2 or CCL5, rabbit polyclonal anti-CCL2 IgG or anti-CCL5 IgG 
(Biorbyt, 1:100 in PBS) was used as primary antibody, followed by goat anti-rabbit 
IgG FITC (1:100) (Invitrogen, 1:100 in PBS), respectively. The rabbit polyclonal anti-
CXCL8 IgG (Mybiosource, 1:100 in PBS) was used as control. All the results of IF 
stainings were analyzed by confocal microscopy. By using the software imaging 
system ImageJ, the percentage of pixels positive for CCL2 or CCL5 was determined. 
Two ROIs were chosen for the quantification of the expression of CCL2 or CCL5. 
Figure 1: EHV-1 neurological strain 03P37 infected equine nasal mucosa with two regions of interest. 
ROIWI is the region of interest including the epithelium and the lamina propria with EHV-1 infection in the 
epithelium whereas ROIWOI is the region of interest without EHV-1 infection in the epithelium. The white 
line drawn on the image represents the basement membrane (BM). Scale bar: 50µm.  
 
Epithelium 
Basement membrane (BM) 
Lamina propria 
50µm Submucosa 
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One was the region where the epithelial cells were infected with EHV-1 (ROIWI) and 
the other was the region without EHV-1 infection in the epithelial cells (ROIWOI) 
(Figure 1). Three independent replicates were performed for each experiment.  
 
2.5 Evaluation of tissue toxicity of rosiglitazone (RSG) and quinacrine (QC) on nasal 
mucosa explants 
 
As DC migration inhibitors might be useful to inhibit the deep invasion of EHV-1 in 
respiratory mucosa via infected monocytic cells, two DC migration inhibitors RSG or 
QC (Sigma-Aldrich) were used to treat equine nasal mucosa explants. TUNEL 
staining was performed to assess the tissue toxicity of RSG or QC (1µM, 3µM, 10µM, 
30µM) (Angeli et al., 2003) on the nasal mucosa explants. Briefly, after 24 h culture 
on fine-meshed gauze, these explants were transferred into 24-well plate and 
immersed with RSG or QC at different concentrations (1µM, 3µM, 10µM, 30µM) for 
1h at 37°C with 5% CO2. Afterwards, the explants were transferred back to the gauze 
and cultured within the medium in the presence of RSG or QC at corresponding 
concentrations. Untreated explants were immersed in and incubated with medium in 
the absence of RSG or QC. At 0, 24, 48 and 72 hpi, the explants were collected and 
frozen in methocelTM at -70°C. Cryosections were made and the TUNEL reaction was 
performed according to the manufacturer’s guidelines. TUNEL-positive cells were 
counted in five randomly chosen fields of 100 cells in the epithelium as well as in the 
lamina propria with confocal microscopy.  
 
2.6 The effect of RSG or QC on EHV-1 infection of nasal mucosa explants 
 
The equine nasal mucosa explants were inoculated with EHV-1 neurovirulent strains 
03P37, 95P105 or non-neurovirulent strains 97P70, 94P247 and treated with RSG or 
QC (1µM, 3µM, 10µM, 30µM), respectively. Mock inoculations and treatments were 
carried out in parallel. The RSG or QC treatment was performed 12 h prior to or at the 
same time of EHV-1 inoculation, respectively. The supernatant of cultured explants 
was collected at 2, 24, 48, 72 hpi for viral titration. The explants were collected and 
snap frozen at 0, 24, 48, 72 hpi. Cryosections were made and IF stainings were 
performed to analyze EHV-1 infection by confocal microscopy. In the epithelium, the 
plaque formation was analyzed. In the lamina propria of the mucosa, two regions of 
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interest (ROI) were chosen for analysis of EHV-1 replication. One was the region 
where the epithelial cells were infected with EHV-1 (ROIWI) and the other was the 
region without EHV-1 infection in the epithelial cells (ROIWOI). Three independent 
replicates were performed for each experiment.       
 
2.7 The effect of RSG treatment on the distribution and numbers of CD172a+ 
monocytic cells in nasal mucosa explants infected with EHV-1   
 
The EHV-1 infected cell types in the lamina propria of which their recruitment was 
affected by treatment with RSG were identified by a double IF staining. For the 
staining of EHV-1, the protocol described above was followed. To detect CD172a+ 
monocytic cells, CD5+ T lymphocytes or B lymphocytes (IgM+), mAbs DH59B, 
HT23A or 1.9/3.2 (VMRD Inc., Pullman) were used as primary antibodies and FITC-
labeled goat anti-mouse IgG was used as secondary antibody. Proper controls were 
included for testing the specificity of the stainings. The nuclei were counterstained 
with Hoechst 33342. All the stained cryosections were analyzed by confocal 
microscopy. Three independent replicates were performed for each experiment.       
 
2.8   Data analysis  
 
Three independent experiments were performed and the data are presented as means ± 
standard deviations (Givens and Marley). Two-way ANOVA was used to calculate 
statistical significance among multiple groups. Data were classified: P>0.05, not 
significantly different; P≤0.05 (*), significantly different; P≤0.01 (**), very 
significantly different; P≤0.001 (***), extremely significantly different.  
 
3. Results 
 
3.1 The localization and quantification of CD172a+ monocytic cells in the equine 
nasal mucosa explants infected with EHV-1  
 
In mock-inoculated nasal mucosa, the CD172a+ monocytic cells were mainly 
localized in the lamina propria underneath the BM. In the epithelium, the CD172a+ 
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monocytic cells were present in a scattered manner (Figure 2A). Cultivation for 72 
hours had no impact on the distribution and number of CD172a+ monocytic cells. For 
the neurovirulent EHV-1 strain 03P37 inoculated nasal mucosa explants, a basal to  
apical migration in the infected nasal mucosa area was observed. At 24 hpi, EHV-1 
infected CD172a+ monocytic cells were observed mainly in the epithelium and less 
frequently underneath the BM. There was no significant difference for the number of 
total CD172a+ monocytic cells in ROIWI or ROIWOI compared with the mock. At 48 
hpi, more EHV-1 infected CD172a+ cells were found in the epithelium and a few 
underneath the BM. Compared with the mock, the number of total CD172a+ 
monocytic cells in the ROIWI was 30.5±21.6% (P<0.05) higher, while in the ROIWOI 
there was no significant difference (P>0.05) (Figure 2B). At 72 hpi, nearly no EHV-1 
infected CD172a+ monocytic cells were found in the epithelium while there were 
much more EHV-1 infected CD172a+ monocytic cells observed underneath the BM. 
The number of total CD172a+ monocytic cells in the ROIWI was 44.2±19.5% (P<0.01) 
higher than that in the mock (Figure 2B). The percentage of EHV-1 positive cells in the 
population of CD172a+ positive cells in the ROIWI was 77.8±31.5% (P<0.01) higher at 
48hpi and 76.8±27.9% (P<0.01) higher at 72 hpi compared with the ROIWOI (Figure 
2C). Similar results were observed when inoculated with another EHV-1 neurovirulent 
strain 95P105 (Figure 2D&E). For the EHV-1 non-neurovirulent strains 97P70 and 
94P247, there were no significant differences for the number and distribution of 
CD172a+ monocytic cells between ROIWI or ROIWOI and the mock at all time points 
(Figure 2).   
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Figure 2: The localization (A) and quantification of CD172a+ cells in mock inoculated and EHV-
1 neurovirulent strains 03P37 (B), 95P105 (D) and non-neurovirulent strain 97P70 (B), 
94P247(D)  inoculated nasal mucosa at 0, 24, 48 and 72 hpi. The percentage of EHV-1 infected 
cells in the population of CD172a+ cells in the nasal mucosa was shown in (C) and (E). ROIWI is 
the region including the epithelium and the lamina propria of EHV-1 infection in the epithelium 
whereas ROIWOI is the region without EHV-1 infection in the epithelium (Two-way ANOVA; *: 
P<0.05; **: P<0.01). EHV-1 infected cells (red); CD172a+ cells (green). The white line drawn on the 
image represents the BM. Scale bar: 50µm. 
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Figure 3: The expression of CCL2 (A) and CCL5 (B) in mock inoculated, EHV-1 neurovirulent strains 
03P37, 95P105 and non-neurovirulent strains 97P70, 94P247 inoculated (at ROIWI and ROIWOI) as 
well as their UV inactivated viruses (UV-03P37 and UV-97P70) inoculated nasal mucosa at 0, 24, 48 
and 72hpi. (Two-way ANOVA; **: P<0.01; ***: P<0.001) EHV-1 infected cells (red); CCL2 or CCL5 
(green). The white line drawn on the image represents the BM. Scale bar: 50µm.  
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3.2 The expression of chemokine CCL2 and CCL5 in EHV-1 infected nasal mucosa 
explants 
 
Both CCL2 and CCL5 positive cells were scattered underneath the epithelial cells of 
mock-inoculated nasal mucosal tissues at all the time points of cultivation, whereas 
CXCL8 positive cells were not observed (Figure 3A and 3B). Upon inoculation with 
the EHV-1 neurovirulent strain 03P37, the expression of CCL2 and CCL5 strongly 
increased and colocalized with the EHV-1 infected epithelial cells, whereas CXCL8 
positive cells were not observed (Figure 3A and 3B). The total expression of CCL2 
was much higher than that of CCL5. The expression of CCL2 in nasal mucosa at 
ROIWI increased 8-fold (P<0.01) compared to the mock at 24 hpi, 9-fold (P<0.01) at 
48hpi and 11-fold (P<0.001) at 72 hpi (Figure 3A). For CCL5, its expression in the 
ROIWI of the nasal mucosa explant inoculated with EHV-1 was 4-fold (P<0.01) and 8-
fold (P<0.01) higher than the mock at 48 hpi and 72 hpi, respectively (Figure 3B). 
There were no significant differences (P>0.05) for CCL2 and CCL5 production 
between EHV-1 (ROIWOI), UV-EHV-1 and mock-inoculated explants at all the time 
points mentioned. The neurovirulent strain 95P105 showed similar results as strain 
03P37 (Figure 3). For nasal mucosa inoculated with the non-neurovirulent EHV-1 
strains 97P70 and 94P247, the expression of CCL2 and CCL5 was not significantly 
different compared with mock-inoculated nasal mucosa (Figure 3). CCL2 and CCL5 
positive cells were distributed in a scattered way underneath the epithelium in the 
nasal mucosa in scratch-wound assay and their expression was similar with the mock 
(data not shown). 
 
3.3 Viability analysis during treatment with RSG or QC in in vitro cultures 
 
Apoptotic cell death was detected at different concentrations (1, 3, 10, 30µM) with 
RSG or QC. The number of apoptotic cells in the epithelium had a slight, but not 
significant increase during the 72 hours cultivation period with both products. The 
number of apoptotic cells in the epithelium did not increase significantly for either 
RSG or QC (Table 1, only the data at 72hpi were shown).  
 
3.4 The effect of RSG or QC on EHV-1 infection in nasal mucosa explants  
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During RSG or QC 12 h pre-treatment or treatment at the same time with the 
neurovirulent EHV-1 strain 03P37 inoculation, the viral titers in the supernatant of 
cultured explants and the plaque formation in the epithelium were similar, so only the 
data of RSG or QC treatment at the same time with EHV-1 inoculation were shown. 
Viral titers (Figure 4A) and plaque formation among different concentrations of RSG 
and QC treatment did not differ significantly (Figure 4B). In the lamina propria of 
nasal mucosa infected with the neurovirulent 03P37 strain, the number of EHV-1 
infected cells was remarkably lower at 72 hpi when treated with RSG 12 h before 
inoculation or at the same time, with 41.2±11.7% (P<0.01) or 30.3±8.2% (P<0.05) at 
10µM and 67.2±9.8% (P<0.001) or 54.5±16.8% (P<0.01) at 30µM for the ROIWI 
(Figure 4C). This lower number of EHV-1 infected cells was not observed when 
treated with QC. The neurovirulent strain 95P105 showed similar results as strain 
03P37. For strain 97P70 and 94P247, pre-treatment and treatment with RSG or QC 
did not change virus replication in the epithelium and the number of EHV-1 infected 
cells in the lamina propria (Figure 4, only the data for strain 97P70).    
 
Table 1    Absence of toxicity of RSG and QC in nasal mucosa explants. Viability of 
nasal mucosa explants treated with RSG or QC at different concentrations was 
determined in the TUNEL assay at 72 hpi. Values are given as means ± SD of 3 
different experiments. 
 
Localization 
(nasal mucosa) Products 
Percentage (%) of TUNEL-positive cells treated at ... µM at 72 hpi 
0  1 3 10 30 
Epithelium RSG	 0.3±0.2 0.4±0.3 0.7±0.6 0.6±0.5 1.1±0.6 
 QC 0.4±0.1 0.7±0.3 1.2±0.6 1.4±0.6 1.6±0.7 
Lamina propria RSG 0.5±0.6 1.4±0.8 3.0±0.7 2.8±1.9 4.0±1.1 
QC 0.6±0.2 1.2±0.7 2.7±0.9 3.2±0.7 4.7±1.6 
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3.5 The RSG treatment inhibited the migration of CD172a+ monocytic cells in the 
EHV-1 inoculated nasal mucosa explants  
 
In the mock-inoculated explants and EHV-1-inoculated explants, the RSG 
pretreatment or treatment at the same time had no effect on the number of CD5+ T and 
B-lymphocytes in the lamina propria. Within the mock-inoculated explants, the RSG 
pretreatment or treatment at the same time had no effect on the number of CD172a+ 
monocytic cells in the lamina propria (Figure 5B). In the EHV-1-inoculated explants, 
at 72 hpi, in the lamina propria of ROIWI the number of total CD172a+ monocytic cells 
decreased with 28.9±6.5% (P<0.01) or 41.3±9.6% (P<0.01) at a pretreatment with 
10µM or 30µM. When treated with RSG at the same time of EHV-1 inoculation, the 
number of total CD172a+ monocytic cells in the lamina propria of ROIWI was reduced 
with 31.1±7.6% (P<0.01) at the concentration of 30µM (Figure 5C). The 
neurovirulent strain 95P105 showed similar results as strain 03P37 (Figure 5D).  
 
  
 
 
 
 
50µm 
             Mock                            RSG-0µM                      RSG-10µM                       RSG-30µM 
Figure 5A 
Figure 4: Viral production (A) at 0, 2, 24, 48 and 72 hpi and plaque formation (B) at 72 hpi in 
nasal mucosa explants inoculated with EHV-1 neurovirulent strain 03P37 and non- 
neurovirulent strain 97P70 and treated at the same time with RSG or QC at different 
concentrations (0µM, 1µM, 3µM, 10µM, 30µM). The number of individual EHV-1 infected cell 
in the lamina propria of nasal mucosa explants (C) treated with RSG or QC 12 h prior to or at 
the same time of EHV-1 inoculation. ROIWI is the region of interest including the epithelium and 
the lamina propria with EHV-1 infection in the epithelium whereas ROIWOI is the region of interest 
without EHV-1 infection in the epithelium. (Two-way ANOVA; **: P<0.01; ***: P<0.001). Scale 
bar: 50µm.  
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Figure 5: The localization (A) and quantification of CD172a+ cells in the lamina propria of mock-
inoculated (B) or EHV-1 neurovirulent strains 03P37 (C) and 95P105 (D)  inoculated nasal mucosa 
explants at 72 hpi and treated with RSG 12 hours prior to or at the same time of the mock or viral 
inoculation at the concentration of 10µM or 30µM. ROIWI is the region of interest including the epithelium 
and the lamina propria with EHV-1 infection in the epithelium whereas ROIWOI is the region of interest without 
EHV-1 infection in the epithelium. (Two-way ANOVA; *: P<0.05; **: P<0.01). EHV-1 infected cells (red); 
CD172a+ cells (green). The white line drawn on the image represents the BM. Scale bar: 50µm.   
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4. Discussion  
 
Monocytic cells play an important role in the pathogenesis of EHV-1 infection (Laval 
et al., 2015b). CD172a+ monocytic cells become infected with EHV-1 in the nasal 
mucosa (the initial infection site), and transport the virus from the apical side of the 
epithelium into the deep lamina propria (Baghi and Nauwynck, 2014). Our data 
demonstrate that a basal to apical side migration of non-infected CD172a+ monocytic 
cells was present during the early stage of the EHV-1 neurovirulent strain infection in 
the epithelial cells. Indeed, at 24 hpi and 48 hpi, CD172a+ monocytic cells migrated 
towards the infected epithelium region as fewer CD172a+ monocytic cells were 
observed underneath the BM while more infected CD172a+ monocytic cells were 
present in the epithelium at these time points. In the infected regions more CD172a+ 
monocytic cells were found at 48 and 72 hpi, most probably due to migration from 
deeper tissues, as there was no reduction of CD172a+ monocytic cells in the area 
lateral from the infected regions. More EHV-1 infected CD172a+ monocytic cells 
gathered in the lamina propria at 72 hpi, which indicated that after getting in contact 
with the virus, the infected CD172a+ monocytic cells migrated into the deep regions 
for further invasion. It has also been reported that a basal-to-apical monocyte 
transepithelial migration in vitro can be elicited by influenza A virus infection of 
primary alveolar epithelial cells and resident alveolar macrophages, which can be 
induced by monocyte chemoattractants CCL2 and CCL5 (Herold et al., 2006; 
Rosseau et al., 2000). Chemokines are secreted in response to signals such as 
proinflammatory cytokines where they play an important role in selectively recruiting 
monocytes, neutrophils, and lymphocytes. Monocyte chemoattractant protein-1 
(MCP-1/CCL2) can be secreted by epithelial cells and many immune cells including 
monocytes and DC and is one of the key chemokines that regulate migration and 
infiltration of monocytes/macrophages (Deshmane et al., 2009; Standiford et al., 
1991). CCL5, previously known as RANTES (regulated upon activation, normal T 
cell expressed and secreted) is a member of the CC chemokine family. It can be 
produced by T lymphocytes, tumor cells and fibroblasts and recruits monocytes, T 
cells, basophils and eosinophils (Vilela et al., 2009). The current data in our study 
showed that the neurovirulent EHV-1 infected nasal mucosa explants displayed a 
release of both CCL2 and CCL5. CCL2 started to be expressed in the epithelial cells 
at 24 hpi, which corresponds with the time point when the number of CD172a+ 
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monocytic cells in the lamina propria decreased. This indicates that the secreted 
CCL2 is most probably involved in the recruitment of CD172a+ monocytic cells 
during an infection with EHV-1 neurovirulent strains. The basal to apical migration 
and chemokine production were shown for neurovirulent strains but not for the non-
neurovirulent strains. This strain specificity may be linked with the cell tropism of 
EHV-1. For the neurovirulent strain 03P37, the majority of individual infected cells 
were CD172a+ monocytic cells while for the non-neurovirulent strain 97P70, 
individual infected cells were equally identified as CD5+ T lymphocytes and CD172a+ 
monocytic cells (Vandekerckhove et al., 2010). For CD5+ T lymphocytes attraction, 
other chemokines such as, CXCL9 and CXCL10 (Wuest et al., 2006; Wuest and Carr, 
2008) may be involved. Current research is looking into the involvement of these T 
lymphocytic chemokines in the early pathogenesis of non-neurovirulent EHV-1 
strains. For the difference between neurovirulent strains and non-neurovirulent 
strains, there is a hypothesis that the mutation in ORF30 (DNA polymerase, 
A2254/G2254), which results in a modified DNA polymerase activity, enhances the 
virulence of this viral strain (Nugent et al., 2006). However, there is compelling 
evidence that this nucleotide substitution is not the only determinant for the induction 
of neurovirulent disease by EHV-1 (Perkins et al., 2009). Not only ORF30, but also 
other ORFs may have an impact on the viral replication rate, with potential 
concomitant effects on neuropathogenicity (Liu et al., 2006). This still needs to be 
further examined. 
 
Absence of CCL2 and CCL5 expression in the wound-scratch assay indicated that cell 
death induced by wounding was not responsible for or at least, had no direct impact 
on their expression. CCL2 and CCL5 were not detected when inoculated with UV 
inactivated EHV-1. This demonstrated that the step of binding to and entry into host 
cells is not sufficient for the production of CCL2 and CCL5. A further stage, including 
viral gene expression and replication is necessary for their expression. The production 
of CCL2 and CCL5 was first detected at 24 hpi in the nasal mucosa infected with 
EHV-1. At 12hpi, there was nothing observed (data not shown). This indicates that the 
chemokines CCL2 and CCL5 become expressed between 12 and 24 hpi. This is the 
time period during which some late viral proteins become expressed in epithelial cells 
and CD172a+ cells (Gryspeerdt et al., 2012; Laval et al., 2015a). It seems to indicate 
that some late viral proteins or transcription factors are involved in the induction of 
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CCL2 and CCL5 expression. It has been reported that human cytomegalovirus 
(HCMV) tegument protein pp71 (Naing et al., 2015) and the viral G protein coupled 
receptor (vGPCR) of human herpesvirus 8 (HHV-8) lead to an increased expression 
of CCL2 during infection (Choi and Nicholas, 2010). In addition, HHV-8 upregulates 
activating transcription factor 4 (ATF4) expression, which induces CCL2 production 
in endothelial cells (Caselli et al., 2012). RNase protection analyses revealed 
increased expression of CCL2 at 8 and 12hpi with EHV-1 strain KyARgp2F (an 
EHV-1 recombinant strain from KyA, expressing the full-length gp2 protein) 
compared to EHV-1 strain KyA (harbors part of gp2 protein) when infecting mice 
(Smith et al., 2005). It is very well possible that the full-length gp2 protein is involved 
in the induction of CCL2 in the early stage of infection. The difference of the time 
points may be explained by the fact that our detection was on the protein level, which 
is later than the detection of RNA transcripts. Except for gp2 protein, other EHV-1 
viral proteins and transcription factors involved in the CCL2 and CCL5 induction also 
need to be further identified.   
 
As we have observed the migration of CD172a+ monocytic cells during the EHV-1 
infection in the nasal mucosa, migration inhibitors were used to treat the nasal 
mucosa. The treatment with RSG of equine nasal mucosa had no impact on the virus 
replication in the epithelium while the number of infected CD172a+ monocytic cells 
in the lamina propria decreased when treated with RSG at 10µM and 30µM. A 
possible explanation is that RSG treatment can inhibit the migration of CD172a+ 
monocytic cells in a dose-dependent manner during an EHV-1 infection. It showed 
that the migration of CD172a+ monocytic cells from the deeper tissues towards the 
infected region was inhibited in our study. This is in agreement with the research of 
Kintscher (Kintscher et al., 2000), demonstrating that RSG function as peroxisome 
proliferator-activated receptor (PPAR) γ agonist and the activation of PPAR γ could 
impede DC migration from the peripheral sites of antigen capture to the DLNs. PPAR 
γ activation could also play a role in the spontaneous migration of intramucosal DCs 
and reduced migration of mice lung DCs under steady state conditions without 
infection (Angeli et al., 2003; Holt et al., 1994). Our data showed that only in the 
condition with EHV-1 infection, the RSG treatment could inhibit the migration of 
CD172a+ monocytic cells, whereas no inhibitory impact was observed with mock-
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inoculation and RSG treatment. This may be due to the species specificity and the 
difference between in vivo and ex vivo cultures.   
 
In conclusion, we have demonstrated that a basal to apical migration of CD172a+ 
monocytic cells in nasal mucosa was present during infections with neurovirulent 
EHV-1 strains, with CCL2 and CCL5 involved in the attraction of CD172a+ 
monocytic cells towards the infected regions. RSG treatment efficiently inhibited the 
CD172a+ monocytic cells migration in a dose-dependent manner while it had no 
effect on the virus replication in the epithelium. A better understanding of the viral 
and cellular factors during this process could give new insights into the early 
pathogenesis of an infection with neurovirulent EHV-1 and provide future therapeutic 
strategies.  
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Abstract 
 
Equine herpesvirus 1 (EHV-1) and equine arteritis virus (EAV) induce respiratory 
problems and abortion in horses and are considered as two serious threats to equine 
industry. Both EHV-1 and EAV misuse patrolling leukocytes in the upper respiratory 
tract to breach the basement membrane (BM) and to migrate to blood vessels. So far, 
the behavior and impact of a double infection in the respiratory mucosa of a horse are 
unknown. In the present study, the outcome of double infections with EHV-1 and the 
low virulent EAV strain 08P187 (superinfection with an interval of 12 h or co-
infection) were compared with single infections in fully susceptible RK-13 cells and 
equine upper respiratory mucosa explants. When RK-13 cells were inoculated with 
either EHV-1 or EAV 12 h prior to the subsequent EAV or EHV-1 inoculation, the 
latter EAV or EHV-1 infection was clearly suppressed at 24 hpi or 36 hpi, 
respectively, without EHV-1 and EAV co-infecting the same RK-13 cells. After 
simultaneous infection with EHV-1 and EAV, higher numbers of EAV infected cells 
but similar numbers of EHV-1 infected cells were found compared to the single 
infections, with a low number of EHV-1 and EAV co-infected RK-13 cells at 48 hpi 
and 72 hpi. In the upper respiratory mucosa exposed to EAV 12 h prior to EHV-1, the 
number and size of the EHV-1-induced plaques were similar to those of the EHV-1 
single infected mucosa explants. In nasal and nasopharyngeal mucosae, EAV and 
EHV-1 pre-infections slightly reduced the number of EHV-1 and EAV infected 
leukocytes compared to the single infections and co-infection. In double EAV and 
EHV-1 infected explants, no co-infected leukocytes were detected. From these results, 
it can be concluded that EAV and EHV-1 are only slightly influencing each other’s 
infection and that they do not infect the same mucosal leukocytes.   
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1. Introduction  
 
Equine herpesvirus 1 (EHV-1) and equine arteritis virus (EAV) are two important 
pathogens of horses, which have significant economical impacts on the equine 
breeding industry worldwide (Allen and Bryans, 1985; Bażanów et al., 2014; 
Timoney and McCollum, 1990). EHV-1 is an important cause of respiratory distress, 
abortion, neonatal foal death and myeloencephalopathy (Lunn et al., 2009; Pusterla et 
al., 2009). Likewise, a clinical infection with EAV is characterized by influenza-like 
illness in adult horses, abortion in pregnant mares and interstitial pneumonia in young 
foals (Timoney, 2000). EHV-1 is a member of the subfamily Alphaherpesvirinae with 
a 150 kilobases double stranded DNA genome (Telford et al., 1992), whereas EAV is 
a single-stranded, positive-sense RNA genome of approximately 12.7 kilobases that 
belongs to the family Arteriviridae (Snijder and Meulenberg, 1998).  
 
Different EHV-1 strains induce different clinical signs in the field. Studies indicated 
that a single nucleotide polymorphism (A2254/G2254) in the EHV-1 DNA 
polymerase gene (ORF30) is associated with the neuropathogenic potential of 
naturally occurring strains (Nugent et al., 2006; Van de Walle et al., 2009). Although 
no difference exists in the cell tropism between the neurovirulent and non-
neurovirulent strains of EHV-1, it has been reported that the former infect a higher 
number of CD172a+ monocytic cells than the latter in the upper respiratory mucosa 
(Vandekerckhove et al., 2010). Although EAV has only one known serotype, 
geographical and temporal distinct strains of EAV differ in the severity of clinical 
signs they induce and in their abortigenic potential (Stadejek et al., 1999; Zhang et al., 
2007).   
 
For both EHV-1 and EAV, primary replication takes place in the mucosa of the upper 
respiratory tract. Subsequently, both viruses disseminate via a leukocyte-associated 
viremia, which enables both viruses to reach endothelia of capillaries in multiple 
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secondary organs (Bryans and Allen, 1989; Kydd et al., 1994). Viral replication in 
clinical organs lead to abortion for both viruses and central nervous disorders for 
certain strains of EHV-1 (Balasuriya, 2014). During the invasion process of both 
viruses into the deeper tissues of the upper respiratory tract, the CD172a+ monocytic 
cells and to a lesser degree CD3+ T cells function as Trojan horses (Vairo et al., 2013a; 
Vandekerckhove et al., 2010).    
 
So far, clinical outcomes of EHV-1 and EAV infections are indistinguishable (Givens 
and Marley, 2008) and co-infection may occur in horses under field conditions. 
However, up till now, there is no information available on the behavior of a co-
infection with EHV-1 and EAV in the equine respiratory mucosa. The research on the 
interaction between EAV and EHV-1 in the respiratory mucosa will allow a better 
understanding of the pathogenesis of dual infections (DaPalma et al., 2010). The 
present study was designed to assess the outcome of double infections with 
neurovirulent and non-neurovirulent EHV-1 strains and a low virulent strain of EAV 
in the fully susceptible rabbit kidney epithelial cells (RK-13 cells) and equine nasal 
and nasopharyngeal mucosa explants and to reveal that whether EHV-1 and EAV 
(initiated from upper respiratory) by co-infection (or superinfection) can be more 
prone to penetrate the upper respiratory mucosa, and facilitate infection compared 
with single infection.   
 
2. Material and Methods  
 
2.1 Animals and explants 
 
The nasal septum and nasopharynx were collected from 3 healthy horses, between 4 
and 6 years old at a local slaughterhouse. Horses were seropositive for EHV-1 and 
EAV (Vairo et al., 2012; Vandekerckhove et al., 2010). The collected tissues were 
transported on ice in phosphate buffered saline (PBS) supplemented with 10µg/ml 
128                                     Chapter 5: Dual infections of EHV-1 and EAV in equine respiratory mucosa                                      
 
	 	
	
	
gentamicin (Gibco), 1mg/ml streptomycin (Certa, Braine l’Alleud, Belgium), 
1000U/ml penicillin (Continental Pharma, Puurs, Belgium), 1mg/ml kanamycin 
(Sigma, Bornem, Belgium), and 5µg/ml fungizone (Bristol-Myers Squibb, New York, 
USA). Nasal and nasopharyngeal mucosae were stripped from the nasal surface and 
divided into pieces of 50mm2. The explants were placed on fine-meshed gauze with 
the epithelium upwards for culture on an air-liquid interface at 37°C with 5% CO2.  
 
2.2  Cell culture 
 
RK-13 cells were used and cultured in Dulbecco’s Modified Eagle Medium (DMEM) 
(Invitrogen, Paisley, UK) supplemented with 10% fetal calf serum (Invitrogen), 
100U/ml penicillin, 0.1mg/ml streptomycin and 1µg/ml gentamicin.  
 
2.3 Viruses   
 
EHV-1 neurovirulent strain 03P37, EHV-1 non-neurovirulent strain 97P70 and EAV 
strain 08P187 were used for this study. All strains were isolated from clinical cases of 
horses in Belgium as described earlier (Vairo et al., 2013a; Vandekerckhove et al., 
2010). Both EHV-1 03P37 and 97P70 strains were at the sixth passage, four passages 
in equine embryonic lung cells (EEL) and two subsequent passages in RK-13 cells, 
with a titer of 106.5 tissue culture infectious dose with 50% endpoint per milliliter 
(TCID50/ml). The 08P187 strain was at the fourth passage in RK-13 cells with a titer 
of 106.5 TCID50/ml.  
 
2.4   Single and dual infections with EHV-1 and EAV 
 
2.4.1  In RK-13 cell cultures  
2.4.1.1  EHV-1 and EAV inoculation method 
RK-13 cells were seeded in 24-well culture plates (Nunc A/S, Roskilde, Denmark) 
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with inserts at a density of 2.5×105 cells/ml and cultured at 37°C with 5% CO2. The 
cells were divided into five different groups. Groups 1 and 2 were single infections 
and group 3 was a co-infection. In detail, RK-13 cells were MOCK incubated for 12 h 
then inoculated with 200µl containing 7.0×102 TCID50 EHV-1 (group 1-MOCK/EHV-
1), EAV (group 2-MOCK/EAV) or inoculated with both 7.0×102 TCID50 EHV-1 and 
7.0×102 TCID50 EAV [group 3-MOCK/(EHV-1+EAV)]. Groups 4 and 5 were 
superinfections. In detail, we first inoculated with 200µl containing 7.0×102 TCID50 
EHV-1 or EAV on RK-13 cells (Glorieux et al., 2012) for 1 h, then removed the 
inoculum, washed with PBS and overlaid with 1% high viscosity 
carboxymethylcellulose (CMC) (Sigma) medium for 12h. Subsequently, the 
overlaying medium was removed and RK-13 cells were washed and inoculated with 
the same amount of EAV (group 4-EHV-1/EAV) or EHV-1 (group 5-EAV/EHV-1) for 
another 1 h and afterwards performed the same way as the inoculation for the first 
virus. All the viruses were inoculated at 37°C with 5% CO2.  
 
2.4.1.2  Confocal microscopy  
The time point after one-hour incubation with the 2nd virus was taken as 0h post 
inoculation (pi). At 0 h, 12 h, 24 h, 36 h, 48 h and 72 hpi, cells were fixed with 4% 
paraformaldehyde for 10min at room temperature (RT) and permeabilized with 0.1% 
Triton X-100 for 5 min at RT. To detect EHV-1 positive cells, cells were incubated 
with equine biotinylated equine polyclonal anti-EHV-1 IgG (diluted 1:10 in PBS) 
(van der Meulen et al., 2000), followed by Texas Red®-labeled Streptavidin 
(Invitrogen, 1:200 in PBS). To detect EAV positive cells, cells were incubated with 
monoclonal antibody 17D3 against EAV nucleocapsid (N) protein (VMRD, 1:100 in 
PBS), followed by FITC®-labelled goat anti-mouse IgG antibody (Invitrogen, 1:200 in 
PBS). Isotype-matched control antibodies were used to confirm the specificity of each 
staining. All the antibodies were incubated at 37°C for 1 h with 5% CO2. The nuclei 
were counterstained with Hoechst 33342 (10µg/ml, Molecular Probes) at 37°C. Cells 
were washed with PBS and mounted with glycerin/1,4-diazabicyclo[2.2.2]octane. 
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Samples were analyzed with a Leica TCS SP2 confocal microscope (Leica 
Microsystems GmbH, Wetzlar, Germany). For each group, 5 regions of interest (ROI) 
were chosen per well. The number of EHV-1 and EAV infected cells were counted 
separately. Three independent replicates were performed for each experiment.  
 
2.4.2 In upper respiratory mucosa explants 
After 24h of culture, explants were washed twice with warm medium and transferred 
on top of solid agarose. The margins were filled with agarose. All the explants were 
divided into five different groups with the same way as described for RK-13 cells. In 
brief, explants were MOCK incubated for 12 h then inoculated with 500µl medium 
containing 106.5 TCID50 EHV-1 (group 1- MOCK/EHV-1), EAV (group 2-
MOCK/EAV) or inoculated with both EHV-1 and EAV (group 3-MOCK/(EHV-
1+EAV)). In addition, explants were inoculated with 500µl medium containing 106.5 
TCID50 EHV-1 or EAV first, then 12 h later inoculated with the same amount of EAV 
(group 4-EHV-1/EAV) or EHV-1 (group 5-EAV/EHV-1). All the viruses were 
inoculated at 37°C for 1 h with 5% CO2. After each inoculation, the explants were 
rinsed and further incubated with fresh medium (Vairo et al., 2013b). Finally, the 
explants were collected at 0, 12, 24, 36, 48 and 72 hpi, embedded in methocelTM, and 
frozen at -70°C.   
 
Of each explant, 50 serial 16µm cryosections of 8mm2 were made for 
immunofluorescence stainings. Briefly, the cryosections were fixed with 100% 
methanol for 20 min at -20oC. Subsequently, EHV-1 and/or EAV infected cells were 
stained following the aforementioned protocol. After staining, the cryosections were 
rinsed three times in PBS and mounted with glycerin/1,4-diazabicyclo[2.2.2]octane. 
All the results of the IF stainings were analyzed by confocal microscopy. In the 
lamina propria of the mucosa, two regions of interest (ROI) were chosen for analysis 
of EHV-1 replication. One region was underneath a plaque of EHV-1 infected 
epithelial cells (ROIUIE) and the other region was underneath non-infected epithelium 
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(ROIUNE) (Figure 1). As EAV infected cells are limited in number and scattered, all 
the regions of the mucosa were taken into account.  
 
 
 
 
 
 
 
2.5  Data analysis 
 
Three independent experiments were performed and the data are presented as means ± 
standard deviations (Givens and Marley). Two-way ANOVA was used to calculate 
statistical significance among multiple groups. Data were classified: P>0.05, not 
significantly different; P≤0.05 (*), significantly different; P≤0.01 (**), very 
significantly different; P≤0.001 (***), extremely significantly different.  
 
3 Results 
 
3.1  EHV-1 and/or EAV infections in RK-13 cells  
 
3.1.1 Single infections (Figure 2A and 2B) 
Single infection with EHV-1 or EAV was performed in RK-13 cells as a reference for 
double infections with both EHV-1 and EAV. The number of EHV-1 and EAV 
infected RK-13 cells increased gradually over time post inoculation. As the results of 
Figure 1: EHV-1 infected equine nasal mucosa with two regions of interest. ROIUIE is the region of 
interest in the lamina propria underneath a plaque of EHV-1 infected epithelial cells whereas ROIUNE is 
the region of interest in the lamina propria underneath non-infected epithelial cells. Scale bar: 50µm. 
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dual infections with EAV and EHV-1 neurovirulent strain 03P37 were similar to those 
with EAV and EHV-1 non-neurovirulent strain 97P70 in RK-13 cells, only the former 
was presented. 
 
3.1.2  Superinfections (Figure 2A and 2B) 
EAV/EHV-1 superinfection (cells were inoculated with EAV 12 h before EHV-1 
inoculation) The number of EHV-1 infected cells in this superinfection was 
significantly lower compared to the single EHV-1 infection up till 48 hpi (26.4±7.6% 
at 36hpi (P<0.05) and 43±6.2% at 48 hpi (P<0.01)). No significant difference was 
observed at 0, 12, 24 and 72 hpi. No colocalization of EAV and EHV-1 viral antigens 
was detected in the same cell over time.  
 
EHV-1/EAV superinfection (cells were inoculated with EHV-1 12 h before EAV 
inoculation) The number of EAV infected cells in EHV-1/EAV superinfection was 
47.6±11.3% lower (P<0.01) at 24 hpi compared with the EAV single infection and 
27.1±13.7% lower (P<0.05) at 36 hpi. There were no significant differences at 0, 12, 
48 and 72 hpi. Colocalization of EAV and EHV-1 was not observed.  
 
3.1.3 Co-infection (Figure 2A and 2B) 
MOCK/(EHV-1+EAV) co-infection (first incubated with medium and 12 h later 
inoculated with both EHV-1 and EAV)  
The number of EHV-1 infected cells in the EHV-1 and EAV co-infection was not 
significantly different from that in EHV-1 single infection over time. The number of 
EAV infected cells in the EHV-1 and EAV co-infection was 27.5±6.7% (P<0.05) at 36 
hpi and 31.2±10.9% (P<0.05) higher at 48 hpi than that in EAV single infection. No 
difference was found at 0, 12, 24, and 72 hpi. EHV-1 and EAV co-infected cells were 
detected at 48 hpi (12.3±1.7%) and 72 hpi (16.2±3.9%). 
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Figure 2: Quantification of EHV-1 and EAV infected cells in RK-13 cells inoculated with 
EHV-1 alone (MOCK/EHV-1), EAV alone (MOCK/EAV), EHV-1 and EAV with a time 
interval of 12 hours (EHV-1/EAV) and (EAV/EHV-1) or simultaneously (MOCK/(EHV-
1+EAV)). (Two-way ANOVA; *: P<0.05; **: P<0.01). The images of MOCK/(EHV-1+EAV) in 
A and B are identical.  EHV-1 infected cells (red); EAV infected cells (green). Scale bar: 50µm.  
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3.2  EHV-1 and/or EAV infections in the upper respiratory mucosa  
 
3.2.1 Single infections  
In nasal mucosa, some EHV-1 single infected cells were found at 12 hpi in the 
epithelium and EHV-1-induced plaques firstly appeared in the epithelium from 24 hpi 
onwards with increasing plaque number and plaque latitude over time (Figure 3B and 
3C). Individual EAV infected cells were detected from 12 hpi and small clusters of 
EAV infected cells appeared from 24 hpi onwards. The plaque formation with EHV-1 
in the nasopharyngeal mucosa showed a similar pattern with that in the nasal mucosa. 
The number of EHV-1 infected cells in the nasal mucosa was higher than that in the 
nasopharyngeal mucosa at all time points (max. 35.9±7.6% higher at 36 hpi). In 
contrast, the number of EAV infected cells in the nasopharyngeal mucosa was 
significantly higher than that in the nasal mucosa (max. 75.6±21.7% higher at 72 hpi). 
As the results of double infections with EAV and EHV-1 neurovirulent strain 03P37 
were similar with that of double infections with EAV and EHV-1 non-neurovirulent 
strain 97P70 in upper respiratory mucosa explants, only the data of dual infections 
with EAV and EHV-1 neurovirulent strain 03P37 were shown in the following 
experiments.  
 
3.2.2 Superinfections  
EAV/EHV-1 superinfection (explants were inoculated with EAV 12 h before EHV-1 
inoculation)  
 
Upon EAV/EHV-1 superinfection, similar EHV-1-induced plaques were observed in 
the epithelium compared with EHV-1 single infection at all the time points. In the 
lamina propria underneath a plaque of EHV-1 infected epithelial cells (ROIUIE) in the 
nasal mucosa, the number of EHV-1 infected cells in the EAV/EHV-1 superinfection 
group was 19.6±2.1% lower compared to EHV-1 single infection group at 24hpi 
(P<0.05) and 8.2±2.1% lower at 36hpi (P>0.05) (Figure 3D). In the ROIUIE region of 
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the nasopharyngeal mucosa, the number of EHV-1 infected cells in the EAV/EHV-1 
superinfection group was 29.6±8.3% lower (P<0.01) than that in the EHV-1 single 
infection group at 36 hpi and 15.3±2.7% lower (P<0.05) at 48 hpi (Figure 3E). In the 
lamina propria underneath non-infected epithelial cells (ROIUNE), no significant 
differences for the number of EHV-1 infected cells between the EAV/EHV-1 
superinfection and EHV-1 single infection were observed in both mucosae. 
Colocalization of EAV and EHV-1 was not observed in both mucosae.  
 
EHV-1/EAV superinfection (explants were inoculated with EHV-1 12 h before EAV 
inoculation)  
 
In the nasal mucosa, the number of EAV infected cells in the EHV-1/EAV 
superinfection group was reduced with 21.8±2.3% at 24 hpi (P<0.05) and 17.9±5.2% 
at 36 hpi (P<0.05) when compared with that of EAV single infection (Figure 4B). In 
the nasopharyngeal mucosa, only at 24 hpi there was a significant difference between 
the EHV-1/EAV superinfection and EAV single infection (P<0.05), with a decrease of 
18.7±5.4% EAV infected cells in EHV-1/EAV superinfection (Figure 4C). No 
colocalization of EAV and EHV-1 was observed in both mucosae.  
 
3.2.3 Co-infection 
MOCK/(EHV-1+EAV) co-infection (first incubated with medium and then 12 h later 
inoculated with both EHV-1 and EAV)  
 
In the epithelium of the nasal and nasopharyngeal mucosa, a similar EHV-1-induced 
plaque formation in the EHV-1 and EAV co-infection group was observed compared 
to the EHV-1 single infection group. No EHV-1 and EAV co-infected cells were 
observed in both mucosae in EHV-1 and EAV co-infection. The EHV-1 and EAV 
infected regions were not close to each other and the distance between the two regions 
was too far away to be shown in one image even if the minimum magnification was 
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used.  
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Figure 3: The number of EHV-1 induced plaques in 8mm2 (B) and plaque latitude (C) in the nasal mucosa and 
quantification of EHV-1 infected cells in the lamina propria of the nasal (D) and nasopharyngeal mucosa (E) 
after a MOCK/EHV-1 single infection, EAV/EHV-1 superinfection and MOCK/(EHV-1+EAV) co-infection at 0, 
12, 24, 36, 48 and 72 hpi. ROIUIE is the region of interest in the lamina propria underneath a plaque of EHV-1 infected 
epithelial cells whereas ROIUNE is the region of interest in the lamina propria underneath non-infected epithelial cells. 
(Two-way ANOVA; *: P<0.05; **: P<0.01). EHV-1 infected cells (red) . Scale bar: 50µm. 
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In the lamina propria of nasal mucosa, there was no significant difference for the 
number of EHV-1 and EAV infected cells in the EHV-1 and EAV co-infection group 
compared to the single infection groups. In the lamina propria of the nasopharyngeal 
mucosa, the number of EHV-1 infected cells in the EHV-1 and EAV co-infection 
group was reduced with 13.1±1.9% at 36 hpi (P<0.05) in the region underneath the 
plaques (Figure 3E), while the number of EAV infected cells decreased with 5.8±2.1% 
(P>0.05) at 36 hpi (Figure 4C).  
 
 
 
 
Figure 4: Quantification of EAV infected cells in the nasal (B) and nasopharyngeal mucosa (C) 
after a MOCK/EAV single infection, EHV-1/EAV superinfection and MOCK/(EHV-1+EAV) 
co-infection. (Two-way ANOVA; *: P<0.05.) EAV infected cells (green). Scale bar: 50µm. 
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4. Discussion 
 
Respiratory disease, neonatal foal death and abortion induced by EHV-1 infection 
may be confused with other equine viral diseases especially EAV infection. Nowadays 
most of the studies focused on infection with either EHV-1 or EAV. The outcome of 
dual infections with both EHV-1 and EAV has never been reported before. In the 
present study, we established an in vitro and ex vivo model to investigate how the 
presence of EHV-1 (EAV) either prior to or at the same time with EAV (EHV-1) 
inoculation impacts replication and invasion of both viruses. Here, two Belgian 
isolates of EHV-1, the non-neurovirulent strain 97P70 and the neurovirulent strain 
03P37, as well as the Belgian EAV strain 08P187 were used in this study. The 
inoculation time interval between the two viruses was limited to 12 h, which is 
approximately identical to the duration of the replication cycle of both viruses.  
 
In the present study, it was found that in RK-13 cells, EHV-1 replication was 
temporarily (24 hpi and 36 hpi) suppressed by an earlier infection with EAV. On the 
other hand, EAV replication was also temporarily (24 hpi, 36 hpi and 48 hpi) 
restrained with a prior EHV-1 inoculation. In addition, some co-infected RK-13 cells 
with both EHV-1 and EAV viral antigens were found in the co-infection whereas no 
colocalization of EHV-1 and EAV was detected during the superinfection. The results 
were independent on the MOI used as no significant difference on the inhibitory effect 
was detected at different MOI (data not shown). Therefore, an inhibitory effect 
induced by either EHV-1 or EAV in the dual infections was present regardless of the 
MOI used and the order of virus exposure. An inhibitory effect has been reported 
before with retroviruses (Nethe et al., 2005), designated superinfection resistance 
which is established after a primary infection with one retrovirus type, preventing the 
infected cell from being superinfected by a similar type of virus. The interference 
mechanism was mediated by the expression of a related viral protein to occupy the 
cellular receptors (Berg et al., 2003) or inhibition of the viral transcriptional activator 
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protein Tas (Meiering and Linial, 2002; Russell et al., 2005). For the superinfection 
resistance of another retrovirus HIV, down regulation of the CD4 receptor is indicated 
as mechanism (Nethe et al., 2005). A superinfection resistance with totally different 
viruses, including EHV-1 (DNA virus) against EAV (RNA virus) and EAV against 
EHV-1, was observed in the present study. The first possible explanation is that both 
EHV-1 and EAV compete for the same receptor or attachment factor or use a similar 
entry pathway. A recent publication showed that EAV uses CXCL16 as the main 
receptor to enter the equine cells. The antibody blocking assay also showed that EAV 
can use alternative molecules to EqCXCL16 as an entry receptor (Sarkar et al., 2016) 
while EHV-1 uses MHC-I to infect equine cells (Brian et al., 2010). However, the 
entry receptor or associated attachment factors are still not known for both viruses in 
RK-13 cells. In RK-13 cells, the unstable attachment of EHV-1 is mediated by 
heparin sulfate moieties on cell surface proteoglycans (Osterrieder, 1999; Sugahara et 
al., 1997), which might also serve as an attachment factor for EAV similar to PRRSV 
(Delputte et al., 2002). In this way, during the early phase of infection, EHV-1 and 
EAV may compete for the attachment with heparin sulfate moieties. Thus, the virus 
that was used for the first infection will have more opportunity for attachment and 
simultaneously inhibit the subsequent attachment of the second virus. However, 
heparinase treatment of RK-13 cells and/or the addition of heparin could not reduce 
EAV infection with more than 13%, which is indicative for the existence of other EAV 
attachment factors (Asagoe et al., 1997). The second explanation may be due to the 
induction of cytokines, such as interferon (IFN). The IFN synthesized and secreted by 
the first viral infection can inhibit virus replication in the infected cells as well as 
neighbouring uninfected cells to induce a global antiviral state (Sarkar, 2014). Thus 
the RK-13 cells that have already been infected with the first virus may not be 
infected with a secondary virus. Although it has been reported that in vitro EHV-1 can 
cause a transient induction of type I IFN mRNA at an early stage of infection (3h), a 
suppression of type I IFN transcription and translation later on (12h) was found in 
equine endothelial cells (EECs) (Sarkar et al., 2015). EAV does not induce IFN 
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production on both mRNA and protein level in EECs (Go et al., 2014). However, 
there is no report on the IFN expression in RK-13 cells and equine epithelial cells. In 
our study, we were not able to detect IFN in the supernatant of infected RK-13 cells 
via IFN assay on the protein level. The results of RT-PCR showed that IFN-α and 
IFN-γ mRNA were detected in the early stage of infection (at 12 hpi and/or 24 hpi, 
data not shown). It meant that the expression of IFNs was present at the level of 
mRNA. As the inhibitory effect appeared later compared with the time point when 
IFNs mRNA was expressed, the IFN-α and IFN-γ may not or at least not directly 
contribute to the inhibitory effect. In this way, other cytokines may be also involved 
and induce this inhibitory effect. The production of IFNs, cytokines and chemokines 
and associated mechanisms in epithelial cells and upper respiratory mucosa upon 
infection with EHV-1 or EAV are ongoing and will be further unraveled. Last but not 
least, it is also possible that RK-13 cells that were infected with the first virus die, and 
as a consequence have no ability to be infected with the second virus.   
 
In the upper respiratory mucosa, the number and latitude of EHV-1 induced plaques 
in dual infections were similar to those of the EHV-1 single infected mucosa explants. 
It demonstrates that there is no impact of an EAV infection on EHV-1 replication in 
the respiratory epithelium. It has been reported that EAV targets CD172a+ monocytic 
cells and T lymphocytes in nasal and nasopharyngeal mucosae, whereas epithelial 
cells are not involved (Go et al., 2011; Vairo, 2013). On the other hand, in the 
epithelium of the respiratory mucosa the type of EHV-1 infected cells are mainly 
epithelial cells. The different cell tropism for EHV-1 and EAV in the epithelium of 
respiratory mucosa may explain why there is no impact of an EAV infection on the 
formation of EHV-1 induced plaques.  
 
In nasal and nasopharyngeal mucosae, EAV and EHV-1 pre-infections slightly 
reduced the number of EHV-1 and EAV infected leukocytes upon superinfection with 
no co-infected leukocytes being detected. CD172a+ monocytic cells are main targets 
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cells for both EAV and EHV-1 and are used as Trojan horses for dissemination from 
the upper respiratory tract to the blood circulation (Vairo et al., 2013a; 
Vandekerckhove et al., 2010). Competition for both viruses to be captured by 
CD172a+ cells during the dual infections may be one explanation for the inhibition on 
each other. Another explanation may be given by the disappearance of CD172a+ 
monocytic cells due to migration. CD172a+ monocytic cells are present at low level 
underneath the BM under normal circumstance. After EHV-1 (EAV) inoculation, 
CD172a+ monocytic cells start to migrate to the region where the infected cells gather 
(unpublished data). As a consequence, the secondary virus may have less chance to 
find and infect the CD172a+ monocytic cells in the early stage of infection.  
	
In this study, we clearly showed the existence of a minor inhibitory effect of dual 
infections with EHV-1 and EAV in vitro and ex vivo and revealed that the inhibitory 
effect is only limited during the early stage of infection. In addition, it was found that 
EHV-1 and EAV do not infect the same mucosal leukocytes.       
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General discussion 
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The primary entry site for alphaherpesviruses and	 arteriviruses in mammals is the 
upper respiratory mucosa. Different alphaherpesviruses have developed various ways 
to invade the deeper tissues. For PRV and BHV-1, viruses spread across the basement 
membrane (BM) by breaching it while EHV-1 hitchhikes across the BM mainly via 
CD172a+ monocytic cells. For BHV-1, many viral proteins such as gE/gI, are 
involved in the stromal invasion in the respiratory mucosa. A basal sorting of BHV-1 
in basal epithelial cells towards the BM depends on gE/gI (Steukers, 2013). BHV-1 
Us3 can alter the intracellular localization of the virus and has been found to 
colocalize with microtubules in cell protrusions, which implicates possible direct 
interactions of Us3 with kinesin or dynein motors (Brzozowska et al., 2010). The 
directional transport of BHV-1 towards the BM is important for virus dissemination 
and invasion to penetrate the BM. There is some evidence that Us9 and UL56 
together with kinesins might contribute to the directional transport of alphaherpes 
viral glycoproteins in the epithelial cells of the respiratory mucosa (Steukers, 2013). 
BHV-1 lacks UL56. Therefore, for the stromal invasion of BHV-1, Us3 and Us9 
proteins were mainly studied. 
 
The EHV-1 infected CD172a+ monocytic cells carry EHV-1 from the respiratory 
mucosa to the deep internal organs, ultimately reaching the CNS and/or uterus. 
Totally disguised, they transfer the virus to endothelial cells and corresponding tissues 
leading to neurological disorders and/or abortion. The commercially available 
inactivated and attenuated vaccines do not provide full protection against EHV-1 
infection and fail to completely prevent virus shedding, cell-associated viremia as 
well as severe EHV-1 symptoms. Even after vaccination, EHV-1 can still spread via a 
cell-associated viremia in vaccinated animals and induce clinical disorders. In 
addition, no efficacious antiviral treatment is available for EHV-1 infection and 
treatment is mainly limited to supportive and symptomatic care. In this way, 
inhibition of the recruitment of ‘virus carriers’ may prevent migration of these 
infected monocytic cells towards internal organs. This might be an effective way to 
impede the invasion of infected CD172a+ monocytic cells into the deeper tissue layers 
and reduce the viremia.  
 
Another important pathogen of horses, EAV, also uses CD172a+ monocytic cells as 
virus carrier during the infection of the respiratory mucosa. Moreover, under field 
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conditions, clinical cases of EHV-1 and EAV infections are not easy to distinguish as 
they both may result in respiratory disease, neonatal foal death and abortion (Givens 
and Marley, 2008). Up till now, there is no information available on the behavior of 
double infections with EHV-1 and EAV in equine respiratory mucosa. Research on 
the interaction between EHV-1 and EAV in the respiratory mucosa will allow a better 
understanding of the pathogenesis of dual infections (DaPalma et al., 2010).  
 
BHV-1 Us3 and Us9 contribute to stromal invasion of BHV-1 in the respiratory 
mucosa 
 
In Chapter 3 of the current thesis, we found that the Us3 protein could contribute to 
the cell-to-cell spread in both MDBK cells and tracheal mucosa epithelium, while a 
Us9-deleted BHV-1 strain displayed no defect in cell-to-cell spread in MDBK cells 
and respiratory mucosa epithelium. The kinetic defect of BHV-1 Us3 null virus in 
MDBK cells and trachea mucosa was demonstrated by both viral titers and plaque 
size. Although speculative at this point, it is possible that this defect is related with a 
hampered rearrangement of the cytoskeleton. The Us3 protein of BHV-1 or PRV 
contributes to the formation of cellular projections, which are filled with virus 
particles (Brzozowska et al., 2010). For PRV, these Us3-induced branched cell 
projections contain both actin and microtubules and are associated with enhanced 
virus spread (Deruelle and Favoreel, 2011). Whether cellular projections are formed 
in between epithelial cells of the respiratory tract allowing the virus to spread needs 
further research. In contrast to Us3 protein, BHV-1 Us9 protein is not involved in 
cell-to-cell spread in MDBK cells (Brideau et al., 2000). However, BHV-1 and HSV-
1 Us9 deleted viruses demonstrated a defective anterograde neuronal spread in neuron 
culture systems (Butchi et al., 2007; Coats, 2010; Haugo et al., 2011). In addition, 
deletion of Us9 in PRV is also associated with failure of neuron to cell spread and 
viral spread in the rat nervous system (Brideau et al., 2000; Ch'ng and Enquist, 2005b; 
Lyman et al., 2007).  
 
Both Us3 and Us9 proteins of BHV-1 were found to contribute to the viral passage 
across the BM barrier during BHV-1 infection in bovine trachea mucosa. Knockout of 
Us3 or Us9 caused a remarkable reduction of penetration depth underneath the BM in 
trachea mucosa though not a complete inhibition. The defect in BM passage observed 
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with a Us3 null virus may involve cellular signal pathways affected by the 
serine/threonine kinase activity of US3. The Us3 protein of PRV was found to 
contribute to invasion in respiratory mucosa via its modulation of Rho GTPase 
signaling (Lamote et al., 2016). The Us3 protein of HSV-1 has been reported to 
display Akt-like activity (Chuluunbaatar and Mohr, 2011) and Akt has been reported 
to contribute to the BM passage of mesenchymal stem cells (Sun et al., 2013), which 
suggests that HSV-1 Us3 protein may be involved in BM crossing as well. 
Additionally, the Us3 deletion in BHV-1 induces a functional change in specific viral 
proteins that are phospho-targets of Us3. The Us3 protein of BHV-1 has been 
reported to be involved in the phosphorylation of tegument proteins VP8 and VP22 
(Labiuk and Babiuk, 2009; Labiuk et al., 2010). In line with these findings in BHV-1, 
HSV Us3 has also been shown to modulate different viral proteins at various time 
points during the course of infection (Jiang et al., 1998; Kato et al., 2005; Matsuzaki 
et al., 2005). The signaling pathways and/or viral proteins involved in BHV-1 Us3-
induced BM crossing will be further identified in the future.  
 
The Us9 proteins of both BHV-1 (Al-Mubarak et al., 2007) and PRV (Kramer et al., 
2012; Kratchmarov et al., 2013), together with gE or gE/I, are crucial for efficient 
anterograde-directed transport of viral particles in neurons. In our study, we showed 
that Us9 deletion had no effect on the expression of gE (Us8) or gE/gI (Us8/7) 
whereas gE or gE/gI knockout could induce an increased phosphorylation of Us9 
protein. It may be due to the fact that gE is required for a correct localization of some 
viral proteins in the Golgi apparatus where proteins are posttranslationally modified 
(Ch'ng and Enquist, 2005a). In neurons, the expression and localization of Us9 is 
independent of gE expression, however, in our study an increased expression of Us9 
was observed in trachea mucosa explants inoculated with gE and gE/gI null viruses. 
These data indicated that some interactions exist between Us9 and gE or gE/gI during 
BHV-1 infection in the trachea mucosa. This appears to correspond with a recent 
report that gE, gI and Us9 form a trimolecular complex in HSV-infected Vero cells 
and that the interaction between gE and Us9 is specific (Awasthi and Friedman, 
2016). Together with a previous study from our lab, it was shown that BHV-1 gE/gI is 
required for BHV-1 invasion and are involved in basal sorting of virus towards basal 
domains in basal cells (Steukers, 2013) and we hypothesize now that Us9 works with 
gE/gI during viral penetration in the respiratory mucosa. Hence, the deleted BHV-1 
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Us9 or gE/gI/Us9 strains might be promising candidates for vaccine development. 
These deleted mutant strains will be severely impaired in spreading across the BM 
barrier. Further work is needed to completely elucidate the process of viral invasion 
across the BM in the respiratory tract.   
 
Alphaherpesviruses BHV-1 and PRV can invade the lamina propria via penetrating 
the BM in the respiratory mucosa. It has been reported that a trypsin-like serine 
protease is involved in the PRV invasion process (Glorieux et al., 2011). Interestingly, 
a remarkable decrease of plaque penetration through the BM was also observed when 
BHV-1 inoculated trachea mucosae were treated with AEBSF, a serine protease 
inhibitor (unpublished data), which indicates a conserved role of serine protease 
activity in invasion of different alphaherpesviruses across the BM. The main 
functional serine proteases mediating extracellular matrix (ECM) degradation include 
the plasmin/urokinase-type plasminogen activator (uPA) system. We have observed 
that plasmin inhibitor (tranexamic acid) treatment of BHV-1 inoculated trachea 
mucosae could significantly reduce the plaque penetration while uPA inhibitor (WX-
340) treatment had no effect on viral invasion (unpublished data). Hence, plasmin 
appears to direct or facilitate BHV-1 crossing of the trachea mucosal BM barrier. The 
plasmin inhibitor, tranexamic acid, may be a potential antiviral compound, which is 
complementary to current existing drugs. Matrix metalloproteinase (MMP) activity 
has also been reported to be involved in different viral-induced alterations of BM 
barrier (Kelley et al., 2014). Whether MMP are also involved in the passage of BHV-
1 or other alphaherpesviruses across the respiratory mucosal BM needs to be further 
addressed. 
 
CCL2 and CCL5 driven attraction of CD172a+ monocytic cells during an EHV-1 
infection in equine nasal mucosa  
 
In Chapter 4 of the thesis, we localized and quantified CD172a+ monocytic cells in 
equine nasal mucosa explants infected with EHV-1 and examined the expression of 
CCL2 and CCL5 (Figure 1). In mock-inoculated equine nasal mucosa (without EHV-
1 inoculation), the majority of CD172a+ monocytic cells were localized in the lamina 
propria underneath the BM and a low number of CD172a+ monocytic cells were 
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distributed in a scattered way in the epithelium. CCL2 and CCL5 positive cells 
scattered underneath the epithelial cells. No CCL2 or CCL5 expression could be 
detected in epithelial cells in non-inoculated nasal mucosa. The ex vivo cultivation 
had no impact on the survival and localization of CD172a+ monocytic cells or on the 
expression of CCL2 and CCL5 in the nasal mucosa explants.  
 
Inoculation with EHV-1 neurovirulent and non-neurovirulent strains had quite 
different effects on the distribution of CD172a+ monocytic cells in the lamina propria 
as well as the expression of CCL2 and CCL5 in the epithelial cells. The EHV-1 
neurovirulent strains (03P37 and 95P105), but not the non-neurovirulent strains 
(97P70 and 94P247), induced a basal to apical migration of CD172a+ monocytic cells 
during the early stage of infection in the nasal mucosa and the migration was mainly 
focused on the epithelial regions infected with EHV-1 (Figure 1). The expression of 
CCL2 and CCL5 strongly increased and colocalized with the EHV-1 infected 
epithelial cells. The expression of CCL2 was much stronger than that of CCL5. The 
time point at which CCL2 and CCL5 started to be produced corresponded with the 
time point when the CD172a+ monocytic cells migrated in nasal mucosa infected with 
EHV-1 neurovirulent strains. This indicates that CCL2 and CCL5 were released and 
induced the migration of CD172a+ monocytic cells. This is in line with a previous 
study, which reported that a basal to apical monocyte transepithelial migration 
induced by CCL2/CCL5 in vitro could be elicited by influenza A virus infection of 
primary alveolar epithelial cells (Herold et al., 2006; Rosseau et al., 2000). In 
contrast, the EHV-1 non-neurovirulent strains did not induce CCL2/CCL5 expression. 
 
The above strain specificity of EHV-1 may be linked with the cell tropism of the 
virus. In the respiratory mucosa, the majority of individual infected cells were 
CD172a+ monocytic cells for the neurovirulent strains, while for the non-
neurovirulent strains, less leukocytes were infected and were equally identified as 
CD5+ T lymphocytes and CD172a+ monocytic cells (Vandekerckhove et al., 2010a). 
The higher infection rate of CD172a+ monocytic cells may be associated with the 
basal to apical migration during the infection with EHV-1 neurovirulent strains, 
although it is currently unclear what is cause and what is consequence. More 
molecular work is necessary to clarify this point in the pathogenesis. Besides, there 
are still other possibilities to explain the difference between the neurovirulent and 
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non-neurovirulent strains. Currently, there is a hypothesis that the mutation in ORF30 
(DNA polymerase, A2254/G2254), which results in a modified DNA polymerase 
activity, enhances the virulence of this viral strain (Nugent et al., 2006). However, 
there is compelling evidence that this nucleotide substitution is not the only 
determinant for the induction of neurological disease by EHV-1 (Perkins et al., 2009). 
Not only ORF30, but also other ORFs may have an impact on the viral replication 
rate, with potential concomitant effects on neuropathogenicity. The induction of 
CCL2 and CCL5 and massive infiltration of CD172a+ monocytic cells may be an 
important pathogenetic feature of neurovirulent strains. It will be interesting to try to 
identify the viral components that are responsible for this process in future research. 
 
In chapter 4, the production of CCL2 and CCL5 was first detected at 24 hpi in the 
nasal mucosa infected with EHV-1 but not yet at 12 hpi. This indicates that CCL2 and 
CCL5 become expressed between 12 and 24 hpi, during which some late viral 
proteins become expressed in epithelial cells and CD172a+ monocytic cells 
(Gryspeerdt et al., 2012; Laval et al., 2015). This also suggests that some late viral 
proteins or transcription factors may be involved in the induction of CCL2 and CCL5 
expression. It has been reported that human cytomegalovirus (HCMV) tegument 
protein pp71 (Naing et al., 2015) and the viral G protein coupled receptor (vGPCR) of 
human herpesvirus 8 (HHV-8) lead to an increased expression of CCL2 during 
infection (Choi and Nicholas, 2010). HHV-8 could also upregulate activating 
transcription factor 4 (ATF4) expression, which induces CCL2 production in 
endothelial cells (Caselli et al., 2012). With EHV-1 strain KyARgp2F (an EHV-1 
recombinant strain from KyA, expressing the full-length gp2), increased expression of 
CCL2 was detected at 8 and 12 hpi compared to EHV-1 strain KyA (which harbors 
only part of gp2) by RNase protection analyses (Smith et al., 2005). It is very well 
possible that the full-length gp2 is involved in the induction of CCL2 in the early 
stage of infection. The difference in time points of CCL2 expression may be 
explained by the fact that our detection was at the protein level, which is later than the 
detection of RNA transcripts in the study of Smith et al. Besides gp2, the involvement 
of other EHV-1 viral proteins and transcription factors in the induction of CCL2 and 
CCL5 expression cannot be ruled out and will need to be investigated.   
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Treatment with rosiglitazone inhibits the migration of CD172a+ monocytic cells 
in the EHV-1 inoculated nasal mucosa  
 
In Chapter 4, two dendritic cell (DC) migration inhibitors rosiglitazone (RSG) or 
quinacrine (QC) were used to analyze their effects on EHV-1 invasion in nasal 
mucosa. Neither RSG nor QC treatment had an impact on EHV-1 neurovirulent strain 
replication in the epithelium of nasal mucosa, while the number of EHV-1 infected 
cells in the lamina propria was remarkably reduced when treated with RSG. For RSG, 
we demonstrated that this decreased number of EHV-1 infected cells was due to an 
inhibitory effect on CD172a+ monocytic cells migration in EHV-1 neurovirulent strain 
inoculated nasal mucosa. Thus, RSG treatment may potentially be used as a 
complementary method to the supportive therapy of EHV-1, which may impede 
deeper EHV-1 invasion in the early stage of the infection. A possible explanation may 
be that RSG functions as peroxisome proliferator-activated receptor (PPAR) γ agonist 
and the activation of PPAR γ could impede DC migration from the peripheral sites of 
antigen capture to the DLNs (Kintscher et al., 2000). PPAR γ activation could play a 
role in the spontaneous migration of intramucosal DCs and reduced migration of mice 
lung DCs under steady state conditions without infection as well (Angeli et al., 2003; 
Holt et al., 1994). This is different from what we have found as no inhibitory impact 
was observed when equine nasal mucosa was mock-inoculated and treated with RSG. 
This may be due to the species specificity and the difference between in vivo and ex 
vivo cultures.   
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Dual infections with EHV-1 and equine arteritis virus (EAV) in equine nasal 
mucosa 
 
In Chapter 5 of the thesis, co-infections and superinfections with EHV-1 and EAV 
were performed in RK-13 cells. An inhibitory effect on infection by the other 
pathogen could be observed in RK-13 cells with either EHV-1 or EAV, regardless of 
the order of virus exposure. During co-infection, double EHV-1 and EAV infected 
RK-13 cells could be found but at a very low level whereas no co-infected cells were 
observed in superinfections. This superinfection exclusion has been observed for a 
wide range of other viruses, including influenza virus (Huang et al., 2008), poxviruses 
(Doceul et al., 2010; Laliberte and Moss, 2014), flaviviruses (Schaller et al., 2007; 
Zou et al., 2009), alphaviruses (Karpf et al., 1997) and alphaherpesviruses (Criddle et 
Figure 1 Hypothetical model of CD172a+ monocytic cell migration in mock-inoculated (A) and EHV-1 
neurovirulent strain-inoculated (B and C, displaying the process of EHV-1 infection) equine nasal mucosa. 
A basal to apical migration of CD172a+ cells, coinciding with CCL2 and CCL5 expression in epithelial cells 
could be observed in equine nasal mucosa inoculated with EHV-1 neurovirulent strains. 
Mock-inoculated nasal mucosa                         EHV-1 (neurovirulent)-inoculated nasal mucosa 
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al., 2016; Jarosinski, 2012; Meurens et al., 2004). For alphaherpesvirus infection, the 
presence of a superinfection exclusion mechanism for autologous (same virus) and 
heterologous (different but related) has been identified (Sloutskin et al., 2014). Most 
studies have attributed the mechanism to a gD-mediated process occurring between 4 
and 8 hpi (Dasika and Letchworth, 2000; Johnson and Spear, 1989) whereas a recent 
study demonstrated that the superinfection exclusion is dependent on immediate early 
protein synthesis and independent of gD-mediated receptor interference (Criddle et 
al., 2016). In our study, a superinfection resistance was found with totally different 
viruses: infection with EHV-1, a DNA virus, provided resistance against infection 
with EAV, an RNA virus and vice versa. It may be due to the fact that both EHV-1 
and EAV compete for the same receptor or attachment factor or use a similar entry 
pathway. A recent publication showed that EAV uses CXCL16 as the main receptor 
to enter equine cells (Sarkar et al., 2016) while EHV-1 uses MHC-I to infect equine 
cells (Kurtz et al., 2010). However, the entry receptor is unknown for both viruses in 
RK-13 cells. In RK-13 cells, the unstable attachment of EHV-1 is mediated by 
heparin sulfate moieties on cell surface proteoglycans (Osterrieder, 1999; Sugahara et 
al., 1997). However, heparinase treatment of RK-13 cells and/or the addition of 
heparin could not reduce EAV infection with more than 13%, which is indicative for 
the existence of other EAV attachment factors (Asagoe et al., 1997). A second 
potential explanation may involve the induction of cytokines, such as interferon 
(IFN). The IFN synthesized and secreted by the first viral infection may inhibit virus 
replication in the infected cells as well as in neighboring uninfected cells as it induces 
a global antiviral state (Sarkar, 2014). In this way, RK-13 cells that have already been 
infected with the first virus may not be infected with a second virus. Although it has 
been reported that in vitro EHV-1 can cause a transient induction of type I IFN 
mRNA at an early stage of infection (3h), a suppression of type I IFN transcription 
and translation later on (12h) was found in equine endothelial cells (Sarkar et al., 
2015). EAV does not induce a detectable IFN production at both mRNA and protein 
level in endothelial cells (Go et al., 2014). In our study, we were not able to detect 
IFN in the supernatant of infected RK-13 cells, which is generally in line with the 
results in endothelial cells. Finally, it is also possible that RK-13 cells that were 
infected with the first virus have initiated cell death, and consequently have no ability 
to be infected with the second virus. This may also be a reason why there is no 
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inhibitory effect at 72 hpi as with time more infected cells had succumbed to the 
infection and had no effect on the later infection.   
 
Co-infections and superinfections with EHV-1 and EAV in upper respiratory mucosa 
explants demonstrated that there was no impact of an EAV infection on the formation 
of EHV-1 induced plaques in the respiratory epithelium. This may be due to the 
different cell tropism for EHV-1 and EAV in the epithelium of respiratory mucosa. 
EAV targets CD172a+ monocytic cells and T lymphocytes in respiratory mucosa, 
whereas epithelial cells are not involved (Go et al., 2011; Vairo, 2013). For EHV-1, in 
contrast, most of the infected cells in the respiratory mucosa are epithelial cells. EAV 
and EHV-1 pre-infections (superinfection) slightly reduced the number of EHV-1 and 
EAV infected leukocytes without co-infected leukocytes being detected. CD172a+ 
monocytic cells are main target cells for both EAV and EHV-1, which are used as 
Trojan horses for dissemination from the upper respiratory tract to the blood 
circulation (Vairo et al., 2013; Vandekerckhove et al., 2010b). Competition for both 
viruses to be captured by CD172a+ monocytic cells during the dual infections may be 
one explanation for the inhibitory effect these viruses appear to have on each other 
with regard to leukocyte infection. Another explanation may be due to the migration 
of CD172a+ monocytic cells. CD172a+ monocytic cells are present at low level 
underneath the BM under normal circumstances. After EHV-1 or EAV inoculation, 
CD172a+ monocytic cells start to migrate to the region where the infected cells gather 
(Chapter 3). Consequently, the secondary virus may have less chance to find and 
infect the CD172a+ monocytic cells in the early stage of infection.  	
In conclusion, the work in this thesis provides new insights in the respiratory mucosa 
invasion of two alphaherpesviruses, BHV-1 and EHV-1. During BHV-1 infection, 
knockout of Us3 or Us9 caused a remarkable reduction of penetration depth 
underneath the BM in trachea mucosa though not a complete inhibition. In addition, 
the Us3 protein of BHV-1 contributed to the lateral cell-to-cell spread in both MDBK 
cell cultures and tracheal mucosa epithelium while BHV-1 Us9 null virus showed no 
defect in this respect. For EHV-1, a basal to apical migration of CD172a+ cells was 
observed during the early stage of infection in EHV-1 neurovirulent strains-inoculated 
nasal mucosa, which correlated with CCL2 and CCL5 expression in infected mucosa 
explants. Treatment with RSG inhibited the migration of CD172a+ cells in EHV-1 
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neurovirulent strains-inoculated nasal mucosa. During the dual infections with EHV-1 
and EAV, EAV and EHV-1 pre-infections slightly reduced the number of EHV-1 and 
EAV infected cells in RK-13 cells and respiratory mucosa, which was only observed 
during the early stage of infection. In addition, it was found that EHV-1 and EAV do 
not infect the same mucosal leukocytes during co-infection or superinfection assays in 
mucosal explants. All new insights may show the way for the development of 
attenuated BHV-1 and EHV-1 vaccines and provide new direction for the 
development of new therapeutics against EHV-1 infections. 
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Bovine herpesvirus 1 (BHV-1) is able to induce prominent epithelial plaques and 
penetrate the basement membrane (BM) in a plaque-wise manner in the respiratory 
mucosa. The directional transport of BHV-1 towards the BM is important for virus 
dissemination and invasion to penetrate the BM. BHV-1 Us3 can alter intracellular 
localization of the virus and has been found to colocalize with microtubules in cell 
protrusions, which implicates possible direct interactions of Us3 with kinesin or 
dynein motors. Us9 together with kinesins might also contribute to the directional 
transport of alphaherpes viral glycoproteins in the epithelial cells of the respiratory 
mucosa. Thus, we examined the function of Us3 and Us9 protein on the stromal 
invasion of BHV-1 in the respiratory mucosa. 
 
Equine herpesvirus 1 (EHV-1) and equine arteritis virus (EAV) are two important 
pathogens of horses, which have significant economical impacts on the equine 
breeding industry worldwide every year. In upper respiratory mucosa, CD172a+ cells 
become infected with both EHV-1 and EAV and transport the viruses to the lymph 
and blood circulation for further invasion. Up to now, commercial vaccines do not 
provide full protection against EHV-1 infection and there is no efficacious antiviral 
treatment available. As CD172a+ monocytic cells function as Trojan horses in the 
respiratory mucosa, inhibition of the recruitment of these monocytic cells may 
prevent migration of infected monocytic cells into the deep tissues. Thus, we 
examined whether CD172a+ monocytic cells are specifically recruited to the EHV-1 
infection sites in order to capture virus and whether treatment with dendritic cell 
migration inhibitors rosiglitazone (RSG) or quinacrine (QC) in the respiratory mucosa 
can impede EHV-1 deeper invasion. In addition, as the clinical outcomes of EHV-1 
and EAV infections are indistinguishable under field conditions, a study on the 
behavior of dual infections with EHV-1 and EAV in the equine respiratory mucosa 
was performed. 
 
In Chapter 1, an introduction of the current knowledge of EHV-1, BHV-1 and EAV 
was given on the history and taxonomy, the virus characteristics, replication cycles 
and pathogenesis. In addition, an overview of monocytic cells and cytokines was 
provided. 
In Chapter 2, the specific aims of this thesis were formulated. 
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In Chapter 3, it was found that Us3 and Us9 play an important role in the invasion of 
BHV-1 through the BM of the respiratory mucosa. Knockout of Us3 resulted in a 
remarkable reduction in viral titer and plaque size (latitude) in MDBK cells and 
trachea mucosa while there was no defect on cell-to-cell spread observed for BHV-1 
Us9 null virus. Both BHV-1 Us3 null and Us9 null viruses showed a significant 
reduction of plaque penetration underneath the BM, however the penetration was not 
completely inhibited.  
 
In Chapter 4, it was shown that with neurovirulent strains but not with the non-
neurovirulent strains, CD172a+ monocytic cells specifically migrated towards EHV-1 
infected regions and that CCL2 and CCL5 were involved. CCL2 started to be 
expressed in infected epithelial cells at 24hpi and CCL5 at 48hpi, which corresponded 
with the CD172a+ monocytic cells migration. RSG treatment of EHV-1-inoculated 
equine nasal mucosa decreased the migration of CD172a+ monocytic cells in the 
lamina propria without having an effect on the virus replication in the epithelium.  
 
In Chapter 5, it was found that an inhibitory effect induced by either EHV-1 or EAV 
in the dual infections was present in RK-13 cells regardless of the order of virus 
exposure. In addition, RK-13 cells co-infected with both EHV-1 and EAV were not 
found upon superinfections. Only a few were found in co-infection. In nasal and 
nasopharyngeal mucosae, there was no effect of an EAV infection on EHV-1 
replication in the respiratory epithelium. EAV and EHV-1 pre-infections slightly 
reduced the number of EHV-1 and EAV infected leukocytes compared to the single 
infections and co-infection. In double EAV and EHV-1 infected explants, no co-
infected leukocytes were detected. 
 
In Chapter 6, all data on invasion of equine and bovine alphaherpesviruses through 
the respiratory mucosa obtained in the present thesis were reviewed and discussed.  
 
The main conclusions drawn in this thesis are: 
• BHV-1 Us3 and Us9 proteins play a crucial role in viral passage across the BM 
barrier during infection of bovine trachea mucosa explants. BHV-1 Us3 protein 
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also contributes to the lateral cell-to-cell spread in both MDBK cell cultures and 
tracheal mucosa epithelium while BHV-1 Us9 null virus showed no defect. 
 
• A basal to apical migration of CD172a+ monocytic cells was present in nasal 
mucosa during infections with neurovirulent EHV-1 strains, with CCL2 and 
CCL5 involved in the attraction of CD172a+ monocytic cells towards the infected 
regions. RSG treatment efficiently inhibited the CD172a+ monocytic cells 
migration in a dose-dependent manner while it had no effect on the virus 
replication in the epithelium of nasal mucosa. 
 
• There was a minor inhibitory effect of dual infections with EHV-1 and EAV in 
vitro and ex vivo, which is only limited during the early stage of infection. EHV-1 
and EAV do not infect the same mucosal leukocytes.             
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Boviene herpesvirus 1 (BHV-1) induceert prominente, epitheliale plaques en dringt 
via deze plaques de basale membraan (BM) van de respiratoire mucosa binnen. Dit 
directioneel transport van BHV-1 naar de basale membraan is belangrijk voor virus 
disseminatie en invasie van de basale membraan. Het Us3 eiwit van BHV-1 kan de 
intracellulaire lokalisatie van het virus wijzigen en het werd reeds gerapporteerd te 
co-lokaliseren met de microtubuli in projecties van de cel, hetgeen directe interacties 
van het Us3 eiwit met kinesine of dyneine motoreiwitten suggereert. Het Us9 eiwit 
kan, samen met kinesines, ook bijdragen tot het directionele transport van 
alphaherpesvirale glycoproteïnen in epitheelcellen van de respiratoire mucosa. De rol 
van het Us3 en het Us9 eiwit tijdens stromale invasie door BHV-1 in de respiratoire 
mucosa werd bestudeerd. 
 
Het equine herpesvirus 1 (EHV-1) en het equine arteritis virus (EAV) zijn twee 
belangrijke pathogenen van paarden, die een significante, economische impact hebben 
op de globale paardenindustrie. CD172a+ cellen worden geïnfecteerd met zowel 
EHV-1 als EAV in de respiratoire mucosa van de bovenste luchtwegen. Deze 
geïnfecteerde CD172a+ cellen transporteren vervolgens de virussen doorheen het 
lymfevaten- en bloedvatenstelsel en mediëren op deze manier verdere disseminatie.  
 
Tot op heden toe, bieden commerciële vaccins geen volledige bescherming tegen 
EHV-1 infectie en effectieve antivirale middelen zijn niet beschikbaar. Aangezien 
CD172a+ monocytaire cellen dus fungeren als ‘Trojaanse paarden’ in de respiratoire 
mucosa, kan inhibitie van de rekrutering van deze monocyten de verdere migratie van 
geïnfecteerde monocyten naar de diepe weefsellagen tegengaan. Daarom werd 
nagegaan of CD172a+ monocytaire cellen specifiek gerekruteerd worden naar EHV-1 
infectie sites om het virus te elimineren en of behandeling van de respiratoire mucosa 
met inhibitoren van dendritische cel migratie zoals rosiglitazone (RSG) en quinacrine 
(QC), de invasie van EHV-1 naar de diepere weefsels kan verhinderen.  Verder, 
aangezien infectie met EHV-1 en EAV klinisch niet te onderscheiden zijn, werd het 
verloop van duale infecties met EHV-1 en EAV in de equine respiratoire mucosa 
bestudeerd. 
 
In hoofdstuk 1, werd een introductie gegeven over de huidige kennis van EHV-1, 
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BHV-1 en EAV. Hierin kwamen de historie en taxonomie aan bod, evenals de virus 
eigenschappen, replicatie cyclus en pathogenese. Ook werd een overzicht gegeven 
over monocytaire cellen en cytokines.  
 
In hoofdstuk 2, werden de doelstellingen van deze thesis uiteengezet. 
  
In hoofdstuk 3, werd achterhaald dat het Us3 en Us9 eiwit een belangrijke rol spelen 
bij de invasie van de BM van de respiratoire mucosa door BHV-1. Deletie van Us3 
resulteerde in een significante reductie in de infectieuze titer en plaque grootte 
(breedte) in MDBK-cellen en de mucosa van de trachea. Wanneer echter Us9 
gedeleteerd werd, kon er geen effect op de celgemedieerde spreiding van BHV-1 
waargenomen worden. Zowel de BHV-1 Us3 nul-mutanten als de Us9 nul-mutanten 
vertoonden een sterke reductie van plaque penetratie doorheen de BM, maar deze 
penetratie werd niet volledig geïnhibeerd.  
 
In hoofdstuk 4, werd aangetoond dat CD172a+ cellen specifiek gerekruteerd werden 
naar EHV-1-geïnfecteerde regio’s bij infectie met neurovirulente stammen maar niet 
bij infectie met niet-neurovirulente stammen en dat CCL2 en CCL5 betrokken waren 
bij dit rekruteringsproces. Vanaf 24 uur post-inoculatie begonnen geïnfecteerde 
epitheelcellen CCL2 tot expressie te brengen en vanaf 48 uur post-inoculatie CCL5, 
hetgeen overeenstemt met de migratie van de CD172a+ cellen. RSG-behandeling van 
EHV-1-geïnoculeerde equine nasale mucosa verhinderde de migratie van CD172a+ 
cellen in de lamina propria zonder een effect te hebben op de replicatie van het virus 
in het epitheel.   
 
In hoofdstuk 5, werd gevonden dat een inhibitorisch effect geïnduceerd werd in 
RK13-cellen door ofwel EHV-1 of EAV in de duale infecties, onafhankelijk van de 
volgorde van virus blootstelling. Meer nog, na superinfectie werden geen RK13-
cellen teruggevonden die co-geïnfecteerd waren met zowel EHV-1 als EAV terwijl na 
co-infectie slechts enkele co-geïnfecteerde cellen werden gevonden. In de nasale en 
nasopharyngeale mucosa had EAV infectie geen effect op EHV-1 replicatie in het 
respiratoire epitheel. EAV en EHV-1 pre-infectie zorgden voor een minieme reductie 
van het aantal EHV-1 en EAV-geïnfecteerde leukocyten in vergelijking met 
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enkelvoudige infecties en co-infectie. In explanten geïnfecteerd met zowel EAV- en 
EHV-1 werden geen co-geïnfecteerde leukocyten gedetecteerd. 
 
In hoofdstuk 6, werd de bekomen data van de invasie van de respiratoire mucosa 
door equine en boviene alphaherpesvirussen geëvalueerd en kritisch besproken. 
 
Op basis van de studies uitgevoerd in deze thesis kunnen de volgende algemene 
conclusies naar voor gebracht worden: 
 
• Het Us3 en Us9 eiwit van BHV-1 spelen een cruciale rol in virale passage 
doorheen de BM gedurende infectie van boviene trachea mucosa explanten. 
Het BHV-1 Us3 eiwit draagt eveneens bij tot laterale, celgemedieerde 
spreiding in zowel MDBK-celculturen als het epitheel van de mucosa van de 
trachea. De BHV-1 Us9 nulmutanten daarentegen vertoonden geen effect. 
 
• Gedurende infecties met neurovirulente EHV-1 stammen werd een migratie 
van CD172a+ cellen van de basale naar de apicale zijde waargenomen waarbij 
zowel CCL2 als CCL5 betrokken waren in de rekrutering van CD172a+ cellen 
naar de geïnfecteerde regio’s. Behandeling met RSG leidde tot een efficiënte 
inhibitie van CD172a+ cel migratie in een dosis-afhankelijke manier terwijl dit 
geen effect had op de virus replicatie in het epitheel van de nasale mucosa. 
 
• Er was een geringe inhibitie bij duale infecties met EHV-1 en EAV in vitro en 
ex vivo, hetgeen enkel beperkt was gedurende de vroege stadia van infectie. 
EHV-1 en EAV infecteerden niet dezelfde mucosale leukocyten. 
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